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SUMMARY OF CONTENTS 
 
Left ventricular hypertrophy is a marker of poor prognosis that commonly 
affects patients with ischaemic heart disease. It has been associated with an 
increased risk of all-cause mortality and cardiovascular events including 
myocardial infarction, heart failure, stroke and arrhythmias. Previous studies of 
mainly antihypertensive therapies have shown left ventricular hypertrophy to be 
a reversible risk factor. The LIFE study has shown LVH regression per se to be 
associated with reduced cardiovascular morbidity and mortality, independent of 
blood pressure reduction. Therefore, novel ways of regressing left ventricular 
hypertrophy, independent of blood pressure, in patients with IHD could reduce 
cardiovascular events and mortality in this patient group. 
 
Allopurinol is a xanthine oxidase inhibitor that received FDA approval in 1966 
and has been used primarily as a prophylactic treatment for gout. It is a safe, well 
tolerated drug with minimal side effects. 
 
There are a number of reasons why allopurinol may reduce LV mass in patients 
with LVH and IHD. Firstly, allopurinol has been shown to regress LV mass in 
animal studies and more recently in patients with CKD. Secondly, LV afterload 
is the main determinant of LV mass. Previous studies have shown allopurinol to 
improve LV afterload by improving arterial stiffness and arterial compliance, 
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which may result in regression of LV mass. Thirdly, patients with IHD have 
increased levels of oxidative stress, which contribute to both endothelial 
dysfunction and left ventricular hypertrophy. Xanthine oxidase is a major 
producer of reactive oxygen species and allopurinol therapy, being a xanthine 
oxidase inhibitor, has been shown to reduce vascular oxidative stress. 
 
This was a randomized, double-blinded, placebo controlled study of 66 patients 
with IHD and LVH, prescribed allopurinol 600mg/day or placebo therapy over a 
9 month follow up study period. LV mass was measured at baseline and 9 
months using cardiac magnetic resonance imaging. At baseline, 6 months and 9 
months, measurements were made of endothelial function using flow-mediated 
dilatation and assessments of arterial stiffness by measuring augmentation index 
and pulse wave velocity using applanation tonometry. 
 
In this study, we demonstrated high dose allopurinol therapy over a 9 month 
treatment period to significantly regress LV mass, improve endothelial 
dysfunction and measurements of arterial stiffness without a significant 
reduction in BP. 
 
The improvement in endothelial function and regression of LV mass 
demonstrated in this study with high dose allopurinol suggests that allopurinol 
might reduce cardiovascular events and mortality. Future studies should 
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investigate if this beneficial effect of allopurinol on LV mass, being a surrogate 
marker, results in a beneficial effect on harder clinical end points such as 
cardiovascular events and mortality. 
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1 INTRODUCTION 
 
1.1 Oxidative stress 
 
1.1.1 Background of oxidative stress 
 
 
Oxidative stress occurs when there is an accumulation of reactive oxygen species 
(ROS), which is often due to the inadequacy of the body’s intrinsic antioxidant 
defence system ie. there is an imbalance in the “redox state” of a cell. ROS are 
chemically reactive molecules derived from oxygen. They include free radicals 
[superoxide radical (O2-), hydroxyl radical (OH)] and non-radical molecules 
[hydrogen peroxide (H2O2), hypochlorous acid (HOCl)].  
 
ROS in low concentration plays a cell protecting role in modulating 
inflammation and is involved in cellular “redox signalling” pathways. 
Additionally, transcription factors activated by ROS also stimulate antioxidants 
such as manganese superoxide dismutase and NOS. When produced in excess, 
ROS has harmful effects on cell protein (denaturing and inactivating enzymes), 
lipid (damaging membranes of cells and cellular organelles), carbohydrate and 
DNA leading to cell damage and death (1). 
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Gerschman et al. first proposed the harmful effects of ROS formed from 
excessive oxygen. In 1969, McCord and Fridovich supported this theory with the 
discovery of superoxide dismutase (2). Growing evidence suggests that oxidative 
stress (OS) is involved in the pathogenesis of various cardiovascular diseases 
including hypertension, atherosclerosis, endothelial dysfunction, 
hypercholesterolemia, ventricular hypertrophy, myocardial infarction and heart 
failure (3). Myocardial ischaemia results in the production of ROS and 
inflammatory cytokines (such as TNF-α, IL-1β and IL-6), resulting in cardiac 
remodelling (4, 5). Additionally, in human studies, administration of 
antioxidants during an acute MI, angioplasty or heart surgery reduces infarct size 
and the amount of cardiac dysfunction (3).  
 
1.1.2 Generation of oxidative stress 
 
The superoxide radical (O2-) is formed by the addition of an electron to an 
oxygen molecule leading to a reduced form of oxygen. Hydrogen peroxide 
(H2O2) is produced by the addition of an electron to O2- and then undergoing 
protonation. This reaction is catalysed by superoxide dismutase. 
 
                                2O2- + 2H+                 O2  + H2O2 
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 Under normal conditions, H2O2 is broken down by catalase and glutathione 
peroxidase to form H20. However, in pathological conditions, H2O2 goes on to 
form highly reactive radicals like OH and HOCl. Highly reactive hydroxyl 
radicals (OH) can be formed by the Fenton reaction and the Haber-Weiss 
reaction, which are catalysed most commonly by iron and copper. In the Fenton 
reaction, the hydroxyl radical is formed when a reduced metal ion donates an 
electron to H2O2. 
                                  Fe 2+ + H2O2                  Fe3+ + OH + OH- 
 
In the Haber-Weiss reaction, OH is generated when the superoxide radical 
interacts with hydrogen peroxide (1). 
 
                                   O2- + H2O2                      O2 + H2O + OH 
 
Hypochlorous acid (HOCl) is formed when H2O2 reacts with chloride ion in the 
presence of myeloperoxidase. 
 
                               H2O2 + H+ + Cl-                   H2O + HOCl 
 
The role of NO on myocardial function has been controversial, partly due to the 
presence of NOS isoforms (eNOS and nNOS) expressed in cardiomyocytes, 
resulting in both myocardial relaxation and contraction. NO has been reported to 
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modulate the function of proteins involved in excitation-contraction coupling 
such as the L-type calcium channels and ryanodine receptor calcium release 
channel (RyR2) which causes myocardial calcium uptake and the sarcoplasmic 
reticulum calcium ATPase (SERCA2a) which causes calcium uptake into the 
sarcoplasmic reticulum, resulting in reduced myocardial calcium levels. NO 
causes S-nitrosylation of proteins whereby protein cysteine thiol is modified into 
S-nitrosothiol (SNO), resulting in changes in protein function (6, 7). However, 
increased O2- levels inhibits nitrosylation and interacts with nitric oxide (NO) to 
form a peroxynitrite (ONOO-) (1). This highly reactive molecule mediates 
damaging processes including lipid peroxidation, protein nitration and oxidation 
of LDL (8) and activation of matrix metalloproteinases (MMPs). Hence, nitroso-
redox imbalance may lead to cardiac remodelling and alter excitation-contraction 
coupling (9). Figure 1 illustrates the ROS production in the heart. 
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Figure 1. ROS production and antioxidant system in the heart (10) 
 
 
1.1.3 Sources of ROS  
 
 
ROS can be generated by neutrophils, vascular endothelial cells and 
cardiomyocytes by various mechanisms including mitochondria oxidative 
phosphorylation, NADP/NADPH oxidase, xanthine oxidase and uncoupling of 
NO synthase (11).  
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1.1.3.1 Mitochondria 
 
 
ROS is produced by the mitochondria during cellular aerobic metabolism. 
“Electron leakage” during oxidative phosphorylation reacts with oxygen 
molecule to form O2- (1). However, normally ROS are controlled by intrinsic 
antioxidants. During reperfusion in the setting of ischaemia, experimental studies 
have shown the huge increase in oxygen supply to result in a surge of ROS 
production by the mitochondria, which can’t be adequately managed by the 
intrinsic antioxidants (12). 
 
1.1.3.2 NADH/NADPH oxidase  
 
 
NADPH oxidase is an enzyme found in phagocytes, endothelium, vascular 
smooth muscle cells and cardiomyocytes (13). It is a major source of ROS.  All 
NADPH oxidases have a catalytic Nox subunit, which transfers electrons from 
NADPH to oxygen leading to the formation of superoxide radical. There are 5 
isoforms of Nox identified so far but Nox 2 and 4 are the two main isoforms 
found in cardiomyocytes and endothelial cells (14).  
 
Increased levels of NADPH oxidase activity has been shown in human subjects 
with heart failure and experimental models of left ventricular hypertrophy (13). 
NADPH oxidase activity is stimulated by numerous factors including 
mechanical stretch, angiotensin II, α-adrenergic agonists, endothelin-1 and TNF-
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α (14). ROS generated by NADPH oxidase is the mechanism whereby 
angiotensin II induces cardiac hypertrophy and remodelling and endothelial 
dysfunction (14). Hence, inhibitors of the renin-angiotensin system such as ACE 
inhibitors and angiotensin II receptor blockers have resulted in regression of 
LVM (independent of BP reduction) (15, 16) and have shown improvement in 
endothelial dysfunction (17, 18). ROS produced by NADPH oxidase also 
activates other OS generating systems such as xanthine oxidase and uncoupling 
NOS (13). O2- produced by NADPH oxidase oxidises NOS co-factor BH4 
leading to uncoupling of NOS. This will promote further ROS production ie. a 
vicious cycle may occur (13). 
 
1.1.3.3 Xanthine oxidase (XO) 
 
 
This enzyme is another important source of ROS and is the primary focus of this 
research study. Increased enzyme activity has been detected in a range of 
cardiovascular conditions associated with increased oxidative stress (19-23).   
 
Xanthine oxidoreductase (XOR) is a member of the molybdoenzyme family and 
was first identified in 1902 by Schardinger in milk. It is a butterfly shaped 
homodimer that is made of 2 subunits (of approximately 150kDa each) that are 
independent catalysts. XOR activity requires the presence of 3 cofactors: 
molybdopterin (Mo-Co), iron-sulphur centres (Fe2-S2) and FAD (24). XOR is 
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present as two interchangeable forms – xanthine oxidase (XO) and xanthine 
dehydrogenase (XDH). The enzyme tends to be formed as a dehydrogenase in 
vivo, which is converted to the oxidase form by sulfhydryl oxidation or 
proteolysis. The XOR gene is located on the short arm of chromosome 2 (24).  
 
Normally XO is found mainly in the liver and small intestine and at very low 
levels in the heart and endothelium. However, XOR gene transcription is 
stimulated by numerous factors including hypoxia, lipopolysaccharide, 
interferon γ, IL-1, IL-6, TNFα and steroids (25). As previously mentioned, 
xanthine oxidase is also activated by ROS produced by NADPH oxidase (13). 
NO may also have an effect on XOR activity although there is conflicting 
evidence (26, 27). There is considerable variation in XO activity in different 
species. A study by de Jong et al. in 1990 found the XO activity (mU/g) to be 33 
± 3 in mice, 28.5 ± 1.4 in rats, 0.59 ± 0.09 in rabbits, <0.1 in pigs and 0.31 ± 
0.04 in humans (28). In humans, XO has more than a threefold variation in 
activity (29).  
 
XOR is a rate-limiting enzyme involved in the final two stages of the purine 
degradation pathway (see Figure 2). XDH oxidises the conversion of 
hypoxanthine to xanthine and then xanthine to uric acid whilst reducing NAD+ 
for which it has higher affinity. XO also can oxidise the xanthines whilst 
reducing oxygen to superoxide radicals (O2- and H2O2) (30).  
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Figure 2. Purine degradation pathway (30) 
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The conversion of xanthine to uric acid results in the donation of 2 electrons to 
XOR, which reduces Mo (VI) to Mo (IV). The electrons are then transferred 
from the Mo-Co to FAD via Fe2-S2. A fully reduced XO has 6 electrons, which 
is transferred from FAD to oxygen molecules on reoxidation leading to the 
generation of 2H2O2 and 2O2-. XDH on the other hand tends to preferentially 
donate its electrons to NAD+ instead of O2 resulting in NADH generation (see 
Figure 3) (24). The O2- generated can combine with NO resulting in cytotoxic 
peroxynitrite. In the presence of hypoxia, NO is produced by XOR as evidenced 
by allopurinol therapy inhibiting NO production that is not seen with NOS 
inhibitors (31).  
 
 
 
Figure 3. Mechanism of XOR reaction with xanthine (24)  
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1.1.3.4 Uncoupling NOS3 
 
 
Normally, NOS3 (an endothelial NOS) reacts with NADPH, L-arginine and O2 
to form NO and L-citrulline. NO inhibits XO and NADPH oxidase activation, 
cardiac hypertrophy and fibrosis and cardiac dysfunction. Cofactor 
tetrahydrobiopterin (BH4) is required for NOS3 to remain in a coupled state. 
When exposed to oxidative stress or to the lack of BH4 or L-arginine, this leads 
to instability and uncoupling of NOS3 and electrons react with oxygen 
molecules to form O2-. The O2- formed then reacts with NO to form peroxynitrite 
resulting in cytotoxic effects (11). Landmesser et al. has reported that O2- from 
NADPH oxidase oxidises BH4, which triggers uncoupling of NOS3 (32). 
 
1.1.4 Antioxidants 
 
 
There are enzymatic and non-enzymatic pathways that act as antioxidants to 
degrade and convert ROS into non-toxic molecules. The enzymatic antioxidants 
include catalase, glutathione peroxidase, superoxide dismutase, thioredoxin and 
thioredoxin reductase. Superoxide dismutase (SOD) converts O2- to H2O2 whilst 
catalase and glutathione peroxidase catalyse the conversion of H2O2 to water. 
Thioredoxin and thioredoxin reductase on the other hand are involved in the 
production of antioxidants including ubiquinone, lipoic acid and ascorbic acid. 
Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that 
regulates the genes of enzymes involved in the antioxidant pathway such as 
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NAD(P)H quinone oxidoreductase 1, heme oxygenase 1, glutamate-cysteine 
ligase and glutathione S transferase  (33, 34). Non-enzymatic antioxidants 
include vitamin E and C, β-carotene, ubiquinone, lipoic acid and uric acid (1).  
 
1.1.5 Oxidative stress in cardiovascular diseases 
 
 
1.1.5.1 Atherosclerosis 
 
 
Cardiovascular risk factors such as hypertension, hypercholesterolemia, diabetes 
and smoking are associated with increased levels of oxidative stress. ROS play a 
role in the development and progression of atherosclerosis by the formation of 
oxidised LDL, proliferation and migration of vascular smooth muscle cells and 
endothelial dysfunction (1, 35). Plaque stability is also affected by the activation 
of MMPs by ROS (2).  
  
In endothelial dysfunction, there is a reduction in vasodilator NO bioavailability. 
Increased levels of O2- interacts with NO, resulting in the formation of toxic 
peroxynitrite and hence inactivates NO. This will be discussed further in a later 
section of this thesis on endothelial dysfunction. 
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1.1.5.2 Myocardial Ischaemia 
 
 
Myocardial ischaemia especially during reperfusion is associated with the 
production of ROS and inflammatory cytokines. During an MI, ROS directly 
causes cell damage and hence affects infarct size. Animal studies have shown 
that in transgenic mice with overexpression of an antioxidant SOD, there is a 
reduction in infarct size (36).  In the setting of an MI, ROS is also involved in 
myocardial stunning and LV remodelling. There are numerous ways in which 
ROS is involved in LV remodelling:  
1. Activation of signalling pathways including Apoptosis signalling kinase-1 
(Ask-1)  
2. Activation of MMPs resulting in changes in extracellular matrix  
3. Apoptosis (36) 
 
LV remodelling post MI results in thinning of infarcted areas and a reactive 
hypertrophy of remote myocardium eventually leading to LV dilatation and 
dysfunction. 
 
1.1.5.3 Heart failure 
 
 
To date, animal and human studies have provided evidence of the role of 
oxidative stress in the setting of heart failure (1). ROS affects cardiac function by 
inhibiting sarcoplasmic reticulum Ca2+ pump SERCA2 (37), suppressing 
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sarcolemma L-type calcium channels (38) and affecting proteins involved in the 
excitation-contraction coupling (39).  
 
1.1.5.4 Cardiac hypertrophy 
 
 
Significant evidence exists for the involvement of oxidative stress in the 
development of cardiac hypertrophy (1, 11, 13). Induced by neurohumoral 
stimuli (such as angiotensin II, endothelin I, norepinephrine), cytokines or 
chronic pressure overload, high levels of ROS lead to cardiac hypertrophy, 
remodelling, contractile dysfunction, fibrosis and apoptosis (13). This occurs via 
apoptosis signalling kinases (ASK), transcription factors and matrix 
metalloproteinases (MMPs). ROS cause cardiac hypertrophy by activating p38 
and Jun-nuclear kinase (JNK) MAPKs (mitogen activated protein kinase), ASK-
1, extracellular response kinase (ERK) 1/2, protein kinase C (PKC), 
phosphoinositol 3-kinase (PI3K), tyrosine kinase Src and GTP binding protein 
Ras (11). Figure 4 shows the molecular signalling pathways in the heart.  
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Figure 4. Molecular signalling pathways linking ROS to cardiac hypertrophy and 
remodelling  
Ica indicates calcium channels; αAR, α  adrenergic; βAR, β  adrenergic; AT1, 
angiotensin II; MAPK, mitogen-activated protein kinases; PI3K, phosphoinositol 
3-kinase; Ask-1, apoptosis signalling kinase-1; PKC, protein kinase C; NFκB, 
nuclear factor κB; AP-1, activator protein-1(11). 
 
Angiotensin II is thought to generate cardiac hypertrophy by ROS generated via 
NADPH oxidase. It acts via G-protein pathways and involves apoptosis 
signalling kinase-1 (ASK-1) and mitogen-activated protein kinases (MAPK) 
signals (1). ROS can also result in cardiac hypertrophy by the action of 
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transcription factors (NF-κB and activation protein-1) in altering gene expression 
(1).  
 
Cardiac fibrosis is involved in both LVH and CCF. ROS causes fibrosis and 
extracellular matrix remodelling by stimulating cardiac fibroblast proliferation, 
increasing MMP expression and activating MMP activity via transcription 
factors NFκB, Ets and AP-1 (11).  
 
Apoptosis occurs in ischemic, hypertrophied and cardiac dysfunction. Apoptosis 
occurs at much higher levels of ROS compared to the kind of ROS levels that 
stimulate hypertrophy. Studies on adult rat cardiac myocytes have shown that 
stimulation of β adrenergic receptors cause apoptosis within 24 hours by ROS. 
ROS cause apoptosis by activating p38 and JNK MAPKs, ASK-1 and Akt (1). 
NOS2 produces high levels of NO that reacts with O2- to form peroxynitrite, 
which causes myocyte apoptosis. In animal MI studies, NOS2 knockout mice 
had less myocyte apoptosis and better contractile function compared to wild type 
mice (40).  
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1.2 Endothelial dysfunction  
 
1.2.1 Background 
 
 
The endothelium is a single cell layer lining the lumen of blood vessels, which 
acts as a physical barrier regulating vascular tone, controlling thrombosis, 
smooth muscle cell proliferation and vascular inflammation in response to 
various mechanical and chemical stimuli (41). It secretes vasodilating substances 
such as NO and vasoconstricting substances such as endothelin-1 (see Table 1). 
Maintenance of vascular tone 
    Nitric oxide 
    Prostaglandins (prostacyclin [PGI2], thromboxane A2 [TxA2]) 
    Endothelial hyperpolarizing factor 
    Endothelin-1 
    Angiotensin II 
    C-type natriuretic peptide 
Balancing blood fluidity and thrombosis 
    Nitric oxide 
    Tissue plasminogen activator 
    Heparins 
    Thrombomodulin 
    Prostaglandins 
    Plasminogen activator inhibitor-1 (PAI-1) 
    Tissue factor 
    Von Willibrand’s factor 
Control of the vascular inflammatory process 
    Monocyte chemotactic factor-1 (MCP-1) 
    Adhesion molecule expression (VCAM-1, ICAM-1, selectins) 
    Interleukins 1,6 and 18 
    Tumour necrosis factor 
 
Table 1. Normal functions of the vascular endothelium and partial list of factors 
elaborated and regulated by endothelium to maintain vascular homeostasis (41) 
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NO is the main vasodilator secreted by the endothelium. It is synthesized from 
L-arginine by endothelial nitric oxide synthase (eNOS) in the presence of 
cofactors such as tetrahydrobiopterin, NADPH and FAD/FMN and regulated by 
Ca-calmodulin, resulting in NO and L-citrulline. NO then diffuses into the 
vascular smooth muscle cells activating guanylate cyclase, by interacting with 
the iron atom of the heme in guanylate cyclase, thereby increasing cGMP 
production and reducing intracellular calcium. This results in vasodilatation (42). 
See Figure 5.  
 
 
 
Figure 5. The nitric oxide signalling pathway. BH4 = tetrahydrobiopterin; Ca++ = 
calcium ion; cGMP = cyclic guanosine monophosphate; eNOS= endothelial nitric 
oxide synthase; GC = guanylate cyclase; GTP = guanosine triphosphate; NADPH = 
reduced nicotinamide-adenine dinucleotide phosphate; NO = nitric oxide. 
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Endothelial dysfunction occurs when the endothelium loses its ability to 
maintain vascular homeostasis in response to risk factors resulting in 
vasoconstriction, thrombosis and vascular smooth muscle cell proliferation. 
Cardiovascular diseases and traditional risk factors result in increased oxidative 
stress, which inactivates NO by combination with superoxide and other reactive 
oxygen species. There is reduced local NO levels which normally acts as a 
vasodilator, inhibits platelet aggregation and monocyte adhesion to endothelium 
and smooth muscle cell proliferation, thereby increasing the risk of 
cardiovascular events (43). The risk of an initial or recurrent cardiovascular 
event correlates with the severity of endothelial dysfunction.  
 
1.2.2 Assessment of endothelial function using FMD 
 
 
Various invasive methods have been used in the past to assess endothelial 
function including coronary artery studies and venous occlusion 
plethysmography. However, a non-invasive technique of assessing endothelial 
function called flow mediated dilatation (FMD) of the brachial artery was 
developed and first described by Celermajer et al. in 1992 (44). This technique 
has been widely used in clinical research for assessing endothelium dependent 
flow mediated dilatation of the brachial artery in response to increased shear wall 
stress using high resolution ultrasound. A reactive hyperaemia in response to 
release of the sphygmomanometer cuff after a five minute upper arm occlusion 
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results in 5 to 7 times increased blood flow and shear stress, resulting in local 
vasodilator production, predominantly NO. FMD is a measure of the endothelial 
bioavailability of NO (local production vs. destruction). This vessel response is 
compared with an endothelium-independent response to GTN.  
 
This technique is an indirect measure of coronary artery endothelial function. 
Several studies have shown a good correlation between brachial FMD and 
coronary endothelial function. In 1995, Anderson et al. showed that brachial 
FMD closely related with coronary artery endothelial tests, with a positive 
predictive value of 95% (45). An advantage of this technique is that it is non-
invasive and so can be performed on large number of patients and repeated on 
the same patient. Additionally, the results are reproducible (46). Limitations of 
this technique include operator skill as it can be difficult to perform and one 
needs an adequate training period and it can be time consuming to perform the 
test and analyze images. Additionally, several factors are known to influence the 
findings of FMD including high fat meals, vitamin C, caffeine, smoking, 
menstrual cycle, exercise, temperature and vasodilators.  
 
EndoPAT (Endothelial-Peripheral Arterial Tonometry) is a more recently 
developed non-invasive method of assessing vasoreactivity. It is a less operator 
dependent method whereby a pleythysmographic probe is placed on the finger 
index of each hand. It detects the endothelium-mediated changes in the digital 
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pulse waveform known as the peripheral arterial tone (PAT). However, the 
EndoPAT method compared to FMD in measuring endothelial function has 
higher variability in measurements and fewer studies have been performed in 
assessing the influence of an intervention on PAT ratio (47). 
 
1.2.3 Endothelial dysfunction in IHD  
 
Endothelial dysfunction has been shown to occur in patients with coronary artery 
disease and in response to traditional risk factors (41). It plays a key role in the 
pathogenesis of atherosclerosis and may be the earliest manifestation of 
atherosclerosis, even in absence of angiographic evidence (43). Patients with 
confirmed CAD on angiogram have worse endothelial function compared to 
those with cardiovascular risk factors and normal coronary arteries (48). It also 
plays a role in plaque instability, resulting in plaque rupture and hence acute 
coronary syndrome (42) (see Figure 6).  
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Figure 6. The role of endothelial dysfunction in the pathogenesis of cardiovascular 
disease events (41) 
 
Patients with stable angina and ACS have similar endothelial dysfunction 
(endothelium-dependent dilatation in stable angina group: 2.3 ± 8.1%, ACS 
group: 2.6 ± 8.9%; p = NS between these two groups, control normal angiogram 
group: 14.9 ± 9.1%; p < 0.001) (49). Endothelial dysfunction is not only related 
to the presence of CAD but also the number of vessels affected (on univariate 
analysis r = - 0.67, p<0.01) and severity of stenosis (r = -0.52, p<0.01) (48).  
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An impaired FMD is associated with an increased risk of cardiovascular events 
(including angina requiring hospitalization, MI, revascularization, death) (41, 43) 
and instent restenosis (OR 4.5, 95% CI 2.4, 12) (50). It has been shown to have a 
prognostic role in patients presenting with chest pain (51), ACS without ST 
elevation (FMD < 1.9% adjusted HR 3.035, 95% CI 1.146, 8.023; p = 0.03) (52) 
and STEMI patients (53). 
 
1.2.4 Endothelial dysfunction and LVH 
 
 
Numerous small-scale studies of hypertensive patients have shown endothelial 
dysfunction to be associated with LVH (54, 55). In a LIFE sub-study of 40 
untreated hypertensives, FMD had a negative correlation to LVMI (r = -0.53, p 
<0.01) (54). However, a study by Muiesan et al. showed no association between 
endothelial dysfunction and LVH or LV geometry in hypertensive patients (55). 
In a sub-study of the Northern Manhattan Study (NOMAS), 2D echo and FMD 
was undertaken on 867 stroke-free, multiethnic population group. On multiple 
linear regression, FMD was inversely associated with LVM (β= -1.21 ± 0.56, 
p=0.03). Univariate logistic regression showed each 1% reduction in FMD to be 
associated with an 8% increased risk of LVH (OR 1.08, 95% CI: 1.03, 1.13 per 
FMD point; p<0.01) (56). Additionally, in a large population-based study of 
6814 cardiovascular disease free adults [Multi-Ethnic Study of Atherosclerosis 
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(MESA)], endothelial dysfunction was associated with LVM assessed using 
CMR, independent of cardiovascular risk factors (57).  
 
1.2.5 Treatments shown to improve endothelial dysfunction 
 
 
As endothelial dysfunction has been associated with an increased risk of 
cardiovascular events and there is a non-invasive reproducible technique to 
assess endothelial function, over the years there has been considerable interest to 
evaluate potential therapeutic options.  
 
Diet high in omega-3 fatty acids and flavonoids such as tea and grape juice have 
been shown to reduce endothelial dysfunction (58-60). High fat meals on the 
other hand worsen endothelial function (61). Exercise is very effective in 
improving endothelial function, likely due to increased NO bioavailability (62). 
Reduction of cardiovascular risk factors such as reduction of BP, smoking 
cessation and treatment of diabetes has also been associated with improved 
endothelial function (41).  
 
Numerous studies have consistently shown statins to improve endothelial 
function. This is felt likely due to a reduction in serum cholesterol levels and the 
pleiotropic effects of statins. It reduces expression of inflammatory cytokines 
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and growth factors, inhibits angiotensin II induced oxidative stress and enhances 
activity of endothelial NOS, thereby increasing NO production (63-65).  
 
ACE inhibitors and ARBs are also effective in reducing endothelial dysfunction. 
ACE inhibitors and ARBs reverse endothelial dysfunction by inhibiting 
angiotensin II induced production of ROS, which usually inactivates NO. ACE 
inhibitors also inhibit bradykinin breakdown, which increases NO production 
(66-69). Antioxidants have been investigated extensively as a therapeutic option 
as oxidative stress is known to play a key role in endothelial dysfunction in 
atherosclerosis. The evidence for vitamin E is conflicting. The HOPE (Heart 
Outcomes Prevention Evaluation) study, a large, randomized study, did not show 
vitamin E to have a beneficial effect on cardiovascular events in high risk 
patients (70). Vitamin C on the other hand has been shown to have an impact on 
endothelial function in smokers, heart failure and CAD. However, a combination 
of antioxidants (beta-carotene, vitamin C, vitamin E) did not demonstrate a 
beneficial effect on endothelial function or cardiovascular events (71, 72). 
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1.2.6 Arterial stiffness 
 
1.2.6.1 Background 
 
Arterial stiffness is a measure of the mechanical property of an artery and is an 
independent risk marker of future cardiovascular events. It tends to affect 
patients with coronary artery disease due to its association with increased age, 
presence of cardiovascular risk factors and with atherosclerosis. It is commonly 
assessed by pulse wave velocity (PWV) directly and pulse wave analysis (PWA) 
indirectly, which are simple techniques with reproducible results (73). Stiffer the 
vessels, higher the augmentation index (AIx) and faster the PWV. Both PWA 
and PWV are inversely related to endothelial function measured with brachial 
FMD (74). 
 
1.2.6.2 Pulse wave analysis and pulse wave velocity 
 
 
We routinely assess peripheral blood pressure noninvasively at the brachial 
artery using a sphygmomanometer. Elevated brachial BP is associated with the 
development of LVH. However, the central aortic pressure especially in the 
ascending aorta directly affects the left ventricle and hence is felt to be a better 
predictor of outcome compared to peripheral BP. The increased LV afterload 
puts strain on the LV, thereby resulting in LVH to maintain cardiac output. We 
are now able to assess the central aortic pressure peripherally via the radial artery 
using applanation tonometry and a validated ‘generalized transfer function’. 
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The arterial pressure waveform is generated by a forward wave by LV ejection 
(incident wave) and a reflected wave from arteries in the peripheral circulation. 
In arterial stiffness, an increased velocity of forward and backward wave results 
in the wave returning in late systole instead of early diastole, thereby augmenting 
systolic pressure and reducing diastolic pressure (75) (see Figure 7). The 
augmented systolic pressure increases cardiac afterload resulting in LVH and 
increases myocardial oxygen demand whilst a reduction in diastolic pressure 
reduces coronary perfusion resulting in myocardial ischaemia (76).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43 
 
 
 
Figure 7. Resultant aortic pressure waveform is a combination of incident wave 
and reflected wave (260) 
 
Augmentation index measures the effect of the reflected wave on the second 
systolic peak resulting in increased LV afterload. It is a composite measure 
including resistance vessel function. This parameter depends on 3 factors: heart 
rate, PWV and the amplitude of the reflected pulse wave (75). 
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1.2.6.3 Arterial stiffness studies 
 
 
Numerous studies have shown arterial stiffness to be a predictor of mortality and 
cardiovascular events in patients with hypertension, type 2 diabetes and end-
stage renal disease (73, 77). Even small changes in PWV of 1m/s have been 
shown to reduce all cause mortality (adjusted RR 0.71; 95% CI 0.6, 0.86) (78). 
 
A cross sectional study of 465 symptomatic men by Weber et al. showed AIx to 
be a strong risk marker for the presence and extent of coronary artery disease 
(79). Arterial stiffness is also a predictor of myocardial ischaemic threshold, 
measured by time to ST depression on the treadmill exercise test for CAD 
patients (80). This may be partly explained by a reduction in coronary flow 
reserve seen with large arterial stiffness (81). In patients undergoing PCI, on 
adjusting for cardiovascular risk factors, angiogram findings and medication, 
each tertile increase in AIx had a RR of 1.8 for primary endpoint (MI, death and 
clinical restenosis) (82). 
 
As increased arterial stiffness would mean increased LV workload, Saba et al. 
found a higher AIx to be associated with a higher LVMI. However, Chen et al. 
only found PWV to be associated with LVMI on univariate analysis (75).  
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1.3 Ischaemic heart disease 
 
1.3.1 Cardiovascular disease and its burden 
 
 
Cardiovascular disease (CVD) leads to significant morbidity and mortality in the 
Western and developing world. It is the leading cause of death in the United 
Kingdom (UK) accounting for 180,000 deaths in 2010, of which 45% were due 
to coronary heart disease (CHD) (83). In the US, CVD mortality rate has 
declined by 32.7% from 1999 to 2009 although it still accounted for 787,931 in 
2009 (84). 
 
CHD is also the most common cause of death before the age of 75 in the UK. 
This is despite the CHD mortality rates falling in the UK since the 1970s. The 
Health Survey for England found that between 1994 and 2006, the prevalence of 
CHD in men increased from 6% to 6.5% whilst it remained stable for women 
(4.1% in 1994 to 4.0% in 2006). According to UK health surveys, an estimated 
1.2 million men and over 900,000 women suffer from chronic angina. It is also 
estimated that there are over 20,000 new cases of angina per year (83). In 2009, 
CHD accounted for 1 in 6 deaths (386,324) in the US. It has been estimated that 
635,000 Americans will have their first coronary event each year (84). 
 
Additionally, the total economic cost of CVD in the UK has been estimated to be 
£19 billion a year of which £6.7 billion is due to coronary artery disease – 27% 
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due to direct healthcare costs, 47% to loss of productivity and 26% for carers 
loss of earnings (83). In 2009, the total direct and indirect cost of CVD in US 
was $312.6 billion (84). In view of its huge health impact and economic costs, 
there is significant interest to develop new therapeutic targets to tackle 
cardiovascular disease.  
 
1.3.2 Chronic stable angina 
 
1.3.2.1 Background of angina 
 
 
The word ‘angina’ arises from the Latin word ‘angere’ which means ‘to throttle’. 
This clinical syndrome is characterised by the development of discomfort in 
chest, jaw, shoulder, arms or back in response to exertion or emotional stress and 
typically is relieved with rest or glyceryl trinitrate (GTN). Occasionally some 
patients may not develop chest pain but breathlessness as a symptom of angina. 
Angina occurs due to the imbalance between myocardial oxygen demand and 
supply, resulting in myocardial ischaemia. Myocardial oxygen supply depends 
on oxygen saturation of arterial blood, myocardial oxygen extraction and 
coronary blood flow (85). Myocardial ischaemia triggers a sequence of events 
known as the ischaemic cascade (Figure 8). It should be noted that angina only 
occurs at the final stage of the ischaemic cascade.  
 
 
 47 
                                  Local ischaemia 
 
                          
                           
 
                       Metabolic abnormalities – lactate production 
 
                                     
                                   
                           Diastolic dysfunction 
 
                                     
                                 
                                 
                            Systolic dysfunction 
 
 
                                        
                                        
                              ECG abnormalities 
 
                                    
                                        
                                         
                                 Angina chest pain 
 
Figure 8. Myocardial ischaemic cascade (86) 
 
The main mediator of angina is adenosine via stimulation of A1 adenosine 
receptors (87). Atherosclerotic coronary artery disease is the most common cause 
of myocardial ischaemia. Normally, the coronary blood flow is able to increase 
5-6 times during exercise. However in the presence of atherosclerosis, especially 
>50% narrowing of the coronary arteries, it is unable to reduce vascular 
resistance and increase coronary flow during exercise, resulting in oxygen 
demand-supply mismatch (88). Other causes include anaemia, coronary artery 
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spasm, endothelial dysfunction, aortic stenosis and hypertrophic 
cardiomyopathy. 
 
Patients with stable angina can go on to develop an acute coronary syndrome 
(ACS), which includes unstable angina, non-ST elevation MI (NSTEMI) and ST 
elevation MI (STEMI). In unstable angina, there is worsening of angina 
symptoms which become more frequent, more prolonged, occur at a lower 
workload and even at rest. During an MI, there is a prolonged attack of angina 
usually lasting > 30minutes which is not really helped by GTN and is associated 
with myocardial damage resulting in an increase in cardiac enzyme levels in the 
blood.  
 
1.3.2.2 Diagnosis of angina 
 
 
Taking a careful history is paramount in making a diagnosis of angina. The 
typical features of angina are discussed in Table 2. Additionally, it is important 
to ask regarding the presence of exposure to cardiovascular risk factors such as 
smoking, diabetes (DM), hypertension (HT), family history of ischaemic heart 
disease (IHD), previous history of peripheral vascular disease or strokes. 
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Typical angina (definite) Meets three of the criteria 
• Substernal chest discomfort of 
characteristic quality and duration 
• Provoked by exertion or emotional stress 
• Relieved by rest and/or GTN 
Atypical angina (probable) Meets two of these characteristics 
Non-cardiac chest pain Meets one or none of the characteristics 
 
Table 2. Clinical classification of chest pain (85) 
 
 
A grading system for angina is commonly used to quantify the severity of 
symptoms and to assess the response to therapy. The Canadian Cardiovascular 
Society (CCS) classification is commonly used. See Table 3.  
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Class Level of symptoms 
Class I ‘Ordinary activity does not cause angina’ 
Angina with strenuous or rapid or prolonged exertion only 
Class II ‘Slight limitation of ordinary activity’ 
Angina on walking or climbing stairs rapidly, walking uphill or 
exertion after meals, in cold weather, under emotional stress or 
only after first few hours after awakening 
Class III ‘Marked limitation of ordinary physical activity’ 
Angina on walking one or two blocks on the level or one flight 
of stairs at a normal pace under normal conditions 
Class IV ‘Inability to carry out any physical activity without discomfort’ 
or ‘angina at rest’ 
 
Table 3. Classification of angina severity according to the Canadian 
Cardiovascular Society (85) 
 
 
The history taking is complemented with a physical examination, laboratory 
investigations and cardiac investigations (non-invasive vs. invasive). 
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1.3.2.2.1 	  Exercise	  stress	  test	  
 
This non-invasive test has traditionally been used commonly in patients with 
suspected coronary artery disease as it is cheap and widely available. It can help 
in diagnosing coronary artery disease. A positive stress test as defined by ST 
depression of 1mm has a mean sensitivity of 68% and specificity of 77% in 
detecting significant coronary artery disease (85). This however depends on the 
pretest probability, which can be influenced by age and gender. It can also be 
used for prognostic information and to evaluate response to treatment (85).  
 
Sensitivity is the ability of a test to correctly identify patients with coronary 
artery disease whilst specificity is the ability of a test to correctly identify 
patients without coronary artery disease. 
 
Sensitivity = (true positive/true positive + false negative) x 100 
Specificity = (true negative/ true negative + false positive) x 100 
 
1.3.2.2.2 	  Myocardial	  perfusion	  stress	  	  
 
It is a non-invasive test whereby using exercise or pharmacological agents such 
as dobutamine or adenosine, radionuclide isotopes such as thallium or 
technetium-99 labelled agents are taken up by cardiac myocytes and hence 
provides information on myocardial perfusion. Images are acquired at rest and 
stress using single-photon emission computed tomography. This technique has a 
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large body of evidence that it can detect inducible perfusion defects in patients 
with coronary artery disease and provide prognostic information. It has a 
sensitivity and specificity of 88% and 77% respectively (89). However, one of 
the main limitations of this test is the exposure to radiation. 
 
1.3.2.2.3 	  Stress	  echocardiogram	  
 
Stress echocardiogram is a non-invasive stress test whereby either exercise or a 
pharmacological agent such as dobutamine or adenosine is used to increase the 
heart rate and then transthoracic echo is performed to assess for any inducible 
wall motion abnormalities or viability. Hence it is widely used if the patient is 
unable to exercise or if the ECG is difficult to interpret for ischaemia such as 
LVH, left bundle branch block or paced rhythm. Its sensitivity and specificity are 
76% and 88% respectively (89). 
 
1.3.2.2.4 	  Cardiac	  Magnetic	  Resonance	  Imaging	  (CMR)	  
 
CMR can diagnose coronary artery disease by two methods: stress induced wall 
motion abnormalities (sensitivity 83%, specificity 86%) or perfusion imaging 
(sensitivity 91%, specificity 81%). It should be noted that CMR is 
contraindicated in patients with claustrophobia or if they have any implanted 
metals such as pacemakers and patients should be able to perform breath hold. 
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1.3.2.2.5 	  Computed	  Tomography	  (CT)	  
 
This non-invasive test assesses coronary arteries by the severity of coronary 
calcification (calcium score) and looking at its anatomy (CT coronary 
angiogram). It is a good rule out test of significant coronary artery disease in 
patients with low to intermediate probability. Calcification of coronary arteries is 
a marker of atherosclerosis that reflects the overall plaque burden and not the 
severity of specific coronary stenosis (85). However, not all coronary plaques are 
calcified and not all calcified plaques are severe lesions. The CT calcium score is 
not very sensitive in detecting plaques without significant calcification (90). The 
Agatston score is the most commonly used calcium score.  A CT calcium scan 
takes 5 minutes to perform and interpret, is performed without contrast and there 
is exposure to a lower radiation dose compared to a CT coronary angiogram. 
 
CT coronary angiogram has a sensitivity of 98% and specificity of 88% (91). Its 
negative predictive value (NPV, proportion of patients with negative test results 
who are correctly diagnosed) is 96-100% whilst its positive predictive value 
(PPV, proportion of patients with positive test results who are correctly 
diagnosed) is 93% (91). However, there is a significant radiation exposure to the 
patient, involves the use of contrast and it is poor in predicting if a coronary 
lesion is functionally significant (92). Hence, if a coronary stenosis appears > 
50% on CT coronary angiography, further investigations such as a functional test 
or invasive coronary angiography are undertaken.  
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1.3.2.2.6 	  Coronary	  angiogram	  	  
 
Whilst the non-invasive techniques gives you a likelihood of obstructive 
coronary artery disease, a coronary angiogram is an invasive technique that gives 
you a definitive anatomical diagnosis of the presence or absence of coronary 
artery disease. Additionally, functional severity of the coronary lesions can be 
assessed by measuring coronary flow velocity or fractional flow reserve (85). 
However, being invasive there are risks associated in undertaking this test and 
there is exposure to radiation.  
 
The 2010 National Institute for Health and Care Excellence guidelines suggests 
that patients with chest pain with an estimated likelihood of coronary artery 
disease of 10-29% should be offered a CT calcium score. If the calcium score is 
zero then it is advised to consider other causes of chest pain. If the calcium score 
is between 1-400, a CT coronary angiogram should be offered. If the calcium 
score is >400, then invasive coronary angiography should be offered instead. 
Intermediate risk patients with an estimated likelihood of coronary artery disease 
of 30-60% should be offered a non-invasive functional test, which includes 
myocardial perfusion scan, stress echocardiography or stress CMR. High risk 
patients, with an estimated likelihood of coronary artery disease of 61-90% 
should be offered invasive coronary angiography (93). 
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1.3.3 Treatment of angina 
 
The aim of treating patients with angina is for symptom relief and for prognostic 
reasons. Management of chronic stable angina includes treating conditions that 
can exacerbate angina (such as anaemia and thyrotoxicosis), treating traditional 
cardiovascular risk factors (including smoking, hypertension, 
hypercholesterolemia, diabetes, obesity), medication (antiplatelets, statins, ACE 
inhibitors, beta blockers, calcium channel blockers, nitrates, potassium channel 
activators, If channel inhibitors such as ivabradine and ranolazine) and coronary 
revascularization by percutaneous coronary intervention (PCI) or coronary artery 
bypass grafting (CABG). These various treatments have improved patients’ 
symptoms and prognosis. However, we seem to have forgotten that LVH itself is 
an independent predictor of cardiovascular disease and is associated with a poor 
prognosis. LVH may be considered to be a ‘silent killer’ as it can remain 
undetected for many years until finally developing arrhythmias, heart failure or 
sudden cardiac death.  Hence, detecting and treating LVH may yet be another 
approach of managing these cardiac patients.  
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1.4 LVH 
 
1.4.1 Definition of LVH 
 
 
LVH occurs when there is an increase in muscle mass of the left ventricle (LV). 
An increase in LV wall thickness or LV cavity size or both occurs in response to 
increased chronic workload and neurohormonal factors. It can occur in response 
to increased physiological workload (such as anaemia and exercise), pressure 
overload (such as hypertension and aortic stenosis) and volume overloaded 
conditions (such as aortic regurgitation and interatrial shunts).  According to 
LaPlace’s law, load on the myocardium is equal to (pressure x radius)/(2 x wall 
thickness). Therefore in the short term, this increase in muscle mass helps 
compensate for the increased wall stress but it may be harmful in the long term. 
Histologically, the cardiomyocytes increase in size (thickness and/or length) and 
fibroblasts proliferate leading to collagen deposition and fibrosis (94).  
 
1.4.2 Types of LVH 
 
 
There are four types of geometric LV patterns depending on the LV mass (LVM) 
and relative wall thickness (RWT). A normal LV has a normal LV mass (LVM) 
and RWT whilst concentric remodelling has a normal LV mass but increased 
RWT. Eccentric LVH tends to occur in response to volume overload and has an 
increased LV mass but normal RWT (95). In this type of hypertrophy, 
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sarcomeres are added in series leading to lengthening of cardiomyocytes.  
Concentric LVH tends to occur in response to pressure overload and has an 
increased LVM and RWT(95). Sarcomeres are added parallel leading to 
increased cardiomyocyte thickness (See Figure 9) (96). 
 
 
 
Figure 9. Differentiation between eccentric and concentric LVH (96) 
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1.4.3 Prevalence 
 
 
The prevalence of LVH quoted in studies varies depending on the population 
group being studied and the different LVM cut-offs that have been used to 
diagnose LVH over the years. The Framingham study was one of the initial big 
studies to assess the presence of LVH in the general population. In the 
Framingham study, a prospective epidemiological study of 4976 Framingham 
residents, LVH was detected in 16% of men and 19% of women using 
echocardiography (97). Whilst in the Tromso study, which looked at 3287 
subjects in Norway, LVH was detected using echo in 14.9% of men and 9.1% of 
women (98).   
 
LVH occurs commonly in patients with hypertension as a sign of end organ 
damage in response to the increased cardiac afterload. Its prevalence ranges from 
20-61% (99-104) depending on the cut-off values used to diagnose LVH. A 
study of uncomplicated hypertensives at a workplace treatment programme by 
Hammond et al. found LVH to be present in approximately 12% of subjects with 
borderline hypertension and 20% of subjects with uncomplicated, mild essential 
hypertension (99).  In the Treatment of Mild Hypertension (TOMHS) study 
involving 844 mild hypertensives, LVH (indexed to BSA) was detected in 13% 
of men and 20% of women whilst LVH (indexed to height) was found in 24% of 
men and 45% of women (100). One of the initial studies of subjects with mild to 
moderate hypertension found as many as 61% of them to have an abnormally 
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increased IVS or PW thickness (104). However, BP has not been found to be a 
reliable marker of the presence of LVH. In the Framingham, LVH was present in 
28% normotensive women aged > 65 years (97).  The presence of LVH has also 
been noted in normotensive high risk groups such as stable angina patients 
(prevalence of 69%) (105) and diabetics (prevalence of 26%) (106).  
 
Various studies have shown LVH to occur commonly in cardiac patients. In a 
study by East et al. of patients with documented coronary artery disease on 
cardiac catheterization, LVH was detected in 35% (107). Liao et al. also 
undertook a study on angiographically confirmed coronary artery disease but in a 
black, Chicago population group and found the prevalence of LVH to be 55.6% 
(108). More recently, a study of stable angina patients in Dundee, Scotland by 
Ang et al. found LVH to be prevalent in 73% (when LVM indexed to BSA) and 
75% (when LVM indexed to ht2.7) (105). Observational studies have also found 
LVH to be prevalent in other population groups: 41-72% of diabetics (109), 50% 
of patients with peripheral artery disease (110) and 74% of chronic kidney 
disease (CKD) (Table 4) (111, 112). 
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Studies Population studied Echo criteria of LVH 
  Male Female 
Levy (97) General > 150g/m2 >120g/m2 
Schirmer (98) General >145.5g/m >125.4g/m 
Hammond (99) Hypertension >134g/m2 >110g/m2 
Liebson (100) Mild hypertension ≥134g/m2 ≥110g/m2 
Ang (105) Angina >115g/m2 >95g/m2 
East (107) Coronary artery disease >134g/m2 >110g/m2 
Liao (108) Coronary artery disease >131g/m2 >100g/m2 
Rana (106) Diabetes >134g/m2 >110g/m2 
Dawson (109) Diabetes >134g/m2 
>50g/m2.7 
>110g/m2 
>47g/m2.7 
Wright (110) Peripheral artery disease >134g/m2 >110g/m2 
Foley (111) Chronic kidney disease >131g/m2 >100g/m2 
 
Table 4. Echo criteria for LVH that have been used in studies of various population 
groups. 
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1.4.4 Predictors of LVH 
 
 
LVH is a disease process that occurs commonly in cardiac patients as a result of 
haemodynamic and non-haemodynamic factors, including neurohormones. 
  
1.4.4.1 Hypertension 
 
 
Hypertension is a well-known, extensively studied risk factor for developing 
LVH. As already discussed, there is a high prevalence of LVH in the 
hypertensive population and studies have shown a significant positive correlation 
between office systolic BP (SBP) and LVM (r=0.29 to 0.48) (113, 114). High BP 
results in an increased LVM due to the increased cardiac afterload. It is a 
physiological adaptation of the heart to reduce wall stress, thereby preserving LV 
systolic function and preventing cardiac dilatation. In the Framingham Heart 
Study for every 20mmHg increase in SBP, there was a 43% increase in risk of 
LVH in men and 25% in women (97). 
 
However, 24 hr ambulatory BP measurements have been found to be more 
sensitive in indicating those who may have LVH compared to clinic BP 
measurements (115). Verdecchia et al. (1990) found that in the untreated 
hypertensives, the ambulatory SBP showed a closer correlation (r= 0.47) with 
LVMI than office SBP (r=0.35) (116). Higher LVMI has also been detected in 
patients who have morning blood pressure surges and ‘non-dippers’ (patients 
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who display little or no night time drop in blood pressure which is part of the 
normal circadian rhythm) (117, 118).  
 
However, BP is not the only cause of LVH. A study by Chen et al. demonstrated 
that SBP accounted for only 31% of the LVM variance. In fact they found that 
stroke volume was the most important determinant of LVM (50%) (119). 
Additionally, LVH has been detected in normotensive subjects. 
 
1.4.4.2 Obesity 
 
 
Obesity can directly and indirectly have effects on the heart. Increasing body 
weight is associated with haemodynamic changes resulting in increased blood 
volume and cardiac output. This volume overload leads to left ventricular 
dilatation and hypertrophy. Obesity is also associated with arterial hypertension, 
oxidative stress and insulin resistance which can predispose to LVH (120). 
Figure 10 shows the mechanisms whereby obesity can result in development of 
LVH.  
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Figure 10. Potential mechanisms via which obesity can influence structure and 
function of the heart (121) 
 
LVH has a dose response relationship with the severity and duration of obesity. 
In the Framingham study, for every 2kg/m2 increase in BMI there was a 47% 
increased risk of LVH in men and 51% in women. They also demonstrated the 
additive effects of BP and BMI on LVM resulting in a 17 fold increased risk of 
LVH compared to the absence of either risk factor (97). In the Tromso study, 
BMI was the most important variable for having LVH (98). In normotensives, 
the presence of obesity results in an approximately 18 fold increased risk of 
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LVH compared to normal-weight individuals (122). In the Strong Heart Study 
(SHS), LVM was found to correlate better with fat free body mass than with 
adipose mass, waist/hip ratio, height or height 2.7 (123). Obstructive sleep apnoea 
(OSA) is also frequently diagnosed in obese patients. Majority of previous 
studies have found OSA to be associated with LVH. This maybe due to the 
associated increased sympathetic tone, hypertension and intermittent hypoxia. A 
study by Avelar et al. looking at severely obese patients showed that the 
strongest independent predictor of LVH was the average nocturnal oxygen 
saturation <85% which was followed by BP and BMI (124). This study also 
suggested that nocturnal oxygen desaturation and not the apnoea-hypopnoea 
index maybe the true culprit for LVH. 
 
1.4.4.3 Diabetes or insulin resistance 
 
 
Patients with diabetes are well known to have an increased risk of developing 
LVH. In the Framingham study, the presence of diabetes or glucose intolerance 
in women was significantly associated with an increased LV wall thickness and 
LVM corrected for height (125). Additionally, a study of 173 type 2 diabetics 
attending a local diabetic clinic in Dundee found LVH (LVMI >134g/m2 in men 
and >110g/m2 in women) to occur in 32% of the diabetic patients (106). 
Following this, Dawson et al. carried out an echocardiographic study of 500 type 
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2 diabetics in Dundee of which 71% had LVH when LVM was indexed to 
height2.7 compared to 43% when LVM was indexed to BSA (109).  
 
This association between diabetes and LVH may be due to a number of factors 
including insulin resistance, increased oxidative stress, endothelial dysfunction, 
associated obesity and hypertension. Endothelial dysfunction increases LV 
afterload, thereby contributing to the development of LVH. The hyperglycemia 
also leads to non-enzymatic irreversible glycation of proteins resulting in the 
formation of advanced glycation end products (AGE products). These advanced 
glycation products activate protein kinase C, which induces proinflammatory 
cytokines, growth factor release, and fibrosis thereby resulting in endothelial 
dysfunction and cardiac hypertrophy (126).  
 
A number of large observational studies such as Framingham (127), Strong 
Heart Study (128, 129) and Whitehall have found a correlation between LVH 
and insulin resistance although other studies have given conflicting results (130, 
131). In animal studies, infusing insulin leads to an increase in LVM (132) 
whilst inhibiting IGF-1 results in a reduction in LVM (133). In the Progetto 
Ipertensione Umbria Monitoraggio Ambulatoriale (PIUMA) study of patients 
with essential hypertension, Verdecchia et al. concluded that insulin and insulin-
like growth factor-1 (IGF-1) levels independently predicted the LVM (134). 
Insulin is an anabolic hormone that could result in LVH by a number of 
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mechanisms. It binds to insulin or IGF-1 receptors resulting in increased DNA 
and protein synthesis (135). In addition to stimulating myocyte growth, insulin 
also stimulates collagen synthesis of the vascular smooth muscle cells (136). It 
also stimulates the sympathetic nervous system (137) and increases renal sodium 
reabsorption, thereby increasing blood volume (138). Figure 11 shows the 
potential mechanisms whereby insulin resistance can cause LVH. 
 
                                                                 
 
Figure 11. Potential mechanisms by which insulin resistance is associated with 
LVH (modified from Rutter et al.) (127) 
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1.4.4.4 Cardiovascular disease 
 
 
Earlier studies have shown cardiovascular disease to increase the risk of LVH 
development.  In the Tromso study, a history of cardiovascular disease had an 
OR of 2.22 for the presence of LVH (95% CI 1.63, 3.03) (98) whilst Liao et al. 
noted LVH to be more prevalent in the group with coronary artery disease 
(55.6%) compared to those without (44.3%) (108). This was again confirmed in 
the National Health and Nutrition Examination Survey (NHANES) II study 
where LVH patients were more likely to have had a previous MI (11.3% vs 
4.0%; p<0.05) (139). 
 
In the event of an MI, neurohormonal activation (sympathetic nervous system 
and renin-angiotensin-aldosterone system) and generation of ROS and 
inflammatory cytokines stimulate intracellular signalling processes that result in 
cardiac remodelling. There is thinning of the infarcted myocardium with reactive 
hypertrophic changes of remote myocardium and LV dilatation (140). See Figure 
12. 
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Figure 12. Diagram of the various factors involved in LV remodelling post MI 
(140) 
 
Subjects with CVD also tend to have risk factors such as DM and HT, which are 
associated with LVH development as discussed already. 
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1.4.4.5 Sympathetic Nervous System 
 
 
Animal studies have shown noradrenaline to stimulate myocardial cell 
hypertrophy via an α1 adrenergic mechanism (141, 142). Additionally a human 
study by Schlaich et al. showed that in a hypertensive population group, those 
that developed LVH had a significantly higher cardiac noradrenaline spillover 
(thereby indicating greater cardiac sympathetic activation) compared to those 
without LVH. However, the cardiac noradrenaline levels only explained 25% of 
LVM variance (143).  
 
1.4.4.6 Renin-angiotensin-aldosterone system (RAAS) 
 
 
The renin-angiotensin-aldosterone system plays a role in the pathogenesis of 
LVH development. In animal studies, angiotensin II has been demonstrated to 
induce myocyte hypertrophy (144, 145). Additionally, in patients with essential 
hypertension, angiotensin II levels positively correlated with LVH (146). In a 
study of 51 young, male normotensive or mildly hypertensive Caucasians, 
angiotensin II levels at high salt intake demonstrated a positive correlation with 
LVM in the hypertensive group which was independent of 24 hour ambulatory 
BP (147).  
 
Angiotensin II stimulates the development of myocardial hypertrophy by a 
number of mechanisms. Firstly it is a potent vasoconstrictor and secondly it 
 70 
potentiates the actions of the sympathetic nervous system, thereby increasing BP. 
Thirdly it increases oxidative stress by stimulating NADPH oxidase and fourthly 
it stimulates release of cytokines and growth factors that mediate myocyte 
hypertrophy. Fifthly angiotensin II stimulates fibroblastic activity (increasing 
myocardial fibrosis) and finally stimulates production of aldosterone which itself 
causes cardiac hypertrophy directly by its action on cardiac mineralocorticoid 
receptors and indirectly through its effects on blood pressure. 
 
1.4.4.7 Age 
 
 
In the Framingham study, the prevalence of LVH increased with age. LVH 
affected 6% of those aged less than 30 years compared to 43% of those aged 
over 69 years old. In fact the risk of LVH was found to increase by 15% in men 
and 67% in women for every increase in 10 years of age (97). The Tromso study 
found age to be a weak predictor of LVH, on multivariate analysis (98). On the 
other hand, the TOMHS study found that after adjusting for SBP and BMI, age 
was not related to increased LVMI (100).  
 
1.4.4.8 Genes 
 
 
Studies like the Framingham (148) and twin studies (149) have shown 
heritability to help explain some of the variance in LVM seen. In the 
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Framingham, the adjusted intra-class correlation for LVM was 0.15 for parent-
child (p<0.01), 0.16 for siblings (p<0.01), 0.06 for second-degree relatives 
(p=NS) and 0.05 for spouses (p=NS).  Heritability of adjusted LVM ranged 
between 0.24 for second-degree relatives to 0.32 for siblings. However, in a twin 
study undertaken by Swan et al, heritability helped explain 50% of LVM 
variance (p<0.01) (149). As these studies indicate a genetic role in LVM 
variance, recently there has been considerable research interest to help identify 
the responsible genes.  In 1994, Schunkert et al. found deletion polymorphism of 
ACE gene to be associated with LVH on ECG especially in normotensive males 
(150). However in the Framingham, no association was found between the ACE 
gene and echo LVM (151). As the previous studies had been underpowered, a 
meta-analysis of 52 studies was performed recently. This meta-analysis 
demonstrated DD homozygotes to have 1.59 times (95% CI 1.31, 1.92; p<0.01) 
increased risk of developing LVH compared to II genotypes. This associated risk 
was found to be more pronounced in males (OR 1.47; 95% CI 1.2, 1.8; p<0.01) 
and in subjects not on antihypertensives (OR 1.39; 95% CI 1.2, 1.62; p<0.01) 
(152).  
 
An experimental mouse study has also shown the expression of protein kinase C 
ß to result in cardiac hypertrophy (153). There have also been conflicting results 
regarding polymorphisms of the aldosterone synthase gene and LVH (150, 154). 
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The difficulty in identifying the responsible gene may be explained by the fact 
that multiple genes determine LVM and not just a single gene.  
 
1.4.5 Clinical score to identify LVH in patients with CAD 
 
 
A validated clinical risk score has been developed by Ang et al. to help identify 
the presence of LVH in cardiovascular patients (see Table 5). Of the risk factors, 
the presence of bundle branch block on ECG carried the highest adjusted OR of 
6.46 in predicting LVH (155).  
 
Risk factor Adjusted OR (95% CI) p value Points 
Age (>65 years) 1.94 (1.13-3.35) 0.02 1 
BMI (>30kg/m2) 2.17 (1.24-3.80) <0.01 1 
History of hypertension 2.18 (1.28-3.73) <0.01 1 
Previous MI 1.88 (1.01-3.48) 0.05 1 
High BP (>130/80mmHg) 1.73 (0.97-3.07) 0.06 1 
Bundle branch block on 
ECG 
6.46 (2.00-20.60) <0.01 4 
 
Table 5. Risk factors for LVH in CAD patients on multivariable analysis (155) 
 
As the LVH score increased, there was an increase in specificity and PPV but at 
the great expense of sensitivity and NPV (See Table 6) (155). 
 73 
 
LVH score Sensitivity 
(%) 
Specificity 
(%) 
PPV (%) NPV (%) 
≥ 1 98 11 53 88 
≥ 2 72 34 57 74 
≥ 3 66 70 69 67 
≥ 4 33 91 88 57 
≥ 5 16 97 84 53 
 
Table 6. Sensitivity, specificity, PPV and NPV of different cutoffs of LVH score in 
CAD patients (155) 
 
 
1.4.6 Methods diagnosing LVH 
 
1.4.6.1 ECG 
 
 
The 12 lead ECG was one of the initial methods of diagnosing LVH. In the 
Framingham study, LVH on ECG was present in 2.9% men and 1.5% women 
whilst on echo it was detected in 14.2% men and 17.6% women (156). ECG-
LVH has been associated with increased morbidity and mortality (157, 158). It is 
a cheap, easily performed, widely available test with a high specificity. However, 
LVH on ECG has a low sensitivity, thereby limiting its ability as a screening tool 
to identify patients with LVH. The Framingham ECG-LVH criteria had a 
sensitivity of 6.9% and a specificity of 98.8% (156). A study by Ang et al. also 
found the ECG to be insensitive in detecting LVH in patients with stable angina 
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(159). Over the years, more than 30 ECG-LVH criteria have developed that have 
been validated by echo. Despite this, their sensitivities remain between 20-60% 
(160-162). The sensitivity of the ECG however does depend on the population 
group it is applied to. Due to differences in sensitivity and specificity of the 
various ECG criteria, meeting of one set of criteria may not mean meeting other 
criteria also.  
 
Typical ECG changes found to be associated with the presence of LVH include 
increased QRS amplitude and duration, left axis deviation, prolonged intrinsicoid 
deflection and ST-T changes. The Sokolow-Lyon voltage (SLV) criterion, 
developed in 1949 is one of the most widely used criterion. As the QRS duration 
is an independent predictor of LVH, the product of Cornell voltage and QRS 
duration was found to significantly improve the detection of LVH (163).  The 
Cornell product was used in the Losartan Intervention for Endpoint reduction 
(LIFE) study and is in the European Society of Hypertension guidelines (2007) 
for assessing LVH on ECG (164) (Table 7). 
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Name Criterion Sensitivity 
(%) (165) 
Specificity 
(%) (165) 
Sokolow-Lyon 
voltage (166) 
SV1+RV5 or V6≥3.5mV 4-52 53-100 
Cornell-voltage 
(167) 
RaVL + SV3>2.8mV (men) 
RaVL + SV3>2mV (women) 
2-41 89-100 
Cornell-voltage 
duration product 
(168) 
(SV3+RaVL) x QRS duration ≥ 
2440mVms (men) 
[SV3+(RaVL+8mV)] x QRS duration 
>2440mVms (women) 
8-32 83-100 
Romhilt-Estes 
point score(169) 
 
Probable LVH if 
≥4 points 
 
Definite LVH 
if ≥5 points 
1. Any limb lead R wave or S     
wave≥2mV or SV1 or SV2 ≥3mV   or 
RV5 to RV6 ≥3mV  (3 points) 
2. ST-T wave abnormality                    
not on digoxin (3 points) 
on digoxin    (1 point) 
3. Left atrial abnormality                        
P terminal force in V1 > 1mm deep 
with duration ≥40msec (3 points) 
4. L axis deviation  ≥ -30°  (2 points) 
5. Intrinsicoid deflection in V5 or V6 
≥50 ms  (1 point)  
6. QRS duration ≥90 ms  (1point) 
 
 
 
7-68 
 
 
0-41 
 
 
 
85-99 
 
 
71-100 
 
Table 7. Various ECG LVH criteria sensitivity and specificity (165-169) 
 
The presence of left bundle branch block on ECG is often seen in cardiac 
patients post MI or with a conduction abnormality. However, studies of the 
ability of the traditional ECG criteria to diagnose LVH in the presence of left 
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bundle branch block have given conflicting results (170-175).  ECG diagnosis of 
LVH in the presence of left bundle branch block can be made upon fulfilling all 
three criteria (left atrial P wave abnormality, QRS > 155ms and precordial lead 
voltage criteria SV2+RV6 > 4.5mV) (170-175). Bundle branch block on an ECG 
has been shown to be associated with the greatest OR of predicting the presence 
of LVH in CAD patients (155). 
 
1.4.6.2 Echo 
 
 
For many years, echo has been the gold standard investigation for LVH and 
validating ECG-LVH criteria. It is eight times more sensitive in detecting LVH 
than ECG (156).  It is a safe, noninvasive test with widespread availability and 
low cost, thereby resulting in widespread use in clinical practice and in 
epidemiological research studies. It has also been validated in necropsy studies 
(176). 2D M-mode measurement is a commonly used echo method of assessing 
LVM.  In the parasternal long axis view, by aligning the beam perpendicular to 
the septum and just below the tips of the mitral valve, the M-mode obtained has 
clear endocardial border definitions to allow measurements to be made. 
Measurements are then put into a formula (such as Penn or Devereux modified 
cubed formula) to calculate LVM. Validation studies have shown good accuracy 
of using the M-mode calculation of LVM based on these cube formulae with 
necropsy (correlation coefficient > 0.9) (176). 
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Penn formula:    LV mass = 1.04 [(LVIDD+LVPW+IVSd)3 – (LVIDd)3]-13.6 
Devereux modified cubed formula:   
LV mass  = 0.8 [1.04 [(LVIDd+LVPW+IVSd)3 - (LVIDd)3]] + 0.6 
 
 
However, echo is limited by poor image quality in up to a third of cases (177-
179). It is a technique that is operator dependent in terms of accurate beam 
alignment and measuring wall thicknesses. Additionally, echo relies on LV wall 
thickness measurements taken in a 2D plane, a mathematical formula and 
geometric assumptions of the LV shape (a prolate ellipsoid shape with a 2:1 ratio 
of long to short axis lengths) to calculate this 3D structure. Small errors in 
measurements will result in a large effect on LVM due to the cubing in the 
formulas. Erroneous results can be obtained if M-mode is used in distorted 
ventricles. M-mode has also been suggested to overestimate LVM by 
comparison to MRI in studies of patients with hypertension (180) and 
haemodialysis patients (181). However, this was not found to be the case in 
necropsy studies. Compared to MRI, 2D echo has been shown to have poor 
accuracy (SE of the estimate of 29 to 79g; 95% CI 57, 190g) and poor 
reproducibility (SD of difference between successive measurements of 22 to 
40g; 95% CI 45, 78g) (182). Therefore, large patient numbers would need to be 
recruited in research studies and hence 2D echo isn’t the best imaging modality 
to monitor the effects of medication on LVM. 
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According to the latest American Society of Echo (ASE) guidelines (183), LVH 
is defined as LVM indexed to BSA >115g/m2 in men and > 95g/m2 in women. 
However, in the obese, indexing the LVM to BSA underestimates the presence 
of LVH whilst indexing the LVM to ht2.7 seems to be more accurate in this 
population group (184). LVH is defined as > 49g/m 2.7 for men and >45g/m 2.7 
for women. However, it is important to note that LVM is a normally distributed 
variable and is in fact quite artificial to have a specific cut-off value to diagnose 
a person with LVH. 
 
3D modalities such as 3D echo and cardiac MRI provide more robust 
measurements of LVM than 2D echo as it does not make geometric assumptions. 
3D echo has been shown to be comparable to CMR and has a reasonable 
reproducibility (95% CI ± 45g) (182). However, this technique requires skill and 
some patients may not have an adequate acoustic window to obtain images. See 
Figure 13. 
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Figure 13. Comparison of 3D echo and 2D echo with MRI for measurement of 
LVM.  A. 3D echo and CMR comparison for LVM measurement - Regression 
analysis (on left), Bland Altman plot (on right). B. 2D echo and CMR comparison 
for LVM measurement – Regression analysis (on left) and Bland Altman plot (on 
right) (185).  
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1.4.6.3 CMR 
 
 
There is a significant variation and poor correlation in LVM measurements 
obtained by M-mode echo and CMR. M-mode echo tends to overestimate LVM 
(180, 181, 186). In a subgroup study of Prospective Randomized Enalapril Study 
Evaluating Regression of Ventricular Enlargement (PRESERVE), echo was 
found on average to have LVM values 27.6g higher at baseline and 37.1g at 1 
year compared to MRI (187). In the past decade, CMR has been considered to be 
the gold standard of measuring LVM. Short axis stack is the most accurate 
method of assessing LVM. Compared to echo, MRI is more accurate as it does 
not make geometric assumptions and the myocardial borders are easily identified 
due to the superior spatial resolution and the contrast between myocardial tissue 
and blood. In a validation study of human postmortem hearts imaged ex-vivo, 
there is only a SD of difference of ~ 8g (95% CI ~15g) (188, 189). CMR is 
accurate even on assessing distorted ventricles such as post myocardial infarction 
(190) and hypertrophied ventricles (185). CMR is also highly reproducible to 
quantify LVM. CMR inter-study variability has a mean weighted SD of 
difference of 7.8g (95% CI 15.3g) (189, 191-193) compared to 27.7g and 19.2g 
respectively for M-mode and 3D echo (182). It also has a mean weighted intra-
observer variability of 4.8g and inter-observer variability of 9g (193, 194). To 
detect a significant change in LVM of 10g, it is claimed that only 10 to 23 
subjects will be needed for CMR (to power the study 80-99%) due to good 
reproducibility compared to 121 to 283 subjects for M-mode Echo and 58 to 136 
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for 2D echo (182). Other investigators feel the numbers proposed by these 
authors are too low. In addition, CMR will be the best modality to undertake 
serial monitoring to detect changes in LVM, even small ones, as it has a 95% CI 
of ± 12 to 22g (189, 191-193) compared to ± 45 to 78g for M-mode echo (189, 
191), ± 39g for 2D echo (195) and ± 13 to 45g for 3D echo (196). Other 
advantages of MRI include no contrast or ionizing radiation is required and there 
isn’t a problem of acoustic windows as with echo. 
 
However, MRI does have some drawbacks. It is not widely available, is 
expensive, needs specialized expertise and training to perform the scan and 
interpret images and scan time is at least 45 minutes. Additionally, it is difficult 
to obtain adequate images in patients with arrhythmias, patients need to be 
compliant with breath holding and can’t be claustrophobic and patients with 
pacemakers, defibrillators and certain metal implants are contraindicated. Post-
processing and interpretation of images can also be more time consuming 
compared to echo. As discussed already, short axis images are used to determine 
LVM. However, there is a need for subjective determination of the most basal 
slice near the mitral valve. As this basal slice has a large cross-sectional area, it 
will have a significant impact on the measurement of cardiac volume and mass 
(197).  
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Although FLASH (Fast Low Angle Shot MRI also known as fast gradient echo 
cine sequence) has been the traditional method for acquiring cine sequences for 
assessment of LV dimensions, in current practice SSFP (steady-state free 
precession or True FISP) cine sequences are used. It allows quicker imaging and 
improves endocardial and epicardial border definition with less blood flow 
dependence compared to FLASH, thereby enabling more accurate LVM and 
function assessment (198). On comparison with FLASH, LV mass 
measurements at end-systole and end-diastole are 4.8g and 6g respectively lower 
with SSFP (p<0.01) whilst the mean LV end-diastolic volume (LVEDV) and LV 
end-systolic volume (LVESV) are higher (5.6mL and 5.3mL respectively; 
p<0.01) (198).   
 
Most of the CMR studies so far have been undertaken using 1.5T machines. 
However, 3T machines are now starting to be used increasingly in research. It 
has a higher field strength and higher signal-noise ratio (SNR), which improves 
endocardial border definition and image quality compared to 1.5T. Importantly, 
the increased field strength has not shown to affect the measurements of cardiac 
mass or volume. Hence normal values for cardiac mass and volume 
measurements obtained using 1.5T MRI can also be used for 3T scans (199). 
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1.4.7 Implications/prognosis of LVH 
 
 
LVH is a strong risk factor for a poor prognosis due to cardiovascular events and 
all cause mortality in the general population (200), patients with hypertension 
(201), normotensives (139), coronary disease (202) and renal disease (203).  It is 
also reversible. LVH is said to be the ‘most reliable surrogate marker we have in 
cardiovascular medicine’ (204, 205). It has been associated with an increased 
risk of cardiovascular events including coronary heart disease, MI, heart failure, 
stroke and arrhythmias. 
 
In the Framingham study (a predominantly white general population group), the 
presence of LVH on the ECG was associated with a threefold risk of coronary 
heart disease after adjusting for hypertension (158). It also demonstrated LVH on 
echo to be associated with an adjusted relative risk for cardiovascular events of 
1.49 in men and 1.57 in women (200). After adjusting for risk factors, LVH was 
associated with HR of 2.16 for sudden cardiac death (95% CI 1.22, 3.81, p<0.01) 
and for each increment of 50g/m in LV mass, there was a 1.45 adjusted HR for 
sudden cardiac death (95% CI 1.10, 1.92, p<0.01) (206). Additionally, the 
presence of LVH in middle aged subjects had a six-fold increased risk of stroke 
(207). Table 8 summarizes the gender-specific adjusted RR of LVH for outcome 
events for each 50g/m increase in LVM.  
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Outcome event Men 
RR (95% CI) 
Women 
RR (95% CI) 
Cardiovascular disease 1.49 (1.20, 1.85) 1.57 (1.20, 2.04) 
Cardiovascular 
mortality 
1.73 (1.19, 2.52) 2.12 (1.28, 3.49) 
All cause mortality 1.49 (1.14, 1.94) 2.01 (1.44, 2.81) 
 
Table 8. Adjusted relative risk of outcome events for each 50g/m increase (200) 
 
In a 30 year follow up study of the Framingham population, the presence of 
LVH on ECG had similar risks for clinical presentation and mortality from 
coronary heart disease as the presence of unrecognized MI on ECG (208). In the 
MAVI study, an Italian prospective observational multicentre study of 1,033 
hypertensive subjects, the cardiovascular event rate was higher in the group with 
LVM ≥125g/m2 at 3.2 compared to 1.3 in the normal LVM group (<125g/m2) 
(p<0.01) (209). After adjusting for risk factors (such as age, smoking, diabetes 
and creatinine levels), the relative risk of cardiovascular events was 2.08 (95% 
CI 1.22, 3.57; p<0.01) and there was a 40% increased risk of events associated 
with an increase in LVM by 39g/m2 (95% CI 14, 73; p<0.01) (209) (see Figure 
14). 
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Figure 14. Cummulative incidence (left) and crude rate (right) of cardiovascular 
(CV) events in subjects with and without LVH on echocardiography (209). 
 
 
In the PIUMA study of patients with essential hypertension, there was a 
progressive increase in cardiovascular morbidity and all-cause mortality as the 
LVMI increased from quintile 1 to 5 (101). The quintile cut-offs for LVMI were 
gender-specific (men: 92, 105, 120 and 138g/m2; women: 79, 91, 102 and 
116g/m2) (see Figure 15). 
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Figure 15. Progressive increase in cardiovascular morbidity and all-cause 
mortality from first to fifth quintiles of LVMI (101) 
 
On multivariate analysis, patients with an LVMI in the third quintile and above 
(LVMI > 91.2g/m2 in women and >105.4g/m2 in men) had a significantly 
increased risk of cardiovascular events compared to the first quintile. However, 
in terms of all-cause mortality, only the patients in the fifth quintile of LVMI had 
a significantly increased risk compared to the first quintile. This is summarized 
in Table 9. 
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LVMI CVS events All-cause mortality 
 Adjusted HR 
(95 % CI) 
p value Adjusted HR 
(95% CI) 
p value 
Quintile 2 vs 1 1.55 (0.78, 3.08) 0.18 0.94 (0.19, 4.69) 0.94 
Quintile 3 vs 1 1.92 (1.01, 3.98) < 0.05 1.86 (0.48, 7.19) 0.37 
Quintile 4 vs 1 2.97 (1.51, 5.84) < 0.01 2.90 (0.82, 10.48) 0.09 
Quintile 5 vs 1 3.51 (1.82, 6.78) < 0.01 4.30 (1.16, 13.40) < 0.05 
 
Table 9. Adjusted HR of cardiovascular events and all-cause mortality according 
to LVMI quintiles (101) 
 
The authors also commented that there was a significantly increased 
cardiovascular event rate even at LVMI levels > 105g/m2 in men and > 91g/m2 
in women which are below the current cut-off level to diagnose LVH. 
 
Vakili et al. undertook a comprehensive review of 20 studies published between 
1960 and 2000 involving 48,545 subjects to assess the prognosis of LVH (210).  
LVH was diagnosed on ECG or echo using criteria or cut off values that varied 
between studies. The presence of LVH on ECG was associated with a 1.6 to 4 
times increased risk of cardiovascular events and 1.5 to 6.8 times increased risk 
of all-cause mortality. LVH detected on echo had an adjusted RR for 
cardiovascular morbidity of 1.5 to 3.5 and 1.0 to 8.0 increased risk of all-cause 
mortality. Additionally, there was a trend that females with LVH had a worse 
 88 
outcome than males. In the NHANES II mortality study, the presence of LVH 
had prognostic implications in both the hypertensives and normotensives (139).  
 
A number of studies have been carried out to assess if whether the type of LV 
geometry adds any additional prognostic information to LVM. Studies by Koren 
et al. (201) and Ghali et al. (95) showed adverse prognostic significance of 
concentric hypertrophy. However, the Framingham Heart study (211) and a 
study by Verdecchia et al. (212) showed that LVM and not its geometric pattern 
gave prognostic information. 
 
The prognostic value of LVH is independent of LV function and obstructive 
coronary artery disease (213). Cooper et al. (213) and Ghali et al. (202) have 
documented increased LVM to be associated with a worse prognosis of future 
mortality in those without CAD than with CAD.  
 
1.4.7.1 Implications of LVH in patients with CAD 
 
The presence and prognostic implications of LVH in CAD patients has been 
underappreciated despite evidence from a number of studies. A study of a 
predominantly black population undergoing coronary angiography between 1983 
to 1991 found the presence of LVH in patients with CAD to be associated with 
approximately twofold increased risk of five year mortality, after adjusting for 
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baseline characteristics and ejection fraction (108). On multivariate analysis, the 
presence of LVH (RR 2.4) was an even better predictor of mortality than multi-
vessel coronary disease (RR 1.6) or impaired LV function (EF <45%) (RR 2.0) 
(108). East et al. showed that the presence of LVH in patients with 
angiographically confirmed CAD to be the third best prognostic marker after age 
and coronary disease severity and to have a similar prognostic ability as ejection 
fraction. LVH was associated with an adjusted RR of 1.56 (95% CI: 1.35, 1.80) 
for all-cause mortality (107). 
 
In acute MI patients with single vessel disease, LVMI was found to be an 
independent predictor of cardiac events over a mean follow up period of 32 
months (214). The presence of LVH on ECG in acute MI patients is also 
associated with one and a half times increased one and five year mortality rates 
(215) and in patients who have undergone primary PCI,  detection of LVH on 
ECG has an increased risk of future cardiovascular events (216). Some studies 
have found concentric LVH geometry to be associated with the highest risk of 
cardiovascular events in MI patients (217, 218). 
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1.4.8 Mechanisms whereby LVH increases CVD risk 
 
 
1.4.8.1 Myocardial ischaemia 
 
 
The presence of LVH may result in myocardial ischaemia by a number of 
possible mechanisms. Firstly, risk factors of LVH such as age, BP and diabetes 
are also risk factors for the development of atherosclerosis, thereby increasing 
the risk of cardiovascular events. Secondly, LVH has been associated with 
changes in blood components such as white cell count, fibrinogen levels and 
blood viscosity, which increase the risk of cardiac ischaemia (219, 220). Thirdly, 
in LVH there may be a mismatch in myocardial oxygen demand and supply. The 
increased muscle mass increases oxygen consumption whilst there is reduced 
oxygen supply due to impaired coronary flow reserve. Numerous early studies 
have shown the presence of a reduced coronary reserve in hypertensives with 
LVH in the absence of obstructive coronary artery disease (54, 221, 222).  In a 
health screening programme of 70 year old males not known to have coronary 
disease, on exercise test the hypertensives with LVH had a significantly greater 
ST depression when compared to the healthy without LVH.  Additionally, the 
hypertensive and normotensive groups with LVH were more likely to develop 
ST depression than the healthy group without LVH (>20% compared with 5%) 
(223). Hypertensive patients with LVH have also been shown to develop 
thallium perfusion defects in the absence of obstructive coronary disease (224).  
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Reduced coronary flow reserve occurs due to the increased resting myocardial 
blood flow (as a result of increased muscle mass) and blunted coronary 
vasodilatory capacity. The reduced vasodilatory effect may be due to external 
compression of blood vessels by the increased left ventricular muscle mass, 
reduced subendocardial blood flow due to elevated LV end-diastolic pressure, 
increased coronary vascular resistance, reduced capillaries supplying 
myocardium, remodelling of coronary vessels and endothelial dysfunction (222).  
 
However, Vogt et al. found in a study of hypertensives with normal coronary 
arteries that there was no significant correlation between the degree of LVH and 
diminished coronary flow reserve. Instead the authors felt that the reduction in 
coronary flow reserve was secondary to vascular structural changes due to 
hypertension such as media hypertrophy, perivascular fibrosis and rarefication of 
arterioles (225, 226). 
 
1.4.8.2 Heart failure 
 
 
Studies of the general population (227, 228) and high-risk patients (229) have 
shown LVH to be a risk marker for the future development of heart failure. In 
the Cardiovascular Health study of 3,042 participants followed up over 5 years, 
increased baseline LV mass on echo or ECG was an independent predictor of 
depressed LV ejection fraction (228).  In the Heart Outcomes Prevention 
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Evaluation (HOPE) trial of 9541 patients with a history of coronary artery 
disease, stroke, peripheral vascular disease or diabetes with at least another 
cardiovascular risk factor, 793 (8%) had ECG evidence of LVH. Over a mean 
follow up period of 4.5 years, 6.1% of those with ECG-LVH developed heart 
failure compared to 2.9% without ECG-LVH (p<0.01) (229). Heart failure may 
arise in LVH due to neurohormonal activation, myocardial ischaemia or reduced 
LV compliance (resulting in diastolic dysfunction). 
 
1.4.8.3 Atrial fibrillation 
 
 
Traditional risk factors for atrial fibrillation (AF) include age, HT, DM, coronary 
heart disease and congestive cardiac failure. However, there is also a well-
established independent relationship between LVH and AF.  In the Framingham 
study, LVH on ECG was associated with 3-4 times increased risk of AF after 
adjusting for age which reduced to 1.4 times risk upon adjusting for other risk 
factors (230). Additionally, every increase of 4mm in LV wall thickness was 
associated with 28% increased risk of non rheumatic AF (230).  In the PIUMA 
study of 2482 subjects with essential HT, for every 1SD increase in LVM there 
was 1.2 fold increased risk of AF (95% CI 1.07, 1.34) (231) (see Figure 16). 
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Figure 16. Incidence of at least 1 episode of AF in hypertensive subjects in sinus 
rhythm with or without LVH on echocardiography (231) 
 
In LVH, the increased LV stiffness results in elevated LV end-diastolic pressure 
and left atrial pressure eventually leading to left atrial dilatation. In a LIFE sub-
study of 941 hypertensives with LVH on ECG, left atrial enlargement was 
detected in 56% of women and 38% men (p<0.01) (232). Additionally, the 
persistence or new development of LVH on ECG during a 3 year follow up 
period was associated with an increased risk of left atrial enlargement with an 
OR of 1.8 (95% CI 1.1, 3.2) and 3.1 (95% CI 1.3, 7.7) respectively (233). The 
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Framingham Study (230) and the Cardiovascular Health study (234) have shown 
left atrial dilatation to herald AF development. In the Framingham, for every 
5mm increase in left atrial size, there was a 39% increase risk of AF (230). In the 
PIUMA study, left atrial diameter lost its ability to significantly predict AF 
development upon adjusting for LV mass. However, in addition to age and LV 
mass, left atrial diameter independently predicted chronic AF (p<0.01) (231). 
Structural remodelling and fibrosis in left atrial dilatation results in 
electrophysiological changes (influencing atrial depolarisation, shortening of 
refractoriness and prolongation of conduction time) leading to the formation of 
multiple re-entrant wavefronts and hence increased risk of atrial arrhythmias 
(235). LVH is also associated with cardiovascular risk factors that can increase 
the risk of AF development. 
 
Left atrial size itself is an independent risk factor for major cardiovascular 
events. In the LIFE study of 881 hypertensives with LVH on ECG, baseline left 
atrial diameter/ht on Cox regression analysis had a HR of 1.98 (95% CI 1.02, 
3.83 per cm/m; p=0.04) for combined cardiovascular death, MI or stroke after 
adjusting for Framingham risk score and history of AF (236). Additionally in the 
Framingham study, upon multivariate adjustment every 10mm increase in left 
atrial size was associated with a RR for stroke of 2.4 in men (95% CI 1.6, 3.7) 
and 1.4 in women (95% CI 1.1, 1.7). However, this correlation of left atrial size 
and risk of stroke was attenuated on adjusting for LVM (237). 
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1.4.8.4 Ventricular arrhythmias 
 
LVH has been associated with an increased risk of ventricular arrhythmias, 
which may account for the increased risk of SCD seen in this population group.  
Studies of hypertensive populations have shown those with LVH to have an 
increased ventricular ectopic activity (238) and episodes of non-sustained VT 
(239). In a study of 123 men with mild hypertension, Siegel et al. showed the 
presence of echo LVH to have an OR of 2.7 for ≥ 30 ventricular premature 
complexes per hour (95% CI 0.9, 8.0), OR of 1.7 for multiform extrasystoles 
(95% CI 0.8, 3.7) and OR of 2.3 for VT (95% CI 0.7, 7.1) (240). Ghali et al. 
showed that in 49 hypertensive patients without coronary artery disease on 
angiography, the presence of LVH on echo (defined by wall thickness ≥ 1.2 or 
by LVM indexed to ht ≥163g/m in men and ≥121 g/m in women) was 
significantly associated with an increased frequency and complexity of 
ventricular arrhythmias (241).  Every 1mm increase in wall thickness (IVS or 
posterior wall) resulted in a twofold increased risk of ventricular arrhythmias and 
threefold increase in complexity of ventricular arrhythmias (241).  
 
Although not fully understood, there are numerous possible mechanisms to 
explain the arrhythmogenicity of LVH. Structural changes such as patchy 
interstitial fibrosis and collagen deposition affects the smooth propagation of 
electrical impulses through the myocardium. Additionally, there are 
electrophysiological changes of the hypertrophied myocardial cells that make 
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them pro-arrhythmic. They include prolongation of the action potential duration 
(242), slowing of membrane repolarisation (ie. increased QT interval resulting in 
generation of re-entry mechanisms) (243), repolarisation heterogeneity (resulting 
in increased incidence of T wave alternans) (244), generation of early and 
delayed afterdepolarisation (leading to triggered activity) (245) and expression of 
If channels (increasing automaticity) (246). Other possible mechanisms include 
associated myocardial ischaemia and neuroendocrine factors (sympathetic 
activity and RAAS) (247). 
 
1.4.9  LVH regression 
 
1.4.9.1 Implications of LVH regression 
 
 
Numerous studies mainly of the effects of various antihypertensive therapies on 
hypertensive subjects have shown the beneficial effects of LVM regression 
independent of BP. These studies have demonstrated LVH to be a poor 
prognostic risk marker that is reversible.  In the PIUMA study of 430 subjects 
with essential HT treated with antihypertensives and lifestyle measures, there 
was a reduced rate of cardiovascular events in those with LVM reduction (1.78 
per 100 person-years) compared to those with an increase in LVM (3.03 per 100 
patient-years) over a 2.8 years follow up period. In fact, a reduction in LVM was 
associated with a HR of 0.46 (95% CI 0.22, 0.99; p=0.04) for cardiovascular 
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events in a Cox regression model, after adjusting for age and baseline LVH on 
ECG (248) (see Figure 17). 
 
 
Figure 17. Event free survival in those with LVH (thick line) and without LVH 
(thin line) on echo at baseline (248) 
 
On a subgroup analysis of subjects with a baseline LVM>125g/m2, LVM 
regression was associated with a significantly reduced event rate of 1.58 events 
per 100 person-years compared to 6.27 events per 100 person-years in the non-
regressors (248) (see Figure 18). 
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Figure 18. Event rate in subset with echo LVH at baseline visit. Survival curve of 
those with regression (thin line) or persistence of LVH (thick line) at follow-up 
(248) 
 
A meta-analysis by Verdecchia et al. involving four studies and 1064 
hypertensive subjects assessed the impact of LVM reduction on cardiovascular 
risk in hypertension. The authors noted that regression of LVH was associated 
with a 59% reduced risk of cardiovascular events compared to those with 
persistent or new LVH on echo (p< 0.01) (249). 
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The LIFE study has shown LVH regression per se to be associated with reduced 
cardiovascular morbidity (myocardial infarction, stroke, heart failure and AF) 
and mortality, independent of blood pressure reduction (250-252). A 1-SD 
(25.3g/m2) reduction in LVMI on echocardiography was associated with a 38% 
reduction in cardiovascular mortality, a 15% reduction in myocardial infarction 
and a 24% lower rate of strokes (250). On electrocardiography, a reduction of 1-
SD of baseline mean by Cornell voltage-duration product criteria was associated 
with a 15% reduced risk of developing AF (252) and 28% reduced risk of sudden 
cardiac death (253). 1-SD of mean reduction on ECG using Cornell product 
criteria was associated with a 24% reduced risk of heart failure hospitalization 
(254). Additionally, patients with regression of ECG LVH over a 3 year follow 
up period was not significantly associated with an increased risk of left atrial 
enlargement as those with new or persistent ECG LVH changes (233).  This may 
alter these patients’ risks of developing AF in the future. 
 
1.4.9.2 Methods of LVH regression 
 
1.4.9.2.1 	  Pharmacological	  	  
 
In hypertensives, improved BP control has been found to be associated with 
LVH regression. Previous studies have noted that certain antihypertensives may 
be better in LVH regression compared to others and these effects may be even 
independent of blood pressure control. A meta-analysis by Klingbeil and 
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colleagues in 2003 found that in hypertensives, angiotensin II receptor blockers 
(ARBs), ACE inhibitors and calcium channel blockers were better at reducing 
left ventricular mass than beta blockers (255). However, a recent meta-analysis 
by Fagard et al. in 2009 did not show a significant difference in changes in LVM 
between the various drug treatments except that beta-blockers had less LVM 
regression compared to ARBs (256). 
 
The HOPE study, assessing the use of ramipril in high-risk patients with 
controlled BP, found that treatment with ramipril 10mg/day was associated with 
a significant reduction in LVMI compared to placebo (15). In the LIFE study, 
losartan was associated with a significantly greater ECG-LVH reduction and 
LVMI regression compared to atenolol. Importantly both drugs reduced blood 
pressure equally and hence the superiority of losartan over atenolol at LVH 
regression was independent of systemic BP (16, 257). In the Candesartan 
Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study, ARBs 
were noted to be as effective as ACE inhibitors in reducing LVMI in 
hypertensives with LVH.  In fact, a non-significantly higher proportion of 
patients on ARB therapy achieved normalisation of LVMI (36.3% vs 28.6%) 
(258).  Reducing systolic blood pressure (SBP) is effective in regressing LVM 
not only in the hypertensives but also in those patients within the normal BP 
range (259). 
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As aldosterone stimulates myocardial fibrosis and LVH, aldosterone antagonists 
such as spironolactone and eplerenone have been effective in regressing LVM in 
patients with hypertension and CKD (260-262). Statins, a drug commonly 
prescribed to patients with IHD, have also been shown in experimental and small 
scaled human studies to regress LVH by inhibiting neurohumoral activation of 
myocardium and inhibiting activation of Ras and Rho which play a role in 
oxidative stress, the production of nitric oxide and the activation of genes 
involved in myocyte growth (263).  
 
1.4.9.2.2 	  Non-­‐pharmacological	  
 
Non-pharmacological methods of LVH regression include reduction in weight 
and dietary sodium intake. As discussed already, obesity is a risk factor for the 
development of LVH. A study by MacMahon and colleagues of 41 young 
overweight hypertensive patients found that a mean weight reduction of 8.3kg 
was associated with a 16% LVM reduction which was independent of BP change 
(264). Additionally, weight loss by gastroplasty in normotensive morbidly obese 
patients led to a significant reduction in LV mass/ht index and LV dimensions in 
patients with baseline LVH (265). Sodium restriction over one year in mild-
moderate essential hypertension has also been shown to significantly reduce 
LVM by 5.4% and LVMI by 4.7% (266). Interestingly, the TOMHS study of 
844 mild HT found the addition of antihypertensive therapy to be no more 
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effective in LVM regression than just lifestyle changes to reduce weight, dietary 
sodium, alcohol consumption and increase physical activity (100). 
 
1.4.9.3 Normotensive LVH and regression 
 
 
As discussed previously, LVH also occurs in normotensive individuals. This 
may be because BP only accounts for 32% of variance of LVM. Other 
contributing factors for LVH development include age, race, obesity, insulin 
resistance/diabetes and neurohormones. As shown in the NHANES II mortality 
study, normotensives with LVH have a worse survival prognosis compared to 
normotensives or hypertensives without LVH (139). Hence, it is important to 
also treat these patients as aggressively as the HT with LVH (see Figure 19). 
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Figure 19. Age adjusted coronary heart disease survival probability based on Cox 
proportional hazards model (139) 
 
In a HOPE sub-study of high-risk patients with a mean BP of 131/76 and 
preserved LV ejection fraction, the group treated with 10mg ramipril/day was 
associated with a significant reduction in LVMI of 2.02 ± 2.25g/m2 over four 
years (p=0.02) (15). This benefit of ramipril on LVMI remained even after 
adjusting for age, gender, baseline LVMI and changes in BP. Additionally a 
CMR study by Simpson et al. in Dundee recently showed that even in 
normotensive patients with LVH, a further significant reduction in LVM was 
obtained on reducing SBP by ~ 9 mmHg with antihypertensive therapy (259). 
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1.4.10 CMR and Left atrial volumes 
 
The left atrium is an often forgotten chamber that provides information regarding 
the left ventricular diastolic function and is a predictor of cardiovascular events 
such as AF, heart failure, stroke and mortality (267-269). Left atrial volume is 
superior to area or diameter in predicting adverse cardiovascular outcomes (270). 
2D echocardiography has previously been the gold standard for measuring left 
atrial size but it is reliant on geometric assumptions and is user dependent. Left 
atrial volumes measured by 3D echo avoids the geometric assumptions and 
hence has better accuracy than 2D echo. It has been shown to correlate with 
measurements obtained by multidetector CT and MRI (the current gold standard) 
(271, 272). However, echocardiography tends to underestimate left atrial 
volumes compared to MRI, likely due to differences in spatial resolution (272). 
MRI is the current gold standard for measuring atrial volumes as it does not 
make geometric assumptions, there is good visualization of endocardial borders 
and hence there is accuracy and reproducibility.  
 
1.5  B-type natriuretic peptide (BNP) 
 
 
BNP is one of four natriuretic peptides that share a common 17-peptide ring 
structure. It is a neurohormone secreted predominantly by the ventricles in 
response to increased cardiac wall stress and tension. It is synthesized from the 
ventricular cardiomyocytes as a 132-amino acid peptide pre-pro BNP, which is 
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cleaved initially into pro-BNP, a 108 peptide, and then further cleaved into the 
biologically active 32-peptide BNP and the inactive 76-peptide NT-pro BNP 
(273). BNP causes vasodilatation, natriuresis, diuresis and inhibition of the 
renin-angiotensin and sympathetic system (273). BNP has a short half-life of 20 
minutes compared to 60-120 minutes for NT-pro BNP. The levels of natriuretic 
peptides are affected by age, gender, BMI and renal function.  
 
High ventricular filling pressures trigger secretion of BNP. Hence, there is 
considerable evidence using natriuretic peptides for diagnostic and prognostic 
purposes in patients with heart failure. It can also guide heart failure therapy 
(273). BNP levels are also elevated in the presence of myocardial ischaemia in 
patients with stable coronary artery disease and ACS (274-277). Higher BNP 
levels are associated with increased number of diseased coronary arteries (278, 
279). It also has a prognostic role in patients with stable coronary artery disease 
and ACS (274, 280, 281).  
 
BNP levels are elevated in the presence of LVH. In a study of 320 hypertensive 
patients, using a BNP cut-off value of 35pg/ml was 73% sensitive and 72% 
specific in diagnosing echo diagnosed LVH (282). Additionally, in an MRI study 
of hypertensive patients, a NT-proBNP cut-off value of 35pg/ml was 100% 
sensitive and 70.6% specific in diagnosing LVH (283). BNP correlates with 
LVM as pressure and volume overloaded situations stimulate both BNP release 
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by ventricles and ventricular hypertrophy. In a group of 215 patients referred to 
the hospital for breathlessness, NT-proBNP levels were significantly elevated 
patients with LVH whilst the presence of HT did not significantly affect the BNP 
levels (284). In an MRI study of hypertensives, there was a significant 
correlation between left ventricular mass and the NT-proBNP level (r=0.598; 
p<0.01) (283). In patients with hypertrophic cardiomyopathy, plasma NT-
proBNP levels have also shown a positive correlation with LVMI (r=0.27; 
p=0.05) (285) and depended on the severity of hypertrophy (286).  
 
BNP also provides prognostic information in patients with LVH. In a LIFE sub-
study, Olsen and colleagues showed that in 183 patients with HT and LVH, NT-
proBNP above the median value of 21.8 pmol/ml was significantly associated 
with an increased incidence of the composite endpoint of cardiovascular death, 
non-fatal stroke or MI in the 123 patients without a history of diabetes or 
cardiovascular disease. However, there was a non-significant increased risk of 
the composite endpoint with the 60 patients with a history of diabetes or 
cardiovascular disease (287). 
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1.6 Uric acid 
 
As discussed previously, uric acid is an end-product of the purine degradation 
pathway that is excreted by the kidneys. Humans tend to have higher uric acid 
levels than other mammals due to inactivation of the uricase enzyme gene during 
the Miocene period 5-20 million years ago, which tends to breakdown uric acid 
into allantoin (288). Uric acid levels are higher in men, postmenopausal women, 
obesity, renal impairment, metabolic syndrome and those taking diuretics such as 
thiazides (289). Postmenopausal women have raised uric acid levels due to the 
loss of uricosuric effect of oestrogen (290). Uric acid has both pro-oxidant and 
anti-oxidant properties (291). Under normal circumstances, uric acid acts as an 
antioxidant by scavenging reactive oxygen species, chelates transition metals and 
blocks inactivation of antioxidant superoxide dismutase (289). However, 
otherwise uric acid becomes pro-oxidant resulting in endothelial dysfunction. In 
the presence of ruptured atherosclerotic plaques, a antioxidant-prooxidant uric 
acid redox shuttle occurs whereby the leak of iron and copper metal ions from 
the plaque undergoes the Fenton and Haber-Weiss reaction (292). See Figure 20.  
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Figure 20. Antioxidant-prooxidant uric acid redox shuttle. It helps explain how the 
antioxidant uric acid becomes prooxidant in this environment, resulting in damage 
to endothelium and arterial vessel wall remodelling (292). 
 
Increased serum uric acid levels have been shown to be associated with 
increased cardiovascular mortality (293, 294) and having increased 
cardiovascular events (295). Numerous epidemiological studies have shown a 
relationship between serum uric acid levels and hypertension, metabolic 
syndrome, coronary artery disease, stroke, heart failure and CKD (296).  This 
association between serum uric acid levels and cardiovascular disease is not only 
seen in those with significantly raised uric acid levels (>360micromol/l in 
women and >420micromol/l in men) but also in those in the normal to high 
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range (310-330 micromol/l) (296).  Additionally, the effect of serum uric acid 
level on cardiovascular events seems greater in women than in men (293, 295).  
Figure 21 illustrates possible mechanisms uric acid may mediate cardiovascular 
disease, hypertension and CKD (291).  
 
 
Figure 21. Possible mechanisms uric acid might mediate cardiovascular disease, 
hypertension and chronic kidney disease (291) 
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Other studies have suggested that serum uric acid is not a risk factor for 
cardiovascular disease but is associated with other cardiovascular risk factors 
such as hypertension, renal disease and increased lipoprotein levels (297). 
 
1.6.1 Uric acid and hypertension 
 
Elevated serum uric acid levels have been shown in numerous studies to be an 
independent predictor of hypertension (291). A meta-analysis of 18 cohort 
studies in 2011 showed hyperuricaemia to have an increased risk for 
hypertension with an adjusted risk ratio of 1.41 (95% CI 1.23, 1.58). Every 
1mg/dl increase in uric acid level had an adjusted RR of 1.13 (95% CI 1.06, 1.2). 
The increased risk seemed greater in the younger subjects (p=0.02) and in 
women (p=0.06) (298). However, it is still unclear whether uric acid is the cause 
or is the consequence of hypertension. Animal studies have shown uric acid to 
cause hypertension by activating the renin-angiotensin system, downregulating 
NO, inducing endothelial dysfunction and proliferation of smooth muscle cells in 
the endothelium (299, 300). Additionally, the development of hypertension was 
avoided by a XO inhibitor or uricosuric agent (300). However, during the 
production of uric acid there is also generation of superoxide free radicals and so 
some of these effects may be actually related to the presence of the free radicals. 
 
 111 
1.6.2 Uric acid and LVH 
 
Uric acid has been identified to be independently associated with LVMI (301). 
After adjustment, each SD increase in uric acid levels has been associated with a 
75% increased risk of LVH (302). In hypertensive Japanese patients, Kurata et 
al. found serum uric acid levels to correlate with LVM and LVMI in males but 
not females (303). More recently, Mitsuhashi et al. showed high uric acid levels 
to be associated with LVH diagnosed on ECG in healthy Japanese men (304). 
 
Uric acid may be associated with LVH due to its effects on smooth muscle cell 
proliferation, endothelial dysfunction and stimulating inflammatory mediators 
such as TNF-α and MAPK, which are involved in the hypertrophic signalling 
pathway (305-307). It may also be due to its correlation with other factors that 
may be related to developing LVH such as obesity, renal dysfunction, 
hypertension and insulin resistance (301). However, randomized studies are 
required to assess if uric acid is a cause of LVH. In fact these randomized trials 
would need to use probenecid rather than allopurinol since the former reduces 
uric acid only whereas allopurinol reduces both uric acid and oxidative stress and 
either of these mechanisms could be involved in producing LVH. 
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1.6.3 Uric acid and endothelial dysfunction 
 
Some studies have shown uric acid to cause endothelial dysfunction whilst 
others have not. An infusion of uric acid in healthy volunteers has been shown to 
worsen endothelial function (289) whilst lowering of uric acid with XO 
inhibitors improved endothelial function (291). Other studies have shown an 
infusion of uric acid to improve endothelial function in Type 1 diabetics and 
smokers (308), raised serum uric acid level not to be associated with endothelial 
dysfunction in healthy individuals (309) and lowering of serum uric acid in type 
2 diabetics did not improve endothelial function in type 2 diabetics (310). 
 
Uric acid can cause endothelial dysfunction by a number of mechanisms. Firstly, 
uric acid reacts with NO resulting in reduction of NO availability. Secondly, uric 
acid is pro-inflammatory activating MAPKs and nuclear transcription factors 
NFKB, resulting in release of growth factors and vascular smooth muscle cell 
proliferation (289) (see Figure 22). Thirdly, it activates the renin-angiotensin-
aldosterone system (291). However the uric acid molecule is also an antioxidant. 
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Figure 22. Pathway for uric acid mediated smooth muscle cell proliferation. Uric 
acid enters via an anion exchanger/transporter (OAT) where it alters intercellular 
redox, activates mitogen activated protein (MAP) kinases, cyclooxygenase-2 
(COX2) and nuclear transcription factors leading to production of thromboxane, 
platelet derived growth factor (PDGF) and monocyte chemoattractant protein-1 
(MCP-1) (289). 
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1.7 Allopurinol 
 
1.7.1 Background 
 
 
Allopurinol (1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one) is a xanthine 
oxidase inhibitor that was developed in the 1950s during the search for new 
cancer treatments. Its discovery resulted in the 1988 Nobel Prize in Physiology 
and Medicine being awarded to Gertrude Elion and George Hitchings (30). 
Allopurinol also received Food and Drug Administration (FDA) approval as a 
prophylactic treatment for gout in 1966.  
 
As already discussed, XO is an enzyme involved in the terminal part of the 
purine degradation pathway resulting in the formation of uric acid and ROS. As 
this enzyme has also been shown to play a role in various cardiovascular 
conditions such as ischaemia, hypertension, heart failure and endothelial 
dysfunction, XO inhibition has been shown to be beneficial in these conditions 
(30). 
 
Allopurinol, a weak acid (acid dissociation constant, pKa 9.4), is an analogue of 
hypoxanthine. It acts as a competitive XO inhibitor at low concentrations but is a 
non-competitive inhibitor at higher concentrations. It is a prodrug that is 
oxidized by aldehyde oxidoreductase (AOR) into its active metabolite 
oxypurinol. For every 100mg of oral allopurinol, ~ 90mg oxypurinol is formed. 
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Oxypurinol, a stronger acid than allopurinol (pKa 7.7), is an analogue of 
xanthine and a non-competitive XO inhibitor (30). It is mainly responsible for 
the pharmacological effects of allopurinol as it has a very long half-life, hence 
attaining high plasma concentration levels. 
 
There has also been a lot of interest to develop newer, more potent XO inhibitors 
in the last decade (see Figure 23). Febuxostat is one of the newer drugs that has 
been approved in the last 5 years as a treatment for gout. 
 
 
 
Figure 23. Chemical structures of xanthine oxidase inhibitors (30) 
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1.7.2 Pharmacokinetics and Pharmacodynamics 
 
 
Oral allopurinol is absorbed rapidly from the gastrointestinal tract with a good 
oral bioavailability of 79 ± 20%. 300mg allopurinol reaches peak concentrations 
of 2mg/L at ~1.5 hours and has a mean t½ of 1.2 hours. Oxypurinol, on the other 
hand, takes longer to reach peak levels (~ 4 hours to reach peak concentration of 
7mg/L) with a mean t½ of 23 hours in healthy volunteers. However in patients 
with normal renal function, there is considerable variability in t½ of oxypurinol 
of 9-38 hours (311). The steady state plasma concentration levels of oxypurinol 
are proportional to allopurinol dosage. After oral intake, the mean volume of 
distribution (Vd/F) of allopurinol is 1.31 ± 0.41L/kg compared to 0.59 ± 
0.16L/kg for oxypurinol. A single dosage of allopurinol results in uric acid 
concentration levels to fall to its minimum over 6 to 24 hours and takes more 
than 48 hours to recover due to the long t½ of oxypurinol and uric acid. 
 
Oxidation to oxypurinol is the main route of elimination of allopurinol. The 
mean renal clearance (CLR) of allopurinol is 1.54mL/min/kg. Oxypurinol on the 
other hand is mainly renally excreted with a mean CLR of 0.34mL/min/kg (311). 
Therefore, it is important to reduce allopurinol dosage in the presence of renal 
impairment. In the kidneys, oxypurinol easily undergoes glomerular filtration in 
view of being unbound and of small molecular size. However, oxypurinol 
reaches high peak concentrations due to the significant tubular resorption. 
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Allopurinol’s pharmacokinetics and pharmacodynamics per se are not affected 
by ageing. However, oxypurinol is affected by ageing due to the coexisting 
reduction in renal function. In the elderly, oxypurinol undergoes less clearance 
(0.24 ± 0.03 in elderly compared to 0.37 ± 0.05ml/min/kg in the young), has a 
reduced volume of distribution (0.6 ± 0.09 vs. 0.84 ± 0.07l/kg), achieves 
increased peak plasma concentration levels (5.63 ± 0.83 vs. 3.75 ± 0.25mcg/ml) 
but has a reduced ability to inhibit xanthine oxidase (time-dependent reduction of 
plasma uric acid of 83 ± 30 vs. 176  ± 21mcg/ml/h) (312). 
 
1.7.3 Dosage 
 
 
The initial dosage is 100-200mg with a maximum single dosage of 300mg. The 
daily dosage can be adjusted gradually every 2-4 weeks to avoid precipitating 
acute gout and to avoid side effects. Usual maintenance doses in gout are 100-
200mg in mild gout, 300-600mg in moderate gout and 700-900mg in severe 
gout.   
 
1.7.4 Drug interactions 
 
 
Alcohol reduces the pharmacological effects of allopurinol by inhibiting its 
conversion to oxypurinol. Allopurinol increases the risk of rash when given with 
amoxicillin. Allopurinol also increases anticoagulant effect of warfarin therapy. 
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It has been shown to increase plasma concentration of cyclosporin and 
theophylline when given concomitantly and also increases the effects of 
cytotoxics such as azathioprine and mercaptopurine (313). 
 
1.7.5 Side Effects 
 
 
Allopurinol is a safe drug that has been used for over 40 years as a treatment for 
gout. However, there are associated side effects, which tend to be mild. Skin 
rashes are the most common side effect and tend to be reversible on withdrawing 
therapy. They may be pruritic, maculopapular or exfoliative. Other side effects 
include gastrointestinal (nausea and vomiting), malaise, headaches, vertigo, 
visual and taste disturbances, hepatotoxicity, neuropathy and blood disorders 
such as leucopenia, thrombocytopenia, haemolytic and aplastic anaemia (313). A 
rare but potentially fatal reaction associated with allopurinol therapy is 
allopurinol hypersensitivity syndrome (AHS) or drug reaction with eosinophilia 
and systemic symptoms (DRESS syndrome). Patients develop a fever, 
exfoliative rash, lymphadenopathy, arthralgia, eosinophilia, vasculitis, hepatitis 
and deterioration in renal function. These patients should have their allopurinol 
stopped immediately and occasionally corticosteroid therapy may even be 
required. Risk of developing this generalized hypersensitivity reaction is 
increased in the elderly with reduced renal function where the allopurinol dosage 
should have been reduced (313). The EuroSCAR study has shown higher doses 
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of allopurinol (>200mg/day) to be associated with an increased risk of 
developing Stevens-Johnson syndrome and toxic epidermal necrolysis compared 
to lower dosages (314).  The presence of HLA-B*5801 allele is also an 
important genetic risk factor for developing severe cutaneous reactions. This 
genetic allele is more commonly seen in the Han Chinese, Thai and Japanese 
population than in the Western European population (315).  Caution is advised 
for allopurinol therapy in patients with renal or hepatic impairment, pregnancy 
and breastfeeding (313).   
  
1.7.6 Allopurinol therapy in various diseases 
 
1.7.6.1 Myocardial ischaemia/ infarction 
 
 
Ischaemic-reperfusion injury is myocardial damage by ROS that occurs on 
restoration of blood flow to ischaemic tissue. Increasing evidence supports the 
role of XO in ischaemia-reperfusion injury that was hypothesized by Granger et 
al. in 1981 and McCord in 1985. During ischaemia, there is increased ATP 
breakdown leading to the increased hypoxanthine and xanthine levels and 
increased production of XO. During reperfusion, XO generates superoxide 
radicals from the oxygen restored to the tissues resulting in tissue damage (24). 
 
The role of XO in the pathogenesis of an MI has been extensively studied with 
conflicting evidence since the 1980s. Numerous experimental and human studies 
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have shown allopurinol therapy in the setting of an MI to reduce myocardial 
infarct size, reduce LV remodelling, improve ventricular function and reduce 
reperfusion-induced arrhythmias (30). Allopurinol achieves this by inhibiting 
myocardial XO activity, thereby decreasing myocardial lipid peroxidation and 
superoxide formation, and its direct free radical scavenging effects. However, 
other studies have not been able to confirm the beneficial effects of allopurinol 
therapy on myocardial ischaemia-reperfusion injury (30). 
 
In the event of an acute MI, patients are currently treated with primary coronary 
intervention. As during reperfusion there is generation of reactive oxygen 
species, studies have been undertaken assessing the effect of allopurinol in 
patients undergoing primary PCI.  In a randomized controlled trial (RCT) of 38 
acute MI patients undergoing primary coronary angioplasty, a single 400mg 
pretreatment dose of allopurinol inhibited free radical production, resulted in a 
lower incidence of no-reflow or slow reflow of culprit artery (p=0.05), had a 
significantly higher cardiac index immediately post PTCA (p=0.02) and had a 
higher LVEF at 6 months compared to the control group (p=0.04) (316). In 
another small randomized, controlled study of 40 patients presenting with an 
acute STEMI undergoing primary PCI, 400mg of allopurinol/ placebo therapy 
was administered acutely and then 100mg was prescribed for a further month. 
Allopurinol was associated with greater ST elevation recovery (p<0.05), lower 
troponin level (p=0.04) and a lower major adverse cardiac events at one month 
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follow up (p<0.01). However, there was no significant benefit on LV function 
(317). 
 
It is important to note that the theory of ischaemia-reperfusion injury is 
applicable mostly in the setting of an MI resulting in myocardial damage and 
hence reduction in LV function. In the setting of ischaemia alone, the 
phenomenon of ischaemia-reperfusion is less relevant than in an MI ie. LV 
dysfunction is less likely after ischaemia than after infarction.  
 
Allopurinol has been used in the setting of cardiac bypass surgery. Some but not 
all studies have shown allopurinol to reduce inhospital mortality rate, reduce 
perioperative MI, reduce cardiac arrhythmias, improve cardiac function and 
hence reduce the need for inotropic support postoperatively (30). 
 
In a study of ischaemia alone, allopurinol has also been shown to have anti-
ischaemic effects in angina patients. In a double-blind cross over study of 65 
chronic stable angina patients, 600mg allopurinol for 6 weeks significantly 
increased median total exercise time (from 301s at baseline to 393s; p<0.01), 
median time to ST depression (from 232s at baseline to 298s; p<0.01) and time 
to angina chest pain (from 234s at baseline to 304s; p<0.01) on undertaking an 
exercise treadmill test. The anti-ischaemic effects of allopurinol might have been 
due to reduced myocardial oxygen consumption and increased ATP energy 
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supply to ischaemic tissues as a result of reduced oxidative stress (318). On the 
other hand, offloading of the LV by allopurinol may have also contributed to this 
anti-ischaemic effect. It is unlikely that relief of ischaemia-reperfusion injury 
caused this anti-ischaemic effect of allopurinol as the anti-ischaemic effect was 
seen at peak exercise before any reperfusion would have occurred. 
 
1.7.6.2 Heart Failure 
 
 
XO plays a role in heart failure. In animal studies, the myocardial XO activity 
increases approximately four times with heart failure induced by pacing. In 
chronic heart failure, increased XO levels and activity have been shown to 
contribute to the high levels of oxidative stress seen in this condition. 
Additionally high uric acid levels are frequently seen in heart failure due to its 
increased production and reduced renal excretion (30). Hence one would expect 
XO inhibition to be beneficial in this patient group. A retrospective study of 
1760 chronic heart failure patients found that long-term high dose allopurinol 
therapy of ≥ 300mg had a lower long-term mortality than low dose allopurinol 
therapy of <300mg (RR 0.59; 95% CI 0.37, 0.95) (319).  These findings were 
confirmed in a more recent population-based cohort study of 4785 heart failure 
patients (320). 
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“The failing heart - an engine out of fuel” (321). ATP is required for myocardial 
contraction, which is depleted in heart failure. In heart failure a phenomenon 
called “mechanoenergetic uncoupling” occurs which is the reduced efficiency of 
each myocardial contraction or loss of balance between ventricular work 
performed and amount of oxygen consumed. One of the possible mechanisms for 
this phenomenon is the upregulation of XO activity and reduction of NO 
synthase activity in heart failure (322).  
 
Experimental and human studies have shown XO inhibition to have an inotropic 
effect and also improve the efficiency of myocardial contraction (19, 20). 
Cappola et al. administered intracoronary allopurinol to nine optimally medically 
treated heart failure patients with idiopathic dilated cardiomyopathy and found a 
significant reduction in myocardial oxygen consumption (MVO2 peak effect, -16 
± 5%; p<0.01) and an improvement in myocardial efficiency (peak effects: 
dP/dtmax/MVO2 22±9%, SW/MVO2 40 ± 17%; p<0.05) without affecting 
cardiac load or systemic haemodynamics (19).  
 
Opie recently illustrated potential sites of action of allopurinol for heart failure as 
shown in Figure 24. 
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Figure 24. Potential sites of action of allopurinol therapy in heart failure (323) 
Pathways indicated by numbers: 1) hypoxanthine phosphoribosyl transferase; 2) 
inosine kinase activity; 3) low-activity salvage path; 4) myokinase activity; 5) 
oxidative phosphorylation; 6) adenine phosphoribosyl transferase; 7) adenosine 
kinase. AMP=adenosine monophosphate; FFA=free fatty acid; IMP=inosine 
monophosphate. 
 
Hirsch et al. showed allopurinol to improve myocardial energy delivery to 
failing hearts, by increasing high-energy phosphate stores (creatine phosphate, 
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ATP) and increasing ATP flux via creatine kinase (CK) by attenuating the 
inhibition of CK by ROS. Allopurinol also increases the amount of free energy 
released during ATP hydrolysis (324). These mechanisms enable allopurinol to 
improve mechanoenergetic uncoupling seen in heart failure. 
 
Studies have also shown beneficial effects of allopurinol therapy on endothelial 
dysfunction in heart failure (will be discussed in further detail in the section on 
allopurinol therapy in endothelial dysfunction) and significantly reduces BNP 
levels (325, 326), which is a prognostic marker of heart failure and a measure of 
intracardiac pressure. However despite this, there has been no beneficial effect of 
allopurinol therapy noted on the exercise ability in chronic heart failure patients 
(325).  
 
The OPT-CHF (Oxypurinol Therapy for Congestive Heart Failure) study failed 
to show any benefit of XO inhibition on the composite endpoint of heart failure 
morbidity, mortality and quality-of-life. However, a major flaw of the study was 
the inadequate dosage of XOI used. 600mg of oxypurinol was prescribed which 
is bioavailability equivalent to only 81mg allopurinol (327). Currently, the 
EXACT-HF study is enrolling 250 heart failure patients with high uric acid 
levels into a randomized controlled study to assess the effects of allopurinol on 
composite end points, quality of life and six-minute walk test. 
 
 126 
1.7.6.3 LVH 
 
 
Xanthine oxidase inhibitors have been shown to have beneficial effects on LVH 
in animal studies (328-330), in patients with heart failure (331) and in CKD 
patients (332). Allopurinol therapy of patients with CKD stage 3 over a 9 month 
treatment period significantly regressed LVM (332). However, renal patients 
have very high levels of OS compared to optimally treated patients with IHD 
which means we cannot be sure that optimally treated IHD patients will have 
enough OS for allopurinol to alter their LVH. Following on from these studies, 
the primary objective of this research study was to assess if allopurinol can 
regress LVM in patients with IHD and LVH. 
 
1.7.6.4 Endothelial dysfunction  
 
 
Previously published studies have shown allopurinol to reduce endothelial 
dysfunction associated with various conditions known to have high levels of 
oxidative stress including type 2 diabetes (333), heart failure (22, 326), CKD 
(332) and chronic stable angina (334). Allopurinol has also been shown to 
improve arterial stiffness in patients with chronic stable angina (334), stroke 
(335) and CKD (332).  
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2 METHODS 
 
2.1 Study Aims 
 
 
The main aim of this study was to assess the ability of xanthine oxidase 
inhibitors (using high dose allopurinol therapy) to regress LVM in patients with 
LVH and IHD. The secondary aim of this study was to assess the effects of 
allopurinol on endothelial function in patients with LVH and IHD. 
 
2.2 Study Hypothesis 
 
 
That nine months of allopurinol therapy will lead to a reduction in LV mass in 
patients with left ventricular hypertrophy and ischaemic heart disease when 
compared to placebo therapy. 
 
2.3 Study Overview 
 
 
This study was conducted between April 2009 and February 2011 at a single 
centre, Ninewells hospital, Dundee, Scotland. It was approved by the Tayside 
Research Ethics Committee (reference number 09/S1401/3) and was done in 
accordance with the Declaration of Helsinki. Approval was also obtained from 
the Medicines and Healthcare products Regulatory Agency (MHRA) (reference 
number 21726/0264/001-0001). All participants provided written informed 
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consent after receiving a patient information sheet at least 24 hours before. This 
study was registered with the International Standard Randomized Controlled 
Trial Number register ISRCTN 73579730. 
 
2.4 Trial Design, Randomization and Masking 
 
 
This study had a randomized, double-blind, placebo controlled, parallel group 
design which was undertaken over a nine month follow up period. A computer-
generated random allocation sequence was employed and a copy was kept in the 
Clinical Trials Pharmacy department. The participants and the research team 
directly involved in the study did not have access to this allocation sequence. 
Additionally, the serum uric acid samples were not analyzed until end of the 
study.  
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2.5 Study Participants 
 
 
Sixty-six adult participants were recruited from Ninewells hospital cardiology 
databases and local general practices between April 2009 and April 2010.  
 
Inclusion criteria: 
1. History of MI or chronic stable angina with a positive stress test (exercise 
treadmill test or myocardial perfusion scan) or angiographically 
documented significant coronary artery disease 
2. BP < 150/90 mmHg 
3. Presence of LVH on echocardiography based on ASE criteria: LVMI 
>115g/m2 for men and > 95g/m2 for women (183) 
 
Exclusion criteria: 
1. Already taking allopurinol  
2. Prescribed azathioprine which interacts with allopurinol 
3. Previous adverse reaction to allopurinol 
4. Had active gout  
5. Renal dysfunction (eGFR< 60ml/min): These patients were excluded as 
high dose allopurinol will be prescribed in this study and allopurinol is 
known to have increased side effects in renal impairment  
6. Heart failure or LVEF < 45% 
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7. Contraindications to undergoing an MRI scan such as pacemakers or 
claustrophobia  
8.  Malignancy, pregnant, lactating or unable to give informed consent 
 
2.6 Study visits and Investigations 
 
 
After baseline assessments and investigations [blood tests, flow-mediated 
dilatation (FMD) of the brachial artery in response to hyperaemia, applanation 
tonometry and Cardiac Magnetic Resonance Imaging (CMR)], participants were 
randomly assigned to receive either allopurinol 100mg/day or placebo for two 
weeks. If this was tolerated, the trial medication dosage was increased to 
allopurinol 300mg/day for a month. After one month of treatment, the dosage 
was increased to 300mg twice daily of allopurinol or placebo therapy for a 
further 7 ½ months.  
 
Patients were followed up at two weeks, six weeks, ten weeks, six months and 
nine months (see Figure 25). Safety blood tests (FBC, UE, LFT) were performed 
at each visit. Blood tests were taken at baseline and final visit for full blood 
count, renal function, liver function, uric acid, glucose, insulin, BNP and 
oxidized LDL. A urine sample was sent to the laboratory for a urine 
protein/creatinine ratio (UPCR) at baseline, six months and nine months visit. 
Office BP was measured for all the patients at each visit. Due to limited number 
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of ambulatory BP monitors, thirty-two randomly selected patients had a 24 hour 
BP ambulatory monitor attached at baseline and final visit. All investigations 
were carried out at the Centre for Cardiovascular and Lung biology, Ninewells 
hospital, Dundee except the CMR, which was undertaken at the Clinical 
Research Centre, Ninewells hospital, Dundee.  During the study, all patients 
continued their concomitant medication.    
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Figure 25. Flowchart of study visits  
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2.7 Endpoints 
 
 
The primary endpoint was change in LV mass and LV mass index.  Changes in 
endothelial function and arterial stiffness were secondary endpoints. 
 
2.8  Bloods  
 
 
Safety blood tests (full blood count, renal function and liver function) were taken 
at each study visit. Blood tests were performed at baseline and final visit for full 
blood count, renal function, liver function, uric acid, glucose, insulin, BNP and 
oxidized LDL.  
  
2.8.1 Haematology and Biochemistry 
 
 
Blood samples were collected in vacutainer tubes and sent to the Blood Sciences 
laboratory at Ninewells hospital for measuring full blood count, renal function, 
liver function and glucose. The samples were analyzed using a Roche Modular 
Analytics system (COBAS MIRAS) and Roche reagents. The normal reference 
ranges of these tests are shown in Table 10. 
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Blood test Normal range 
Haemoglobin (g/dl) 13.0 – 18.0 (men) 
12.0 – 16.0 (women) 
White cell count (x 109/L) 4.0 – 11.0 
Platelets (x 109/L) 150 - 400 
Sodium (mmol/L) 135 - 147 
Potassium (mmol/L) 3.5 – 5.0 
Urea (mmol/L) 4.0 – 12.0 (men) 
3.3 – 6.6 (women) 
Creatinine (µmol/L) 62 – 106 (men) 
44 – 80 (women) 
Bilirubin (µmol/L) 0 – 15 
Alanine Transaminase (U/L) 13 – 43 
Alkaline Phosphatase (U/L) 40 – 150 
Albumin (g/L) 36 - 50 
Glucose (mmol/L) 3.3 – 5.8 
 
Table 10. Reference ranges of haematology and biochemistry tests 
 
2.8.2 Uric Acid 
 
At the baseline, 6 months and final visit, 5mls of venous blood was drawn into a 
serum tube and allowed to clot for 10 minutes at room temperature before 
centrifuging for 10 minutes at 3000 rpm at 4ºC. The plasma was aliquoted into 
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1.5ml plastic containers and stored at -20ºC. Uric acid was measured using a 
colorimetric assay (Alpha sentinel kit). Inter and intra-assay coefficient of 
variation (CV) was 5% and 5.4% respectively. 
 
2.8.3 BNP 
 
At baseline and final visit, 7mls of venous blood was drawn into EDTA bottles. 
The blood sample was immediately kept on ice and centrifuged as soon as 
possible for 10 minutes at 3000rpm at 4ºC. The plasma was aliquoted into 5ml 
plastic containers and stored at -70ºC. BNP was extracted from the plasma on 
C18 columns and measured using a radioimmunoassay (Bachem, St Helens 
Merseyside, UK). Inter and intra-assay coefficient of variation (CV) was 26% 
and 14% respectively. 
 
2.8.4 Oxidized LDL 
 
At baseline and final visit, 5ml of venous blood was collected into an EDTA 
blood bottle. The blood sample was centrifuged for 10 minutes at 3000rpm at 
4ºC and the plasma was stored at -70ºC. Oxidized LDL was analyzed using a 
Mercodia ELISA kit. Inter and intra- assay coefficient of variation (CV) was 
15% and 8.6% respectively. 
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2.9 BP monitoring 
 
 
Office BP was measured using an Omron 705IT machine for all the patients at 
each visit (2, 6, 10, 28 and 39 weeks) by the same blinded investigator after the 
subject had rested for at least ten minutes. Randomly selected patients had a 24-
hour ambulatory BP monitor (Spacelabs Healthcare, Hertford, UK) attached at 
their baseline and nine month visit. 
 
 
2.10 Echocardiography 
 
 
At the screening visit, the participant had a transthoracic echo to assess if they 
fulfilled the criteria for LVH and to exclude impaired LV function or significant 
valvular abnormality. The study was carried out using a Sequoia 512 (Siemens, 
Camberley, UK) ultrasound machine with a 8 MHz linear array probe. With the 
participant lying on the left decubitus position at a 45º angle, in the parasternal 
long axis view an M-mode measurement of LVM was obtained by aligning the 
beam perpendicular to the septum and just below the tips of the mitral valve 
leaflets. Measurements were made in end-diastole and at the onset of QRS 
complex as according to the American Society of Echocardiography (ASE) 
recommendation. Measurements of the IVS, LV internal dimensions and 
posterior wall thickness were made using the leading edge to leading edge 
convention and an average of 3 readings were taken (see Figure 26).  
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Figure 26. M-mode measurements for calculating LVM 
 
LVM was calculated using the Devereux modified cubed formula:  LV mass = 
0.8 [1.04 [(LVIDd + LVPW + IVSd)3- (LVIDd)3]] + 0.6g (183). LVMI was 
calculated by indexing the LVM by BSA or ht 2.7. LVH was defined as LVM 
indexed by BSA > 115g/m2 in men and > 95g/m2 in women. LVH was also 
defined as LVMI indexed by ht 2.7 > 49 g/m2.7 in men or > 45 g/m2.7 in women 
(183). If it was not obtainable to get the beam perpendicular to the septum, a 2D 
measurement of LVM was taken instead of M-mode. 
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2.11 Cardiac Magnetic Resonance Imaging   
 
 
Cardiac Magnetic Resonance Imaging (CMR) was performed at baseline and at 
nine months on a 3T Magnetom Trio scanner (Siemens, Erlangen, Germany) 
using body array and spine matrix RF coils. The imaging parameters included 
repetition time TR 3·4ms, echo time of 1·5ms and flip angle 50°. Each slice was 
6mm thick. Two slices were taken per breath hold of less than 15 seconds and 
scan time was minimized using parallel imaging “GRAPPA’ factor of two. 
 
2.11.1 Measuring LVM 
 
 
Following acquisition of localizer scans, a stack of short axis images from the 
atrioventricular ring to the left ventricular apex were acquired using 2D ECG-
gated breath-hold segmented CINE TrueFISP sequence with retrospective 
gating. CMR images were analysed offline by an independent, blinded MRI 
Physicist (SG) using commercial software (‘Argus’, Siemens Multi-modality 
Work Platform, version VB 15).  Electronic ‘region of interest’ (ROI) contours 
were placed around endocardial and epicardial left ventricular borders on all MR 
image slices at end-diastole and end-systole that were identified to contain 50% 
or more full-thickness myocardium.  From these contours, quantitative 
measurement of LVM, ejection fraction (EF), end-diastolic volume (EDV), end-
systolic volume (ESV) and stroke volume (SV) were derived (Figure 27).  
Papillary muscles were included in the LVM if the muscle structure was 
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indistinguishable from the myocardial wall, but otherwise assigned to the LV 
blood pool.  The process of contour placement was repeated such that every 
patient dataset at both time-points was analyzed twice in order to optimize the 
measurement precision.  
 
 
Figure 27. CMR acquisition of short axis images for measuring LVM and LV 
volumes (182)  
 140 
Based on our recent departmental 3T CMR study on healthy volunteers, normal 
ranges of LVM and LV volumes are shown in Table 11. 
 
 Mean SD 
LVEF (%) 68.2 5.2 
EDV (ml) 150.8 27.6 
ESV (ml) 47.7 10.8 
SV (ml) 103.1 21.1 
CO (L/min) 6.9 1.6 
LVM (g) 112.2 26.0 
LVMI (g/m2) 60.0 8.6 
 
Table 11. Departmental 3T CMR normal values for LVM and LV volumes. 
 
 
Alfakih et al. reported the normal LVM/BSA using 1.5T CMR SSFP sequences 
was 64 ± 9.3g/m2 in males and 52 ± 7.4g/m2 in females (336). Studies have 
shown that normal values of LVM at 1.5T can also be applied to 3T scans (199).  
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2.11.2 Measuring left atrial volumes 
 
Following acquisition of localizer scans, a stack of multi-slice 2 chamber images 
from the lateral side of left atrium (LA) to the atrial septum perpendicular to the 
plane of the mitral valve were acquired using 2D ECG-gated breath-hold 
segmented CINE TrueFISP sequence with retrospective gating (see Figure 28). 
We elected to use the 2 chamber orientation as recommended by Jarvinen et al 
since the mitral valve plane separating the LA from the LV can be clearly 
identified (337, 338). 
 
CMR images were analysed offline by an independent, blinded MRI Physicist 
(SG) using commercial software (‘Argus’, Siemens Multi-modality Work 
Platform, version VB 15). Image segmentation of the left atrium was performed 
twice at atrial diastole and systole.  Contours for all image slices across the left 
atrium were defined at diastole and systole by measuring the blood volume 
contained by the atrial wall and the mitral valve. The LA appendage and 
pulmonary veins were excluded wherever possible. From these contours, LA 
ejection fraction (LA-EF), end-diastolic volume (LA-EDV), end-systolic volume 
(LA-ESV) and stroke volume (LA-SV) were all derived and indexed to BSA. 
Repeated segmentations were completed over two time-points in order to 
optimize the measurement precision. 
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Figure 28. Measurement of LA volumes using CMR
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2.12 FMD 
 
 
 
Flow-mediated dilatation (FMD) of the brachial artery was performed as set out 
in the International Brachial Artery Reactivity Task Force guidelines (339). It 
was performed at the baseline visit, six months and nine months using a Sequoia 
512 (Siemens, Camberley, UK) ultrasound machine with a 8 MHz linear array 
probe.   
 
Patients were asked to fast for 8 hours and not to take exercise, smoke, consume 
caffeine, high fat food or vitamin C for 4 hours prior to test. If they were on 
nitrate tablets, they were advised to hold it off the morning of the test until after 
the study visit. The study was undertaken in a quiet, temperature controlled room 
(22-24ºC) with the patient lying supine on an examination couch with their right 
arm outstretched on a table. The images of the brachial artery were acquired 
using ECG gating with the image acquired at the peak of the R wave. A baseline 
image of the brachial artery was acquired over a minute. Then a cuff was inflated 
distal to the elbow to 200mmHg for five minutes. On deflation of the cuff, the 
brachial arterial diameter was recorded for two minutes. After a 10 minute rest 
period, endothelial independent dilatation was assessed by the response of 
brachial artery size to 400 micrograms of sublingual glyceryl trinitrate (GTN) 
spray. FMD was the percentage change in maximum diameter achieved after 
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cuff deflation relative to the baseline mean artery diameter (see Figure 29). The 
FMD was analyzed using Vascular Research Tools software (Medical Imaging 
Applications LLC, Coralville, IA, USA). The acquisition and analysis of the 
FMD images were performed by a single trained investigator (SR), who was 
blinded to the allocated treatment.  
 
 
 
 
Figure 29. Brachial artery FMD (339) 
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2.13 Pulse Wave Analysis and Pulse Wave Velocity  
  
2.13.1 Applanation Tonometry method 
 
 
Pulse wave analysis (PWA) and pulse wave velocity (PWV) were each measured 
three times at each study visit (baseline, six months and nine months). An 
average of these three measurements was taken as the value for each study visit. 
This was performed using the validated Sphygmocor (AtCor, Sydney, Australia) 
system by a single trained investigator (SR) who was blinded to the allocated 
treatment.  This technique is in widespread use in our institute. Patients were 
rested in a supine position for at least ten minutes prior to taking measurements. 
For pulse wave analysis, peripheral pressure waveforms were obtained at the 
radial artery by applanation tonometry using a high fidelity micromanometer. 
The central aortic pressure waveform was generated from the radial artery 
waveform by using a validated, generalized transfer function. From the aortic 
pulse wave, Augmentation index (AIx) was calculated as the difference between 
the first and second systolic peak expressed as a percentage of the pulse pressure 
(see Figure 30). As AIx is affected by heart rate, AIx was normalized for a heart 
rate of 75 beats per minute (AIx@75).  
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Figure 30. Calculation of Augmentation Index (AIx) (75) 
 
For PWV, radial-carotid waveforms were obtained with ECG gating. Velocity 
was calculated measuring the time interval between ECG R-wave and the 
recorded waveforms at each site whilst the distance between the sites was 
measured manually with a tape measure.  
 
 Velocity = distance/time 
 
 
 
 
 
 
 147 
2.14 Healthy Volunteers 
 
 
Thirty age and sex matched healthy volunteers (patients without angina or 
diabetes) were recruited as a separate group to the main intervention trial to 
enable comparison of results with the group treated with allopurinol. These 
volunteers were identified from databases of healthy volunteers who have 
participated in previous studies in the department. This sub-study was to test if 
allopurinol improved endothelial function to such an extent that their post 
treatment endothelial function became as good as a healthy person of the same 
age.  
 
The inclusion criteria were healthy volunteers aged between 50 to 80 years old. 
The exclusion criteria included volunteers with diabetes, ischaemic heart disease, 
heart failure or LVEF <45%, previous stroke, renal impairment (eGFR < 60), 
history of gout, on allopurinol therapy, pregnant or breastfeeding or unable to 
consent. These healthy volunteers attended a single study visit when they will 
underwent a blood test (FBC, UE, LFT and uric acid), applanation tonometry 
and FMD of the brachial artery.   
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2.15 Safety 
 
Participants were informed of potential side effects at the screening visit and this 
was also clearly stated in the Patient Information Sheet. They were also 
questioned at each study visit for side effects or adverse events. This was 
documented in the participant’s case report form (CRF) and the sponsor was 
informed of any serious adverse events. Safety blood tests (FBC, UE, LFT) were 
performed at each study visit. 
 
2.16 Statistical Analysis 
 
 
Data for continuous variables are presented as mean ± SD for normally 
distributed data and median and interquartile range (IQR) for non-normally 
distributed data. Categorical data are expressed as numbers (%). Comparison 
between continuous variables were analyzed using the Student t-test or Mann-
Whitney U test whilst categorical variables were analyzed using χ2 test. 
Correlation was performed using Pearson’s or Spearman’s. Multivariable 
regression was performed using the Enter method to correct for the effect of 
confounding variables on the change in LVM. 
 
All statistical analyses were undertaken blinded as completed case analysis using 
SPSS version 18·0 (SPSS, Chicago, IL).  A two-sided p value < 0.05 was 
considered statistically significant. 
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2.17 Sample Size Calculations 
 
 
In order to detect a 10g change in LVM at 90% power, Myerson et al. 
recommended a total sample size of 26 individuals (182) whilst Grothues et al. 
recommended a total sample size of 30 (192). However, we felt that these 
recommendations were unrealistic. Based on a previous study by Kao et al., we 
calculated that we would need 49 patients to detect a 5% change in LVM with 
90% power (332). With regards to FMD, a 2% change in FMD is widely 
regarded as being clinically significant. As our departmental coefficient of 
variation for FMD measurements was 3%, we calculated that we would need 27 
patients per arm to detect a 2.3% change in FMD with 80% power. Hence, 66 
patients were required to achieve 90% power to detect a clinically significant 
change in LVM and 80% power to detect a clinically significant change in FMD 
at a significance level of p < 0·05, allowing for a 20% dropout rate.   
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3 RESULTS 
 
3.1 Screened Participants 
 
A total of 209 participants were screened of which 143 were excluded due to the 
following reasons: 
• 124 participants did not meet the echo criteria for LVH 
• 8 participants had contraindications to undergo 3T CMR  
o Hip replacement (n=2) 
o Valve replacement (n=1) 
o Uncontrolled AF (n=2) 
o Claustrophobia (n=2) 
o Information not available on back surgery metal implant (n=1) 
• 11 participants had other reasons  
o Hypertensive (n=4) 
o Social reasons (n=1) 
o LV impairment (n=2) 
o Abnormal liver function tests (n=2) 
o Renal impairment (n=2) 
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3.2 Randomized Participants 
 
Of the 66 participants recruited, six completely withdrew from the study 
(allopurinol group n=2; placebo group n=4). Reasons for withdrawal are shown 
in the flowchart (Figure 31). Other than the patient who developed recurrent gout 
on allopurinol therapy, the other five study withdrawals were not felt to be 
related to the study medication. Five of the remaining participants were unable to 
undergo a CMR (allopurinol group n=4; placebo group n=1) but remained in the 
study as they underwent the other investigations including bloods, FMD and 
applanation tonometry.  
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Figure 31. Study Flow Diagram 
 
Screened for eligibility (n=209) 
 
Excluded (n= 143) 
Not meeting LVH criteria 
(n=124) 
Contraindicated to undergo 
CMR (n=8) 
Other reasons (n=11) 
Allocated to Allopurinol 
(n=33) 
Study dropout (n=2) 
Reason: 
Recurrent gout (n=1) 
Atypical chest pain (n=1) 
 
Unable undergo CMR (n= 4) 
Reason: 
Claustrophobia (n=3) 
Pacemaker inserted (n=1) 
Allocated to Placebo 
(n=33) 
Study dropout (n=4) 
Reason: 
Study commitment (n=2) 
Comorbidities (n=2) 
 
Unable undergo CMR (n= 1) 
Reason: 
Claustrophobia (n=1) 
Recruited and randomized (n=66) 
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3.3 Baseline Characteristics 
 
 
Baseline characteristics of the recruited patients are shown in Table 12. The 
study participants had a mean age of 65 years, well controlled BP (mean office 
BP 135/77, mean 24 hr BP 123/72) and were predominantly male. Majority of 
the baseline demographics was similar between the treatment groups. 
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Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
Age, years  65 ± 6.7 64 ± 7.2 0.64 
Male (%) 26 (84) 28 (97) 0.10 
BSA, g/m2  2.1 ± 0.2 2.0 ± 0.2 0.26 
Office SBP, mmHg  135 ± 9 134 ± 10 0.87 
24hr SBP, mmHg  124 ± 11 121 ± 9 0.42 
Office DBP, mmHg  78 ± 7 76 ± 7 0.26 
24hr DBP, mmHg  70 ± 5 74 ± 5 0.06 
Past MI (%) 13 (42) 17 (59) 0.20 
Hypertension (%) 23 (74) 16 (55) 0.12 
Diabetes (%) 4 (13) 3 (10) 0.80 
Cerebrovascular disease (%) 4 (13) 2 (7) 0.40 
Peripheral vascular disease (%) 3 (10) 2 (7) 0.70 
Smoking (%) 
Non 
Ex 
Current 
 
7 (23) 
19 (61) 
5 (16) 
 
12 (41) 
12 (41) 
5 (18) 
0.24 
CCS classification 
1 
2 
 
23 (74) 
8 (26) 
 
21 (72) 
8 (28) 
0.88 
ETT/MPS positive (%) 26 (84) 19 (66) 0.15 
No of vessel disease (%) 
1 
2 
3 
 
2 (6) 
11 (35) 
9 (29) 
 
12 (41) 
8 (28) 
6 (21) 
0.05 
PCI (%) 6 (19) 15 (52) 0.01 
CABG (%) 15 (48) 8 (28) 0.1 
 
Table 12. Baseline characteristics of study participants. 
Abbreviations: BSA, body surface area; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; MI, myocardial infarction; CCS, Canadian 
Cardiovascular Society; ETT, exercise treadmill test; MPS, myocardial perfusion 
scan; PCI, percutaneous coronary intervention; CABG, coronary artery bypass 
grafting. Data presented as mean ± SD. Rest of data presented as number (%). 
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Table 13 shows that the participants were on optimum medical therapy. All 
participants were on antiplatelet therapy (aspirin or clopidogrel), 93% were on 
statins, 70 % were on betablockers whilst 75% were on an ACE inhibitor/ARB.  
 
 
 
Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
Aspirin (%) 26 (84) 29 (100) 0.02 
Clopidogrel (%) 4 (13) 4 (14) 0.94 
Statin (%) 29 (94) 27 (93) 0.92 
Ezetimibe (%) 3 (10) 2 (7) 0.70 
Beta blocker (%) 24 (77) 18 (62) 0.20 
Calcium channel blocker (%) 10 (32) 13 (45) 0.30 
Nicorandil (%) 2 (7) 6 (21) 0.10 
Oral nitrate (%) 9 (29) 11 (38) 0.47 
ACE inhibitor (%) 20 (65) 15 (52) 0.32 
ARB (%) 7 (23) 3 (10) 0.20 
 
Table 13. Table of study medication 
Abbreviations: ACE inhibitor, angiotensin converting enzyme inhibitor; ARB, 
angiotensin receptor blocker.  
Data presented as number (%). 
 
 
Table 14 shows the baseline study investigations that were undertaken. There 
was no significant difference in baseline uric acid level, augmentation index or 
LVM/LVMI measured using CMR. However, the allopurinol group had a 
significantly higher BNP level and echo LVM measurement, greater endothelial 
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dysfunction as indicated by a smaller FMD response of brachial artery at 
baseline. 
 
 
 
Allopurinol Placebo p value 
Uric acid, mmol/L  0.6 ± 0.1 0.6 ± 0.1 0.33 
BNP, pg/ml  31 (21 to 60) 21 (13 to 35) 0.03 
FMD, %  4.1 ± 2.1 5.7 ± 2.4 0.01 
AIx, %  20 ± 7 19 ± 9 0.73 
PWV, m/s  7.6 (6.9 to 8.7) 8.5 (7.4 to 9) 0.02 
Echo LVM, g 273 ± 35 251 ± 32 0.02 
Echo LVMI, g/m2 132 ± 14 125 ± 12 0.05 
CMR LVM, g  145.7 ± 23.4 136.4 ± 26 0.17 
CMR LVMI, g/m2  71.0 ± 9.0 68.4 ± 11.1 0.35 
 
Table 14. Table of baseline investigations. 
Abbreviations: BNP, brain natriuretic peptide; FMD, flow-mediated dilatation; 
AIx, augmentation index; PWV, pulse wave velocity; LVM, left ventricular mass; 
LVMI, left ventricular mass index. 
Data presented as mean ± SD or median (IQR).   
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3.4 CMR 
 
3.4.1 Effect of Allopurinol on LVM 
 
 
55 patients underwent CMR (allopurinol, n=27; placebo, n=28).  At baseline, 
there was no significant difference in LVM or LVMI. After 9 months of 
allopurinol therapy, there was a significant reduction in LVM (allopurinol: -5.2 ± 
5.8g, placebo: -1.3 ± 4.5g; p = 0.01) and LVMI ((allopurinol: -2.2 ± 2.8g/m2, 
placebo: -0.5 ± 2.5g/m2; p = 0.02). See Table 15 and Figure 32. Furthermore, the 
within group changes in LVM and LVMI were significant in the allopurinol 
group (p<0.01 for both) but not in the placebo group. 
 
 Allopurinol 
(n=27) 
Placebo 
(n=28) 
p value 
Baseline LVM, g 145.7 ± 23.4 136.4 ± 26 0.17 
Final visit LVM, g 140.5 ± 23.0 135.1 ± 26.2 0.42 
Change in LVM, g -5.2 ± 5.8 -1.3 ± 4.5 0.01 
% Change in LVM, % -3.6 ± 4.0 -1.0 ± 3.3 0.01 
Baseline LVMI, g/m2 71.0 ± 9.0 68.4 ± 11.1 0.35 
Final visit LVMI, g/m2 68.8 ± 8.7 67.9 ± 11.1 0.73 
Change in LVMI, g/m2 -2.2 ± 2.8 -0.5 ± 2.5 0.02 
% Change in LVMI, % -3.3 ± 4.3 -0.9 ± 3.7 0.03 
 
Table 15. The effect of Allopurinol on LVM and LVMI using CMR. 
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 (A) 
 
 
(B) 
 
Figure 32. (A) Mean change in LVMI  (B) Mean change in LVM 
Data are presented as mean ± SEM. 
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Allopurinol regressed LVH more in the above median LVM group compared to 
the below median LVM group. The lack of significant change in LVM in the 
placebo group in those with an above median LVM at baseline indicates that it 
was not simple regression to the mean that caused higher LV masses to fall more 
with allopurinol. See Table 16. 
 
Allopurinol Placebo Between treatment 
groups 
 
Mean 
change  
 ± SD 
p 
value 
Mean 
change ± 
SD 
p 
value 
Mean 
change  
± SD 
p 
value 
Above 
median LVM 
group 
-5.7 ± 6.2 < 0.01 -0.9 ± 5.0 0.54 -4.8 ± 2.2 0.04 
Below 
median LVM 
group 
-4.4 ± 5.2 0.03 -1.7 ± 4.1 0.13 -2.7 ± 1.8 0.15 
Above 
median 
LVMI group 
-2.9 ± 2.5 < 0.01 -0.9 ± 3.1 0.32 -2.0 ±1.1 0.07 
Below 
median 
LVMI group 
-1.1 ± 2.9 0.23 -0.2 ± 2.0 0.64 -0.9 ± 0.9 0.35 
 
Table 16. Change in LVM and LVMI in the above or below median group with 
allopurinol and placebo therapy and between treatment groups 
Data are presented as mean ± SD. 
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The effect of allopurinol on LVM did not significantly differ between the two 
gender groups (change in LVM in males -6.0 ± 5.9g, females -1.7 ± 4.2g; p=0.1) 
(Figure 33) or if they had a past history of MI or not (change in LVM with 
previous MI -6.6 ± 5.5g, no previous MI -3.3 ± 6g; p=0.15). 
 
 
 
Figure 33. Change in LVM with allopurinol therapy according to gender. 
Horizontal line indicates mean. 
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Upon correcting for age, gender, change in office SBP, change in office DBP 
and baseline LVM, the effect of allopurinol therapy on change in LVM remained 
significant (p< 0.01). Allopurinol also significantly affected the change in LVMI 
after adjusting for age, gender, change in office SBP, change in office DBP and 
baseline LVMI (p = 0.03). 
 
No significant correlation was seen between the allopurinol-induced change in 
LVM and either change in FMD (r = 0.06, p = 0.76), change in PWA (r = -0.12, 
p = 0.55), baseline uric acid (r = 0.25, p = 0.22) (Figure 34) or change in uric 
acid (r = -0.18, p = 0.38).   
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Figure 34. Correlation between allopurinol-induced change in LVM and baseline 
serum uric acid level. 
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3.4.2 Effect of Allopurinol on LV volumes 
 
 
At baseline, there were no significant differences between the treatment arms. 
The allopurinol group had a significant reduction in LV ESV (p < 0.05) and a 
non-statistically significant reduction in LV EDV (p = 0.15). See Table 17. 
 
 
 
 Allopurinol 
(n=27) 
Placebo 
(n=28) 
p value 
Baseline EF, % 73.9 ± 8.6 74.2 ± 6.4 0.91 
Final visit EF, % 74.5 ± 8.4 73.5 ± 6.3 0.64 
Change in EF, % 0.6 ± 3.7 -0.6 ± 3.7 0.24 
Baseline EDV, ml 149.2 ± 28.3 136.3 ± 24.3 0.08 
Final visit EDV, ml 143.1 ± 21.4 136.8 ± 23.9 0.31 
Change in EDV, ml -6.1 ± 16.4 0.5 ± 16.9 0.15 
Baseline ESV, ml 39.6 ± 16.3 35.3 ± 10.4 0.25 
Final visit ESV, ml 36.8 ± 13.6 36.6 ± 11.4 0.96 
Change in ESV, ml -2.8 ± 7.8 1.3 ± 7.2 < 0.05 
Baseline SV, ml 109.7 ± 22.2 101 ± 20.4 0.14 
Final visit SV, ml 106.4 ± 19.3 100.2 ± 17.5 0.22 
Change in SV, ml -3.3 ± 12.8 -0.8 ± 13.3 0.49 
Baseline CO, L/min 6.7 ± 1.3 6.1 ± 1.2 0.09 
Final visit CO, L/min 6.6 ± 1.3 6.2 ± 1.3 0.28 
Change in CO, L/min -0.1 ± 0.9 0.1 ± 0.9 0.44 
 
Table 17. The effect of Allopurinol on LV volumes. 
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No correlation was seen between the allopurinol-induced change in ESV and 
baseline uric acid (r = -0.1, p = 0.6) or change in uric acid (r = 0.09, p = 0.66).  
No correlation was also seen between the allopurinol-induced change in EDV 
and baseline uric acid (r = -0.24, p=0.24) or change in uric acid (r = 0.2, p = 0.3).  
 
3.4.3 Effect of Allopurinol on LA volumes 
 
 
At baseline, the allopurinol group unfortunately had a significantly greater LA 
EDV and LA ESV compared to the placebo group. After 9 months of allopurinol 
therapy, although there was reduction in LA EDV of 5.1 ± 8.9 ml this was not 
statistically significant compared to the placebo group (p = 0.4). There was also 
a similar reduction in LA ESV in both treatment groups. See Table 18. 
 
 
 Allopurinol 
(n=24) 
Placebo 
(n=25) 
p value 
Baseline LA EDV, ml 103.1 ± 24.1 86.7 ± 16.2 0.01 
Baseline LA ESV, ml 58.2 ± 18.3 46.9 ± 10.3 0.01 
Final LA EDV, ml 98.0 ± 24.1 83.9 ± 17.9 0.02 
Final LA ESV, ml 56.5 ± 17.1 45.2 ± 11.9 0.01 
Change in LA EDV, ml -5.1 ± 8.9 -2.9 ± 9.6 0.40 
Change in LA ESV, ml -1.7 ± 5.1 -1.7 ± 5.8 0.90 
 
Table 18. The effect of Allopurinol on LA volumes. 
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No significant correlation was seen between allopurinol-induced change in LA 
EDV and the change in LVM (r = 0.17, p=0.4) or change in uric acid (r = -0.017, 
p=0.94).  
 
 
3.5 FMD  
 
The baseline artery size was similar in both treatment groups. There was a 
statistically significant increase in FMD response to hyperaemia after nine 
months of allopurinol therapy (change in FMD response to hyperaemia in 
allopurinol group: +0.8 ± 1.8%, placebo group: -0.7 ± 2.8%; p = 0.02). See Table 
19 and Figure 35.  
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Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
 
Baseline artery size, mm 4.1 ± 0.6 4.2 ± 0.5 0.56 
FMD response to hyperaemia 
at baseline, % 
4.1 ± 2.1 5.7 ± 2.4 0.01 
FMD response to hyperaemia 
at 6 months, % 
4.7 ± 2.2 5.4 ± 2.5 0.22 
Change in FMD response to 
hyperaemia at 6 months, % 
0.6 ± 2.0 -0.3 ± 2.0 0.10 
FMD response to hyperaemia 
at 9 months, % 
4.9 ± 2.2 5.0 ± 2.5 0.93 
Change in FMD response to 
hyperaemia at 9 months, % 
0.8 ± 1.8 -0.7 ± 2.8 0.02 
FMD response to GTN at 
baseline, % 
11.2 ± 4.8 10.3 ± 4.9 0.51 
FMD response to GTN at 6 
months, % 
10.4 ± 5.3 11.4 ± 5.2 0.45 
Change in response to GTN at 
6 months, % 
-0.8 ± 3.0 1.1 ± 3.1 0.04 
FMD response to GTN at 9 
months, % 
9.7 ± 5.0 11.6 ± 5.0 0.17 
Change in response to GTN at 
9 months, % 
-1.5 ± 2.8 1.3 ± 3.3 < 0.01 
 
Table 19. The effect of Allopurinol on FMD 
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Figure 35. Change in FMD in both treatment arms. 
Data presented as mean ± SEM. 
 
FMD response to GTN measures endothelium independent dilatation. There was 
a statistically significant reduction in FMD response to GTN after 6 and 9 
months of allopurinol therapy (see Table 20). This was assessed in more detail 
depending on whether the participants were on regular oral nitrates. The 18 
patients on regular oral nitrates had their dosage omitted the morning of FMD 
test. In this subgroup of patients on oral nitrates, the allopurinol treatment arm 
had a 2.2 ± 2.9% reduction in FMD response to GTN after 9 months compared to 
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placebo group who had a 0.8 ± 4.2% increase in FMD response although this 
failed to reach statistical significance (p=0.097). 
 
 Allopurinol 
(n=8) 
Placebo 
(n=10) 
p value 
FMD response to GTN at 
baseline, % 
10.9 ± 5.7 8.8 ± 4.7 0.43 
FMD response to GTN at 6 
months, % 
10.5 ± 6.9 9.0 ± 2.8 0.56 
Change in response to GTN at 
6 months, % 
-0.4 ± 2.1 0.2 ± 4.3 0.70 
FMD response to GTN at 9 
months, % 
8.7 ± 5.2 9.6 ± 3.2 0.52 
Change in response to GTN at 
9 months, % 
-2.2 ± 2.9 
 
0.8 ± 4.2 
 
0.10 
 
 
Table 20. FMD response to GTN in participants on regular oral nitrates. 
 
 
 
However, there was a significant and unexpected difference in FMD response to 
GTN in the participants who were not on regular oral nitrates. See Table 21. 
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 Allopurinol 
(n=22) 
Placebo 
(n=16) 
p value 
FMD response to GTN at 
baseline, % 
11.5 ± 4.6 11.7 ± 5.0 0.98 
FMD response to GTN at 6 
months, % 
10.3 ± 4.8 12.9 ± 5.9 0.14 
Change in response to GTN at 
6 months, % 
-1.2 ± 3.3 1.2 ± 2.2 0.02 
FMD response to GTN at 9 
months, % 
10.3 ± 5.1 13.2 ± 5.5 0.16 
Change in response to GTN at 
9 months, % 
-1.2 ± 2.8 
 
1.5 ± 2.9 
 
0.01 
 
 
Table 21. FMD response to GTN in participants not on regular oral nitrates. 
 
A negative correlation was seen between baseline FMD response to hyperaemia 
and baseline LVM (r = -0.33, p = 0.01) (Figure 36) and EDV (r = -0.34, p = 
0.01). However, no correlation was seen between the change in FMD response to 
hyperaemia with allopurinol therapy and baseline uric acid  (r = 0.07, p = 0.72), 
change in uric acid (r = 0.03, p = 0.87), change in LVM (r = 0.06, p = 0.76) 
(Figure 37) or change in EDV (r = -0.27, p = 0.17).  
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Figure 36. Correlation between baseline FMD and baseline LVM on CMR 
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Figure 37.  Correlation between change in FMD and change in LVM 
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3.6 Applanation Tonometry 
 
3.6.1 PWA 
 
At baseline, there was no significant difference in AIx between treatment groups. 
After 6 months of allopurinol treatment, there was a reduction in AIx of 3 ± 5% 
compared to a reduction of 1 ± 6% for placebo group, although this was not 
statistically significant. After 9 months of therapy, the allopurinol group had a 3 
± 5% reduction in AIx compared to 1 ± 7% for the placebo group. This 
difference was statistically significant. See Table 22 and Figure 38. 
 
 
 
 Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
 
Baseline visit AIx, %  20 ± 7 19 ± 9 0.73 
6 months visit AIx, % 17 ± 9 18 ± 11 0.73 
Change in AIx baseline to 6 
months, % 
-3 ± 5 -1 ± 6 0.14 
Final visit AIx, % 17 ± 9 20 ± 12 0.30 
Change in AIx baseline to final 
visit, % 
-3 ± 5 1 ± 7 0.02 
 
Table 22. Effect of allopurinol and placebo therapy on PWA. 
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Figure 38. Change in Augmentation index in both treatment arms. 
Data presented as mean ± SEM. 
 
A negative correlation was seen between baseline uric acid and change in AIx, 
that just missed statistical significance (r = - 0.34, p = 0.07). However, there was 
no significant correlation between change in uric acid and change in AIx     (r = 
0.22, p = 0.24). 
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3.6.2 PWV  
 
 
At baseline, the allopurinol group had a significantly slower PWV compared to 
the placebo group. However, allopurinol therapy for up to 9 months did not have 
significant effect on PWV. See Table 23. 
 
 
 Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
Baseline visit, m/s 7.6 (6.9 to 8.7) 8.5 (7.4 to 9.0) 0.02 
6 months visit, m/s 7.7 (6.7 to 7.9) 7.9 (7.3 to 8.8) 0.05 
Change in PWV baseline 
to 6 months visit, m/s 
0 (-0.6 to 0.3) 0 (-0.8 to 0.4) 0.85 
Final visit, m/s 7.5 (6.9 to 8.2) 8 (7.0 to 8.6) 0.19 
Change in PWV baseline 
to final visit, m/s 
-0.14 (-0.8 to 0.3) -0.2 (-1.3 to 0.4) 0.66 
 
Table 23. Effect of Allopurinol on PWV 
Data presented as median (IQR). 
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3.7 Effect of Allopurinol on BP 
 
 
There was no significant change in office BP (measured on all the participants) 
or 24-hour ambulatory BP (measured on a subset of 32 randomly selected 
participants) in the allopurinol group compared to placebo group. See Table 24 
and Table 25. 
 
 
 Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
 
Office SBP (mmHg)    
Baseline visit 135 ± 9 134 ± 10 0.87 
6 months visit 134 ± 12 134 ± 12 0.91 
Final visit  130 ± 14 131 ± 13 0.65 
Change in office SBP  
(baseline to final visit) 
-5 ± 13 -3 ± 15 0.59 
Office DBP (mmHg)    
Baseline visit 78 ± 7 76 ± 7 0.26 
6 months visit 76 ± 7 78 ± 8 0.15 
Final visit  74 ± 8 75 ± 8 0.72 
Change in office DBP  
(baseline to final visit) 
-4 ± 8 -1 ± 8 0.20 
Office MAP (mmHg)    
Baseline visit 97 ± 6 96 ± 7 0.38 
Final visit  92 ± 8 93 ± 8 0.64 
Change in MAP  
(baseline to final visit) 
-5 ± 8 -3 ± 9 0.27 
 
Table 24. Effect of Allopurinol and Placebo therapy on office BP 
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 Allopurinol 
(n=17) 
Placebo 
(n=15) 
p value 
24-hr Ambulatory SBP 
(mmHg) 
   
Baseline visit 124 ± 11 121 ± 9 0.42 
Final visit  126 ± 11 118 ± 12 0.05 
Change in 24-hr SBP 2 ± 11 -3 ± 9 0.17 
24-hr Ambulatory DBP 
(mmHg) 
   
Baseline visit 70 ± 5 74 ± 5 0.06 
Final visit  71 ± 7 71 ± 4 0.89 
Change in 24hr DBP 1 ± 5 -3 ± 4 0.61 
24-hr Ambulatory MAP 
(mmHg) 
   
Baseline visit 89 ± 5 90 ± 6 0.64 
Final visit  89 ± 6 88 ± 7 0.42 
Change in 24-hr MAP 0 ± 7 -2 ± 6 0.20 
 
Table 25. Effect of Allopurinol and Placebo therapy on ambulatory BP 
 
 
3.8 Effect of Allopurinol on Serum Uric Acid  
 
Allopurinol significantly reduced serum uric acid level (allopurinol group: 0.6 ± 
0.1 mmol/L at baseline to 0.3 ± 0.1 mmol/L at nine months; placebo group: 0.6 ± 
0.1mmol/L at baseline to 0.5 ± 0.1 mmol/L at nine months; p < 0.01). Hence, 
allopurinol therapy for nine months lowered serum uric acid level by 46%.   
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3.9 Effect of Allopurinol on Oxidized LDL 
 
 
Oxidized LDL is one of many markers of oxidative stress. Allopurinol did not 
seem to have a significant effect on oxidized LDL levels (change in oxidized 
LDL in allopurinol group: 1.8 ± 8.9 pg/ml, placebo group 0.6  ± 10.7 pg/ml; p = 
0.65). 
 
3.10 Effect of Allopurinol on BNP 
 
At baseline, BNP levels did not correlate with the baseline LVM (Spearman’s 
rho -0.20, p=0.89) Additionally the allopurinol group had a significantly higher 
BNP level compared to placebo [allopurinol group median (IQR): 31 (21 to 60) 
pg/ml vs. 21 (13 to 35) pg/ml placebo group; p = 0.03]. After 9 months of 
allopurinol therapy, BNP levels were reduced by -6 (-19 to 5) pg/ml compared to 
placebo -1 (-7 to 5) pg/ml, which just failed to reach statistical significance (p = 
0.08). This change in BNP did not correlate with change in LVM (Spearman’s 
rho -0.12, p=0.40), EDV (Spearman’s rho 0.08, p=0.59), ESV (Spearman’s rho -
0.09, p= 0.53) or FMD (Spearman’s rho 0.02, p=0.90).  
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3.11 Effect of Allopurinol on UPCR 
 
Allopurinol did not have a significant effect on UPCR [change in UPCR for 
allopurinol group: 1.5 (-1.5 to 4.3) mg/mmol, placebo group: 0 (-2 to 4.5) 
mg/mmol; p = 0.67].  
 
3.12 Correlation between Echo and CMR 
 
As shown in Figure 39 there was a strong positive correlation seen between the 
baseline LVM measured using echo and CMR (r = 0.5, p = 0.01). 
 
 
Figure 39.  Correlation between baseline LVM measured using echo and CMR 
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Figure 40. Bland Altman plot comparing LVM measurement by CMR and echo  
Middle horizontal line is the mean difference in LVM measurements. Outer two 
horizontal lines indicate the mean ± SD difference in LVM measurements. 
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3.13 Safety 
 
3.13.1 Safety Bloods 
 
 
Table 26 shows the safety bloods at baseline and after 9 months of study drug. 
There was a small, statistically significant reduction in white cell count, platelets, 
urea and creatinine and increase in bilirubin and alkaline phosphatase with 
allopurinol therapy. However, none of the changes in safety blood tests were 
clinically significant requiring withdrawal of study drug. The effect of 
allopurinol on full blood count and liver enzymes are well documented. 
 
 Baseline Allopurinol p value Baseline Placebo p-value 
Haemoglobin 14.5 ±1.4 14.2 ± 1.5 0.10 14.8 ± 0.9 14.7 ± 1.2 0.52 
WCC 7.5 ± 2.3 7.0 ± 1.8 0.03 7.2 ± 1.6 6.9 ± 1.4 0.22 
Platelet 209 ± 53.3 187 ± 46.8 < 0.01 224.6 ± 56.9 218 ± 52.8 0.16 
Sodium 140.4 ± 2.2 141 ± 2.7 0.08 141.2 ± 1.9 141.2 ± 1.9 0.95 
Potassium 4.4 ± 0.3 4.5 ± 0.4 0.30 4.4 ± 0.3 4.5 ± 0.3 0.03 
Urea 6.5 ± 1.5 6.1 ± 1.1 0.03 6.5 ± 1.9 5.8 ± 1.7 0.01 
Creatinine 81.8 ± 12.2 75.2 ± 11.6 < 0.01 80.6 ± 13.1 78.1 ± 13.3 0.07 
Bilirubin 8.2 ± 2.7 10.2 ± 3.1 < 0.01 11.3 ± 5.5 11.9 ± 5.1 0.51 
ALP 60.9 ± 18.2 64.7 ± 19.3 0.01 70.5 ± 18.1 68.8 ± 18.6 0.31 
ALT 25.6 ± 8.0 26.9 ± 12 0.31 24.2 ± 7.6 23.6 ± 8.3 0.45 
Albumin 44.8 ± 2.1 44.1 ± 2.5 0.10 45.4 ± 2.3 44.6 ± 2.1 0.07 
 
 
 
Table 26. Safety bloods at baseline and after allopurinol and placebo therapy 
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3.13.2 Adverse Events 
 
 
As allopurinol is a drug that has been prescribed for over 40 years, its side 
effects are well recognized. Table 27 shows the adverse events reported during 
this study. Except for one patient who developed gout, all the other adverse 
events were not felt to be related to the study medication. Allopurinol can 
exacerbate an acute attack of gout due to a sudden reduction in serum uric acid 
level. Rashes can affect up to 2% of those taking allopurinol. However, the rash 
developed by a participant whilst on 300mg study medication was felt not to be 
related to the study medication as the participant had no problems until 
commencing an oral antibiotic and the rash resolved once the antibiotic was 
stopped. The patient with pleurisy had suffered previous episodes prior to 
commencing study drug. The participant who had a permanent pacemaker 
inserted during the study period had a longstanding left bundle branch block 
pattern on 12 lead ECG and he had been admitted with a syncopal episode 
without a documented bradycardic episode. The participant diagnosed with renal 
malignancy and another with recurrent episodes of gout whilst on allopurinol 
600mg daily was withdrawn from the study. Breaking of the randomization code 
was not required for any of these participants. 
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 Allopurinol Placebo 
Hospital admissions for < 24 hours 
with angina 
1 2 
Rash 1 0 
Pleurisy 1 0 
Abdominal pain 0 1 
Insertion of pacemaker 1 0 
Ankle fracture 0 1 
Recurrent gout 1 0 
Renal malignancy  0 1 
 
Table 27. Adverse events 
 
 
3.14 Study drug compliance 
 
This was assessed by measuring the change in serum uric acid levels. As 
previously mentioned, the allopurinol group significantly reduced uric acid 
levels by 46% after 9 months of therapy whilst there was no significant change 
in the placebo arm. All the participants in the allopurinol arm had a reduction in 
uric acid levels except for one who had a 13% increase in uric acid level. This 
suggests that this participant was not compliant in taking his study drug. 
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3.15 Studies of Agreement 
 
A single observer who was blinded to treatment allocation undertook the CMR 
LVM measurements two months apart. Intra-observer (SJG) measurement of 
LVM on CMR images had an intraclass correlation coefficient (ICC) of 0.989 
(95% limits of agreement 0.982 - 0.993, p < 0.01). Figure 41 shows the Bland 
Altman plot of CMR LVM measurements. 
 
 
 
 
Figure 41. Bland Altman plot of CMR LVM measurement 
Middle horizontal line is the mean difference in LVM measurements. Outer two 
horizontal lines indicate the mean ± 2SD difference in LVM measurements. 
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A single observer who was blinded to treatment allocation undertook the FMD 
measurements one month apart. Intra-observer (SR) FMD measurements had an 
ICC of 0.991 (95% limits of agreement 0.978 - 0.997; p < 0.01). Figure 42 shows 
the Bland Altman plot of FMD measurements. 
 
 
 
 
 
Figure 42. Bland Altman plot of FMD measurements 
Middle horizontal line is the mean difference in LVM measurements. Outer two 
horizontal lines indicate the mean ± 2SD difference in LVM measurements. 
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3.16 Medication Changes during Study Period 
 
During the study period, a small number of participants (allopurinol group n=2, 
placebo group, n=3) had changes made to their medication due to clinical 
reasons. Three patients had changes made to antianginals (commenced on an 
antianginal: n=1 allopurinol group, n=1 placebo group; an antianginal stopped: 
n=1 placebo group). One participant in the allopurinol group had an ACE 
inhibitor changed to a beta-blocker whilst a participant in the placebo group was 
commenced on an ACE inhibitor.  
 
3.17 Healthy Volunteers  
 
Table 28 shows the baseline characteristics of the healthy volunteers (HV) 
compared to the two treatment groups. The HV were age and gender matched to 
the treatment groups. There was no significant difference in SBP albeit the HV 
had a lower DBP than the allopurinol group, which just failed to reach statistical 
significance (p=0.07). The HV had a lower baseline uric acid level compared to 
allopurinol group but similar to the placebo group. Upon performing the baseline 
endothelial function testing, the HV had a significantly lower AIx, a greater 
FMD response to GTN and similar PWV compared to patients with IHD and 
LVH. There was also a greater FMD response to hyperaemia in the HV 
compared to the allopurinol treatment group but not the placebo group. 
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 HV 
(n=30) 
Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value 
* 
p value 
# 
Age 65.2 ± 3.8 65 ± 6.7 64 ± 7.2 0.997 0.57 
Male (%) 27 (90) 26 (84) 28 (97) 0.26 0.26 
BSA, g/m2 1.9 ± 0.2 2.1 ± 0.2 2 ± 0.2 <0.01 < 0.01 
Smoking (%) 
No 
Ex 
Current 
 
16 (53) 
12 (40) 
2 (7) 
 
7 (21) 
20 (61) 
6 (18) 
 
14 (42) 
13 (40) 
6 (18) 
0.03 0.36 
Office SBP, 
mmHg 
129 ± 17 135 ± 9 134 ± 10 0.11 0.16 
Office DBP, 
mmHg 
74 ± 11 78 ± 7 76 ± 7 0.07 0.37 
Uric acid, 
mmol/L 
0.6 ± 0.1 0.6 ± 0.1 0.6 ± 0.1 0.04 0.52 
AIx, % 13 ± 11 20 ± 7 20 ± 9 < 0.01 0.01 
PWV, m/s 7.9  
(7.4 to 8.6) 
7.6  
(6.9 to 8.7) 
8.5  
(7.4 to 9) 
0.36 0.17 
FMD, % 6.3 ± 3.7 4.1 ± 2.1 5.7 ± 2.4 <0.01 0.46 
FMD GTN, % 17.2 ± 6.1 11.2 ± 4.8 10.3 ± 4.9 <0.01 <0.01 
 
Table 28. Baseline characteristics of HV and the two treatment groups 
Data presented as mean ± SD or median (IQR) 
* comparison between HV and allopurinol group 
# comparison between HV and placebo group 
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After nine months of treatment, there was an improvement in FMD and 
reduction in AIx in the allopurinol group although it did not reach the extent of 
the HV (see Table 29). 
 
 HV 
(n=30) 
Allopurinol 
(n=31) 
Placebo 
(n=29) 
p value * p value 
# 
 
Baseline FMD, 
% 
6.3 ± 3.7 4.1 ± 2.1 5.7 ± 2.4 < 0.01 0.46 
9 months FMD, 
%  
6.3 ± 3.7 4.9 ± 2.2 5.0 ± 2.5 0.09 0.12 
Baseline FMD 
GTN, % 
17.2 ± 6.1 11.2 ± 4.8 10.3 ± 4.9 <0.01 <0.01 
9 months FMD 
GTN, % 
17.2 ± 6.1 9.7 ± 5 11.6 ± 5 <0.01 <0.01 
Baseline AIx, % 13 ± 11 20 ± 7 20 ± 9 < 0.01 0.01 
9 months AIx, 
% 
13 ± 11 17 ± 9 20 ± 12 0.07 0.02 
Baseline PWV, 
m/s 
7.9  
(7.4 to 8.6) 
7.6  
(6.9 to 8.7) 
8.5  
(7.4 to 9) 
0.36 0.17 
9 months PWV, 
m/s 
7.9  
(7.4 to 8.6) 
7.5  
(6.9 to 8.2) 
8.0  
(7.0 to 8.6) 
0.13 0.85 
 
Table 29. FMD of the brachial artery and applanation tonometry results of the HV 
and the treatment groups 
Data presented as mean ± SD or median (IQR) 
* p value comparing HV and allopurinol group 
# p value comparing HV and placebo group 
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4 DISCUSSION 
 
To summarize, this study showed high dose allopurinol to regress LVM and 
improve arterial stiffness and endothelial dysfunction in patients with IHD. In 
this section of my thesis, I will discuss my study findings in further detail in the 
context of previous scientific evidence, explore potential mechanisms to explain 
my findings, highlight limitations of this study and to complete I will suggest 
potential future studies.   
 
4.1 Effect of Allopurinol on LVM 
 
The main finding of this study is that high dose allopurinol regresses LVM in 
patients with IHD and LVH who are on current evidence-based optimal medical 
therapy (allopurinol: -5.2 ± 5.8g, placebo: -1.3 ± 4.5g; p < 0.01).  Allopurinol 
regressed LVM more in the higher baseline LVM group as might be expected. 
There is no clear explanation as to why there was a slight reduction in LVM in 
the placebo group over the 9 month period as there was no significant change in 
BP or BMI. 
 
Regression in LVM observed in this study with allopurinol therapy is consistent 
with previous experimental and human studies. Laakso et al. found allopurinol to 
prevent LVH development in spontaneously hypertensive rats (SHR) with 
negligible BP lowering effects (328). Additionally, in L-NAME exposed rats, 
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allopurinol prevented an increase in LVMI, which was comparable to an ARB 
(329). Febuxostat, a non-purine XO inhibitor, has also been shown to be 
beneficial in attenuating LVH induction by systolic overload but only if 
commenced early and not delayed until after the development of cardiac 
hypertrophy (330). In the La Plata study, a randomized, double-blind placebo 
controlled study of 60 NYHA class II-III heart failure patients, administration of 
600mg oxypurinol/day for only a month showed some reduction in LVM 
although this just failed to reach statistical significance (p=0.11) (331). The lack 
of significant LVM reduction with oxypurinol therapy may be explained by the 
very short treatment period of only one month and also to the low dosage of XO 
inhibition therapy used (600mg oxypurinol is equivalent to only 83mg 
allopurinol). Recently, a RCT undertaken by Kao et al. in Dundee found 
allopurinol 300mg/day prescribed to 67 patients with CKD stage 3 and LVH for 
a period of 9 months to significantly regress LVMI by 5% (1.4 ± 4.7 g/m2) (332) 
compared to 3.29% (2.2 ± 2.8 g/m2) in my study. The regression of LVM by high 
dose allopurinol in this CKD cohort was felt likely due to the improvement in 
arterial compliance and arterial wave reflection resulting in reduction in LV 
afterload (332). This is because the fall in AIx correlated with the fall in LVM. It 
should be highlighted that CKD patients are likely to have much higher levels of 
OS compared to my study population with optimally treated IHD. Kao et al. 
used a lower dose of allopurinol (300mg/day) compared to our study due to the 
increased risk of allopurinol toxicity with impaired renal function (332).  
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The reduction in LVH in percentage terms shown in our study is surprisingly 
similar to that seen in the LIFE study despite our follow up period being only 9 
months compared to 4.8 years in the LIFE study.  In our study, allopurinol 
produced a mean reduction in LVM of 3.57% and of 3.3% in LVMI.  In the echo 
sub-study of the LIFE study, both losartan and atenolol reduced LVMI by 17.4% 
and 14.4% respectively i.e. the differential effect between losartan and atenolol 
in regressing LVH was only 3% (250). 
 
The next most relevant study is the 4E-LVH study by Pitt et al. because it used 
MRI to measure changes in LVM as in our study (262).  In the 4E-LVH study, 
adding eplerenone to enalapril produced an extra 7.5g reduction in LVM but also 
a 4 mmHg fall in SBP. In our study, allopurinol therapy resulted in a 5.2g 
reduction in LVM with no associated significant BP effect.  The percent change 
in LVM in Pitt et al. (2003) cannot be ascertained as surprisingly they did not 
provide baseline LVM in their paper but their patients were, unlike our study, 
markedly hypertensive (BP 163/97 mmHg) which means their baseline LVM are 
likely to have been much greater than ours so that the percent change in LVM 
seen in our study and this 4E-LVH study might well have been similar, despite 
the extra BP fall in the 4E-LVH study. 
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More recently, a CMR study of hypertensive patients with LVH by Burns et al. 
reported 6 months treatment with a combination of valsartan and moxonidine to 
regress LVM on cardiac MRI by 15% and LVMI by 15.4% whilst a combination 
of bendroflumethiazide and amlodipine therapy reduced LVM by 10.9% and 
LVMI by 14% (340). In this CMR study, the observed regression of LVM and 
LVMI was much greater compared to our study of 3.57% and 3.3% respectively. 
This is most likely due to the much greater observed mean SBP reduction 
associated with the antihypertensive therapy prescribed in this study 
(combination of valsartan and moxonidine: 37mmHg, combination of 
bendroflumethiazide and amlodipine: 38mmHg) compared to allopurinol therapy 
in my study (at most 5mmHg depending on which BP parameter is chosen).  
 
Klingbeil et al. performed a meta-analysis comparing the effect of various 
antihypertensives on LVM using echocardiography in patients with essential 
hypertension (255). They reported a percent reduction in LVMI of 6% for beta 
blockers, 8% for diuretics and 10% for ACE inhibitors.  For ARBs, the fall in 
LVMI was 13% over 1 year, which meant probably around 9.7% in a 9 month 
treatment period.  These results are higher than ours but differences in ultimate 
blood pressure (-12mmHg SBP) would be a big contributor, which did not occur 
in our study or in the LIFE study. A more recent meta-analysis in 2009 by 
Fagard et al. did not show a significant difference in changes in LVM between 
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the various drug treatments except that beta-blockers had less LVM regression 
compared to ARBs (256). 
 
The majority of previous studies, as already discussed, involved BP dependent 
changes in LVM by using antihypertensives. However, SBP accounts for only 
31% of LVM variance (119), the LIFE study demonstrated changes in LVM 
independent of BP (16, 341) and Pitt et al. concluded from the 4E-LVH study 
that “other factors may be as important or more important for reducing LV mass 
than BP reduction per se” (262). OS is increasingly being appreciated to cause 
cardiac hypertrophy. In our study, we focused on BP independent changes in 
LVM, which are bound to be less than using drugs that lower BP. 
 
4.2 Effect of Allopurinol on LV volumes 
 
 
In this study, allopurinol significantly reduced the LVESV (p < 0.05) whilst 
there was a non-statistically significant reduction in EDV (p = 0.15). The effect 
of allopurinol on LV volumes has previously been shown in animal studies. 
After an experimental MI, allopurinol therapy reduced the LV cavity size 
(LVEDD) (21) whilst in another animal model XOI attenuated the increase in 
LVESV and LVEDV post MI by 50%, improved energetics and function without 
any change in LVM (342). Another animal study found short term allopurinol 
therapy of 5 days to have a transient reduction in myocardial ROS associated 
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with a reduction in LV systolic diameter. However, longer periods of allopurinol 
therapy of 10 weeks resulted in a reduction in LV end-diastolic pressure, LV 
systolic and diastolic diameters (343). A recent human study of patients with 
CKD stage 3 and LVH found allopurinol to reduce LVEDV by a mean of 9.6mls 
although it did not reach statistical significance (p=0.08) whilst there was no 
change in ESV (332). 
 
4.3 Effect of Allopurinol on Endothelial function (FMD)  
 
 
In this study, 9 months of allopurinol therapy improved the FMD response to 
hyperaemia by 0.8 ± 1.8% compared to a reduction of 0.7 ± 2.8% in the placebo 
group (p = 0.02) although it did not reach the extent of the healthy volunteers. 
Interestingly, allopurinol significantly reduced the FMD response to GTN 
compared to placebo group.  
 
The findings of this study are in keeping with previous studies that have shown 
xanthine oxidase inhibitors to improve endothelial function in numerous study 
populations including those with diabetes, ischaemic heart disease, congestive 
heart failure, CKD and smokers (22, 326, 332-334, 344, 345). 
 
Butler et al. administered 300mg allopurinol for one month duration to 11 
patients with type 2 DM and mild hypertension and 12 healthy age-matched 
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controls. Allopurinol had a 30% relative improvement in endothelial function to 
near normal levels with an associated significant reduction in malondialdehyde, a 
marker of oxidative stress in the diabetic group but not in the healthy controls 
(333). Farquharson et al. and George et al. have shown allopurinol to relatively 
improve endothelial function of NYHA class II-III chronic heart failure patients 
by 50% and 30% respectively (22, 326). In a study of chronic stable angina 
patients, 600mg of allopurinol for 2 months improved the FMD from 4.2 ± 1.8% 
at baseline to 5.4 ± 1.7% (p<0.01) with complete abolishment of vascular 
oxidative stress (334).  Additionally in a recent study from our department of 
patients with chronic kidney disease and LVH, 300mg of allopurinol for 9 
months resulted in a 30% improvement in FMD (332). George et al. concluded 
that the improvement in endothelial function resulting from allopurinol therapy 
is not related to the reduction of uric acid but to the almost complete mopping up 
of vascular oxidative stress (326). 
 
The beneficial effect of allopurinol on endothelial function is likely to be at the 
level of the resistance vessels as opposed to the capacitance arteries. The 
increase in the brachial artery FMD with allopurinol therapy is likely due to the 
improvement in the hyperaemic response in the small arteries, which increases 
blood flow and greater shear stress resulting in greater dilatation of the brachial 
artery. 
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Although the improvement in FMD with allopurinol was not to the level of 
healthy volunteers, the healthy volunteers only had a single FMD measurement 
undertaken and they did not have a screening echocardiogram to exclude cardiac 
hypertrophy, which all the main study participants had. 
 
As endothelial dysfunction is associated with a poor prognosis, improving 
endothelial function in my study population (chronic stable angina and LVH) 
should reduce cardiovascular event rates and will be a mechanism by which 
allopurinol regressed LV mass. Medication commonly prescribed to patients 
with IHD such as ACE inhibitors, ARBs and statins can also improve endothelial 
function (41).  
 
An unexpected finding of this study was that allopurinol reduced the FMD 
response to GTN compared to the placebo group and this was statistically 
significant in those not on regular nitrates.  Previous studies using allopurinol 
therapy have not detected such an effect but this was not the primary aim of my 
study. Studies of subjects with atherosclerosis have shown either a trend or a 
significantly reduced arterial vasodilator response to GTN which was felt to be 
explained by smooth muscle cell dysfunction and nitrate tolerance in patients 
with IHD on regular nitrates (346). 
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4.4 Effect of Allopurinol on Arterial stiffness 
 
Arterial stiffness occurs not only in the presence of coronary artery disease but 
increases with the number of diseased coronary arteries (79). In this study, 9 
months of treatment with allopurinol significantly reduced AIx without any 
significant change in brachial BP and this was independent of the change in uric 
acid.  
 
The beneficial effect of allopurinol on arterial stiffness found in my study is 
consistent with previous studies of different patient groups including stroke, 
chronic stable angina and CKD stage 3 with LVH (332, 334, 335).  In an RCT of 
stroke survivors with high uric acid levels, allopurinol 300mg for 2 months 
reduced AIx from 26 ± 3% to 20 ± 2% compared to an increase from 24 ± 3% to 
28 ± 3% in placebo group (p=0.03) and it did not correlate with change in uric 
acid level (335). In another study of patients with stable angina, 600mg 
allopurinol for 2 months resulted in a reduction in AIx from 27 ± 5% to 25 ± 5% 
(p < 0.01) without a significant change in placebo group (334). In a study of 
patients with CKD stage 3 and LVH, 300mg allopurinol for 9 months reduced 
AIx by 5 ± 9% compared to an increase of 1 ± 6% in the placebo group (p=0.02) 
(332). In all these studies, there was no significant change in BP associated with 
allopurinol therapy. As AIx correlates with superoxide anion production (347), 
allopurinol is likely to have reduced AIx by reducing the production of ROS by 
XO.  
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There are other commonly prescribed cardiovascular medication including beta-
blockers, ACE inhibitors, ARBs, calcium channel blockers, nitrates and statins 
that also decrease arterial stiffness and arterial wave reflections (73). 
 
 
In arterial stiffness, an increased velocity of forward and backward wave results 
in the wave returning in late systole instead of early diastole, thereby augmenting 
systolic pressure and reducing diastolic pressure (75). The augmented systolic 
pressure increases cardiac afterload, which is the main determinant of LVM, 
resulting in LVH whilst reducing coronary perfusion. Hence, a reduction in 
afterload by allopurinol should result in regression of LVM. A study by 
Hashimoto et al. found AIx to be better at predicting LVM regression than 
brachial BP (348). In a study of CKD stage 3 patients with LVH, the authors 
concluded that the likely explanation for allopurinol to regress LVM in their 
patients was due to the reduction in LV afterload (332).  
 
As arterial stiffness is associated with a poor prognosis in patients with coronary 
artery disease (82), the reduction of arterial stiffness with allopurinol therapy 
should result in a reduction in cardiovascular morbidity and mortality. Noman et 
al. concluded that the reduction in arterial stiffness may have been one of the 
mechanisms by which allopurinol was anti-ischaemic in angina patients (318).   
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In this study, allopurinol did not have an effect on PWV. This could be explained 
by us measuring PWV between the carotid-radial sites instead of carotid-
femoral. The carotid-femoral PWV technique has mainly been used in previous 
epidemiological studies as it measures along the aortic-iliac pathway and so 
gives information as to what pressures the LV is exposed to. In my study we 
decided to use the carotid-radial PWV technique as we felt that having to take 
measurements from the groin of patients may put them off from taking part in 
the study and this was not a primary study outcome measure. However, as shown 
by Tillin et al. the site of measuring PWV does matter and carotid-femoral was 
better than carotid-radial or femoral-posterior tibial (349). 
 
 
 
4.5 Effect of Allopurinol on left atrial volumes 
 
In this study, although there was a reduction in left atrial diastolic volume after 9 
months of allopurinol therapy, this was not statistically significant. There may 
have not been a significant reduction in left atrial volumes due to the relatively 
short follow up period. In LVH the increase in LV end-diastolic pressure results 
in left atrial dilatation. As the LVM regresses, the reduction in LV end-diastolic 
pressure will then indirectly result in reduction in left atrial size, which will 
likely to need a longer follow up to see a change. Previous studies of LVM 
regression have not assessed its effects on left atrial size. However, LVM 
regression has been shown to reduce the incidence of AF in the LIFE study, 
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which has been postulated to be due to reduction in left atrial volumes, a risk 
marker of AF.  
 
4.6 Effect of Allopurinol on BP 
 
In this study, allopurinol did not significantly reduce office BP compared to 
placebo therapy (mean change in office SBP: allopurinol group -5mmHg vs. 
placebo group -3mmHg, p=0.59; mean change in office DBP: allopurinol group  
-4mmHg vs. placebo group -1mmHg, p=0.2). Additionally, a subgroup of 
patients also had a 24-hour BP monitor, a more reliable measure of BP control, 
which did not show a significant difference between the two treatment groups 
(mean change in 24hr SBP: allopurinol group +2mmHg vs. placebo group           
-3mmHg, p=0.17; mean change in 24hr DBP: allopurinol group +1mmHg vs. 
placebo group -3mmHg, p=0.61). 
 
Our findings are consistent with the majority of previous published work using 
allopurinol therapy in patients with IHD (318, 334), heart failure (326), diabetes 
(333), stroke (335) and CKD (332). However, a RCT with cross-over design of 
30 adolescents with hyperuricemia (serum uric acid levels ≥ 0.36 mmol/L) and 
hypertension found allopurinol 200mg twice daily for 1 month to significantly 
reduce office SBP (mean change in SBP: allopurinol -7mmHg vs. placebo           
-2.0mmHg, p < 0.01) and office DBP (mean change in DBP: allopurinol              
-5mmHg vs. placebo -2mmHg, p=0.05). Allopurinol also significantly reduced 
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24-hour ambulatory BP (mean change in 24-hour SBP: allopurinol -6mmHg vs. 
placebo 1mmHg, p<0.01; mean change in 24-hour DBP: allopurinol -5mmHg vs. 
placebo 0mmHg, p< 0.01). Allopurinol therapy resulted in a mean reduction in 
serum uric acid levels from 0.41 mmol/L to 0.25 mmol/L (350). Raised uric acid 
levels have been associated with the presence of hypertension (291). However, it 
is still unclear whether uric acid is the cause or is the consequence of 
hypertension. Uric acid has been shown to stimulate renin release and in this 
adolescent study, there was an associated reduction in plasma renin activity with 
allopurinol therapy which may help explain the reduction in BP (350). 
 
A study of patients with chronic stable angina by Noman et al. found high dose 
allopurinol for 6 weeks to not significantly affect office BP but there was a 
significant reduction in SBP and DBP at stage 1 of exercise testing (318).  
 
 
4.7 Effect of Allopurinol on oxidative stress 
 
There is overwhelming evidence that oxidative stress mediates cardiac 
hypertrophy (1, 11, 13) and inactivates NO resulting in endothelial dysfunction 
(2, 351). A number of experimental and human studies have shown allopurinol 
to reduce oxidative stress (24, 326, 334, 343). 
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In this study, allopurinol regressed LVM and improved endothelial function but 
it did not seem to have an effect on oxidized LDL, a marker of oxidative stress. 
There may be a number of reasons why? Firstly oxidative stress is the oxidation 
of proteins, nucleic acids and lipids by ROS. There are many available urine and 
plasma OS biomarkers that have been used in studies including oxidized LDL, 
isoprostanes and malondialdehyde. Oxidized LDL is only one of the many 
available biomarkers and it was used in my study as we have had some 
experience measuring it in our department. Oxidized LDL is not a single, 
chemically homogenous entity (352) and so there a number of oxidized LDL 
assays that detected different epitopes. The assay used in my study measures 
oxidized apolipoprotein-B. Secondly, OS biomarkers have limitations and for 
example studies using statins have also not always been able to show a reduction 
in OS biomarkers (353, 354). Thirdly, assessment of vascular OS may be better 
than measuring plasma or urine OS biomarkers as it measures vascular function 
instead of blood or urine levels and it is measured in vivo (334). The gold 
standard method of measuring vascular OS is by forearm venous occlusion 
plethysmography (FVOP) and infusing intra-arterial high dose vitamin C, which 
is a scavenger of free radicals. A study by Rajendra et al. found allopurinol to 
have a greater effect on vascular OS than on plasma OS biomarkers (334). FVOP 
was not undertaken in my study as it is an invasive procedure that is quite time 
consuming. Finally, the study was not powered to assess for changes in oxidized 
LDL levels. 
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4.8 Effect of Allopurinol on BNP 
 
In this study, there was a poor correlation between baseline BNP and baseline 
LVM. This is unlike some previous studies that have shown a positive 
correlation between BNP and LVM in the general population (355), in 
hypertensives (283, 356, 357) and patients with hypertrophic cardiomyopathy 
(285, 286). A possible explanation for poor correlation seen in my study is that 
we have not accounted for the degree of myocardial ischaemia in the study 
patients. As previously discussed, BNP levels are also elevated in the presence 
and degree of myocardial ischaemia (274-276, 278, 279). Hence, the BNP levels 
measured at baseline will reflect not only the LVM but also myocardial 
ischaemia. 
 
In my study, allopurinol numerically reduced BNP (median BNP reduction 6 
pg/ml), which just failed to reach statistical significance (p=0.08).  However, 
baseline BNP levels between the active and placebo groups were rather different 
making the change data hard to interpret. As already mentioned, BNP secretion 
is triggered by increased ventricular filling pressures.  Hence, the reduction of 
BNP in my study is likely related to the significant reduction in LVESV and 
arterial compliance and LV afterload and non-significant reduction in LVEDV.  
The other theory is whether the reduction in LVM resulted in the reduction in 
BNP. Studies have shown regression of LVM with ACE inhibitors, ARBs and 
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spironolactone to be associated with a reduction in BNP (257, 358, 359). In other 
studies, regression in LVM in patients with CKD stage 3 and LVH with 
allopurinol therapy (332) and normotensive patients treated with 
antihypertensives (259) were not associated with a significant change in BNP. 
My study did not see a correlation between the change in BNP and change in 
LVM but it was not powered to assess this.  
 
Previous studies have been conflicting in the effect of allopurinol on BNP levels 
(318, 325, 326, 332, 334).  In a study of patients with CKD stage 3 and LVH 
(332) and another study of patients with chronic heart failure NYHA class II-III 
(326), allopurinol did not affect BNP levels.  However, in other studies 
allopurinol significantly reduced BNP in patients with chronic stable angina 
(318) and heart failure (325) whilst non-significantly in another study of patients 
with angina (334). 
 
4.9 Possible mechanisms Allopurinol reduced LVM 
There are numerous possible mechanisms by which allopurinol regressed LVM. 
Firstly, patients with IHD tend to develop endothelial dysfunction and increased 
arterial stiffness. As allopurinol improved endothelial dysfunction and arterial 
stiffness without a significant reduction in BP, the reduction in LV afterload is 
likely to result in regression in LVM, as LV afterload is known to be a better 
predictor of LVM than brachial BP (348). An effect on LV afterload is supported 
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by our significant reduction in end-systolic volume and non-significant 
reductions in both end-diastolic volume and BNP. Secondly allopurinol reduced 
uric acid levels which has been associated with LVH due to its effects on 
endothelial function, stimulation of hypertrophic signalling pathway and its 
correlation with other factors such as obesity, hypertension and renal impairment 
(301, 305-307). However, it is still unclear if uric acid is a cause of hypertrophy. 
Finally, allopurinol being a XO inhibitor is likely to have reduced oxidative 
stress, which plays a role in the development of LVH. We did not detect a 
reduction in oxidized LDL but this is only one of the numerous OS biomarkers 
and all assays have limitations. Previous studies have shown an improvement in 
vascular tissue OS with allopurinol (24, 326, 334, 343) and it would have been 
better if instead we measured vascular OS using FVOP. Findings of this study 
should be confirmed in larger scaled studies. 
 
 
4.10 Prognostic benefit of LVM regression 
 
Patients with IHD commonly develop LVH, which has been said to be the ‘most 
reliable surrogate marker we have in cardiovascular medicine’ (204, 205). LVH 
has been associated with an increased risk of cardiovascular events including 
coronary heart disease, MI, heart failure, stroke and arrhythmias. It is a 
reversible, poor prognostic marker. Numerous landmark studies including HOPE 
and LIFE have shown LVM regression to be associated with an improved 
 205 
prognosis. Majority of the previous studies assessing LVM regression have been 
on hypertensive populations treated with antihypertensive therapy although the 
prognostic benefit of LVM regression was independent of BP reduction. 
  
In the PIUMA study, Verdecchia et al. demonstrated the group with regression 
of LVM to be associated with 1.2 times lower cardiovascular event rate per 100 
person-years compared to the group of non-regressors (p=0.03, log-rank test) 
(248). The reduction in cardiovascular event rate was even greater in the LVM 
regressors (4.5 times) compared to the non-regressors in the subgroup with a 
higher baseline LVMI (LVMI>125g/m2) (p<0.01, log-rank test) (248). Koren et 
al. also showed that hypertensive patients with unchanged or regression of LVM 
had a lower cardiovascular event rate compared to those with an increase in 
LVM (360). In the HOPE substudy, patients with regression or absence of LVH 
on ECG compared to those with development or persistence of LVH had a lower 
risk of primary composite endpoint of cardiovascular death, MI or stroke (12.3% 
vs.15.8% respectively, p<0.01) and of congestive heart failure (9.3% vs. 15.4% 
respectively, p<0.01) (361). In 2003, a meta-analysis by Verdecchia et al. which 
included 4 studies of hypertensive patients, regression of LVH on echo was 
associated with a 59% reduced risk of cardiovascular events compared to 
persistence or new LVH (p<0.01) (249). 
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The reduction in LVH shown in our study is similar in percent terms to that seen 
in the echo substudy of the LIFE study. In the LIFE study, the differential effect 
between losartan and atenolol in regressing LVH was only 3% over 4.8 years 
(250). This was associated with a reduction in all-cause mortality of 28%, 
cardiovascular mortality of 38%, sudden cardiac death of 19%, myocardial 
infarction of 15%, new congestive heart failure of 36%, new onset atrial 
fibrillation of 12% and stroke of 24% in favour of losartan over atenolol and 
were independent of any change in BP (250, 252-254). The LIFE study is the 
best guide as to what effect allopurinol might have on future cardiovascular 
events because it is only in the LIFE study that the effect of LVH changes on 
cardiovascular events can be ascertained in the absence of any differential effect 
on blood pressure. It remains to be seen whether allopurinol induced LVH 
regression can deliver anything like these effects that were seen between the 
groups in the LIFE. 
 
 
4.11 Prognostic benefit of Allopurinol on future 
cardiovascular events 
 
 
The LIFE study is the best possible guide as the effect we saw with allopurinol 
on LVM was comparable to the differential effect seen between losartan and 
atenolol in LIFE.  Hence it is feasible that allopurinol might reduce 
cardiovascular events.  Four factors also amplify the chance that allopurinol will 
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reduce future cardiovascular events.  Firstly, we only gave allopurinol for 9 
months in our study (LIFE was 4.8 years) and allopurinol’s effect on LVM is 
likely to be greater the longer it is given.  It is clear from the echo LIFE sub-
study that this is likely the case ie. LVH regression occurs gradually over 2 years 
and then plateaus.  Secondly, allopurinol also has anti-ischaemic activity (318) 
and this extra effect should also help it to reduce cardiovascular events.  Thirdly, 
the beneficial effect of allopurinol on vascular function, seen in this study, 
should also enhance the chance that allopurinol will reduce cardiovascular 
events. Fourthly, we also found LV ESV to fall significantly after allopurinol in 
this study.  LV ESV has been shown to be a predictor of survival post MI (362) 
and heart failure hospitalizations in patients with stable coronary artery disease 
(363). Overall our suggestion that allopurinol might reduce future cardiovascular 
events is now not just based on its effect on LVM here but also on its anti-
ischaemic effect, its effects on endothelial function and on its effects on LV end 
systolic volume and LV afterload (AIx).  Together they represent a group of 
fairly reliable surrogates which all change in the correct direction.  
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4.12 Choice of dosage 
 
In this study we chose to use 600mg/day allopurinol, which was gradually 
uptitrated over 6 weeks. Previous studies have shown 600mg/day allopurinol to 
be well tolerated and have a greater beneficial effect than lower doses (319, 320, 
326). George et al. found that allopurinol had a steep dose response on 
endothelial function. High dose allopurinol (600mg) had a greater effect on 
endothelial function compared to 300mg allopurinol [mean % change in forearm 
blood flow ± SEM on forearm venous occlusion plethysmography (FVOP): 
240.3 ± 38.2% for 600mg allopurinol vs. 152.1 ± 18.2% for 300mg allopurinol 
vs. 74 ± 10.3% for placebo; p<0.01] (326).  
 
A couple of observational studies have also found higher dose allopurinol (≥ 
300mg) to be associated with a lower cardiovascular event rate and mortality 
compared to lower dose allopurinol (< 300mg) (319, 320). Dosage of allopurinol 
is very important as highlighted in the OPT-CHF (Oxypurinol Therapy for 
Congestive Heart Failure) study. The study failed to show any benefit of XOI on 
the composite endpoint of heart failure morbidity, mortality and quality-of-life 
most likely due to the inadequate dosage of XOI used. 600mg of oxypurinol 
prescribed in the study had a bioavailability equivalent to only 81mg allopurinol 
and reduce serum uric acid levels by 26% compared to 46% in this study (327). 
 
 
 209 
5 STUDY LIMITATIONS 
 
5.1 Study design and population 
 
This was a randomized controlled study with a relatively small sample size 
undertaken at a single centre. However, this was a proof of concept study that 
was adequately powered for the study primary outcome measure. As cardiac 
MRI has a greater accuracy and reproducibility in measuring LVM compared to 
echo, we were able to reliably detect changes in LVM using smaller sample 
sizes. However, my study findings need to be confirmed in larger scale RCT 
studies. 
 
The follow up period of this study was amended early from 1 year to 9 months as 
we were unable to commence the study during my first 6 months due to 
difficulty obtaining study medication. The recent changes in MHRA regulations 
resulted in less pharmaceuticals companies being able to supply the study 
medication at a reasonable cost. In order to complete recruitment and the study 
within my 2 years at University of Dundee, we had to reduce the follow up 
period. In the 4E-LVH study, the effects of eplerenone, enalapril and 
eplerenone/enalapril combination on LVM were measured using CMR over a 9 
month follow up period (262). Additionally, Kao et al. found allopurinol to 
regress LVM in CKD patients over 9 months follow up period (332). Hence, we 
felt that 9 months should be a sufficient follow up period for our study.  
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However, it is possible that if we had given high dose allopurinol over a longer 
treatment period, the treatment effect would have been larger. 
 
In this study, only 10% of the recruited study participants were female. Females 
tend to be under-represented in cardiovascular research despite the increasing 
burden of cardiovascular disease in females. Since 2006, only 30% of study 
participants in cardiovascular clinical trials have been female (364). This has 
implications as the current cardiovascular evidence for females has been 
extrapolated from research studies with predominantly male participants. In view 
of the differences in biological, hormonal and psychosocial factors and the 
implications of cardiovascular risk factors, there are gender differences in the 
presentation and progression of cardiovascular disease and their response to 
treatments (364). 
 
5.2 24-hour ambulatory BP monitoring and central BP 
 
In this study, only around 50% randomly selected participants had a 24-hour BP 
monitor due to the limited availability of 24-hour BP monitors in our 
department. All participants had an office BP measurement at each clinic visit. A 
24-hour BP monitor more accurately reflects BP control compared to office BP 
but this was not a primary outcome measure. However, it is reassuring to see that 
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there was no significant change in BP with allopurinol therapy in both the office 
BP and the subgroup that had a 24-hour BP monitor. 
 
We did not measure central BP noninvasively using Sphygmocor but relied on 
measuring the brachial BP. In some studies, measuring brachial BP seemed just 
as good an estimate of central BP as other noninvasive devices (365, 366). 
Brachial BP is generally used to calibrate the Sphygmocor system but its 
measurement has been shown to be the cause of inaccuracy and underestimation 
of central BP (367). 
 
5.3 Assessment of ongoing cardiac ischaemia 
75% of the recruited study patients had previously had a positive exercise stress 
test or MPS. However, as part of this study we did not assess for the ongoing 
ischaemic burden. This is important as in theory myocardial ischaemia is a 
mechanism by which there is a production of ROS resulting in cardiac 
hypertrophy and possibly the reduction in LVM seen in this study with 
allopurinol therapy may be due to the reduction in myocardial ischaemia as 
shown by Noman et al (318). 
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5.4 Primary endpoint 
 
The primary endpoint was the change in LVM, which is a surrogate marker of 
poor prognosis instead of being a hard clinical endpoint such as morbidity or 
mortality. This should be addressed in future studies. 
 
5.5 Effect of Allopurinol on LVM 
In this study the effect of allopurinol on LVM, although significant, is modest. 
The reduction in LVM may have been larger if the treatment period was longer. 
However, it is similar in percentage terms to what was seen in the change in 
LVM between atenolol and losartan therapy groups, in the echo sub-study of the 
LIFE trial (16). 
 
5.6 Safety of long term high dose Allopurinol therapy  
 
The safety profile of allopurinol is well established as it has been used for 40 
years as a treatment for gout. However, the safety of high dose (600mg/day) 
allopurinol for more than 9 months is unknown. 
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5.7 Healthy volunteers subgroup 
 
Unlike the main study, the healthy volunteers in the sub-study did not undergo a 
screening echocardiogram to exclude any structural cardiac disease such as left 
ventricular hypertrophy. However, this was not part of the main study.  
 
6 FUTURE STUDIES 
 
6.1 Longer follow up studies 
 
In this study we have seen a modest reduction in LVM over a 9 month follow up 
period. An important question remains - if we gave allopurinol for a longer study 
period, does it have a sustained effect on LVM regression and result in a greater 
overall reduction or do we lose the initial beneficial effect we have seen of LVM 
regression? In the LIFE study, most of the LVM reduction occurred within 2 
years of treatment (16). This should be explored in future studies but would 
require greater time commitment from study patients to take the study drug for a 
longer study period and a more costly study to fund the additional study visits. 
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6.2 Greater baseline LVM 
 
A number of studies have shown baseline LVM to significantly correlate with 
the change in LVM seen with allopurinol and antihypertensive therapy (255, 
332). My study group had relatively mild LVH and allopurinol regressed LVM 
more in the higher baseline LVM group. Hence, repeating the study with a 
greater baseline LVM is likely to result in greater reduction in LVM with 
allopurinol therapy. As myocardial ischaemia is one of the mechanisms of 
developing LVH, patients with more severe angina may have greater degrees of 
LVH.    
 
6.3 Hard clinical end points 
 
This study looked at the effect of allopurinol on LVM, which is a surrogate 
marker of poor cardiovascular outcomes. However, it would be more clinically 
important to address hard cardiovascular clinical endpoints. High dose 
allopurinol has been shown in ‘real world’ population-based cohort studies to 
reduce cardiovascular events and mortality in heart failure patients and those 
taking allopurinol therapy (320, 368). Two small RCTs have also shown 
allopurinol to reduce cardiovascular events in acute STEMI patients undergoing 
primary PCI and CKD patients (317, 369). However, it has not been assessed in 
patients with chronic stable angina. Due to the relatively low event rate in 
chronic stable angina patients with an annual non-fatal MI rate of 0.5-2.6% and 
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annual mortality rate of 0.9-1.4% (85), such a study would require a very large 
sample size. 
   
6.4 CMR perfusion with late GAD 
Allopurinol regressed LVM in my study. However, it is unknown if this was 
partly due to its anti-ischaemic effect. This could be assessed further by 
undertaking a CMR perfusion study. Additionally, myocardial fibrosis is a key 
component of LVH especially due to LV remodelling. Fibrosis and scar can be 
detected with CMR using late gadolinium (GAD) enhancement imaging. Hence, 
it would be interesting to see if when allopurinol regressed LVM it also reduces 
the degree of myocardial fibrosis. 
 
6.5 CMR spectroscopy 
In ischaemia, the imbalance in ATP demand vs. supply leads to a reduction in 
phosphocreatine levels thereby resulting in a fall in PCr to ATP ratio. 
Allopurinol has been shown to improve cardiac energetics in heart failure 
patients by increasing ATP synthesis and efficiency (324). Hence, it would be 
worthwhile exploring whether the anti-ischaemic effect of allopurinol therapy on 
IHD patients is associated with improved cardiac energetics. CMR spectroscopy 
is a non-invasive technique that assesses cardiac metabolism without use of an 
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external tracer. Cardiac 31P-MRS gives us information regarding the energy state 
of the heart by the PCr to ATP ratio. 
 
6.6 Acute coronary syndrome  
Allopurinol has been shown to be anti-ischaemic in chronic stable angina 
patients (318). The next step would be to assess allopurinols’ anti-ischaemic 
effect in patients having an ACS or STEMI. As in these situations there would 
also be increased levels of oxidative stress, the effect of allopurinol on the degree 
of myocardial damage should be assessed by measuring troponin levels, LV 
function using echocardiography and infarct size using CMR with late 
gadolinium enhancement. Small scaled RCTs have assessed the use of oral 
allopurinol on STEMI patients (316, 317) which will need to be confirmed in 
larger scaled RCTs. Additionally, instead of giving allopurinol orally other 
options include intravenous or intracoronary if the patient is undergoing 
coronary angiography.  
 
6.7 Other patient groups 
Similar to my patient cohort, patients with peripheral artery disease have 
increased level of oxidative stress and commonly develop LVH (50%) and 
endothelial dysfunction (110, 370). As shown by the beneficial effects of 
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allopurinol in my study, it is likely that allopurinol will have a similar effect on 
endothelial function and LVM in the patients with peripheral artery disease. 
 
The other group worth exploring is the effect of allopurinol on LVM in patients 
with LVH and resistant hypertension despite numerous antihypertensive 
therapies. As allopurinol does not significantly reduce BP it may be able to 
regress LVH, which is commonly seen in this patient group, by reducing 
oxidative stress and improving endothelial function. In this group of patients, 
allopurinol might protect the heart (LVH) against the continuing high BP. 
 
6.8 Other inhibitors of Xanthine oxidase  
 
As allopurinol has been shown to be effective in regressing LVM, other XO 
inhibitors such as febuxostat and oxypurinol should also be assessed in future 
human studies. Febuxostat is a non-purine, selective XO inhibitor that has been 
approved in the last 5 years for the treatment of gout, especially for those 
intolerant to allopurinol. It is an orally administered drug that is more effective in 
reducing uric acid levels in gout patients compared to allopurinol with similar 
adverse event rates (371). Febuxostat has been shown in experimental studies to 
reduce oxidative stress and inhibit the development of LVH in a pressure 
overloaded ventricle (330). As it is a more potent XO inhibitor, future studies 
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should examine if febuxostat is more effective than allopurinol in regressing 
LVM. 
 
Oxypurinol is another XO inhibitor that is the active metabolite of allopurinol 
and has a longer half-life. In the La-PLATA study, oxypurinol regressed LVM 
just short of statistical significance despite having a short follow up period of 
only one month and being prescribed at a fairly low dose of 600mg/day, which 
has a relative bioavailability that is equivalent to only 81mg of allopurinol (327, 
331). Hence, it would be worthwhile repeating the study to assess the effects of 
oxypurinol on LVM using a higher dose over a longer follow up period.  
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8 PUBLICATIONS AND PRESENTATIONS 
8.1 Original articles 
High dose Allopurinol reduces left ventricular mass in patients with 
ischemic heart disease.  JACC 2013 March 5; 61(9): 926-32. 
 
8.2 Abstracts and Presentations at Scientific Meetings 
8.2.1 Abstracts 
High dose Allopurinol improves endothelial dysfunction in patients with 
ischemic heart disease and left ventricular hypertrophy but does not match 
age and gender matched controls. Circulation 2012; 126: A13446 
 
8.2.2 Presentations 
 
8.2.2.1 Oral 
 
European Society of Cardiology congress 2012, Munich – High dose 
allopurinol regresses LVH and improves endothelial function in patients 
with chronic stable angina.  
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8.2.2.2 Moderator Poster 
 
British Cardiovascular Society Annual Conference 2013, London. High dose 
Allopurinol improves endothelial dysfunction in patients with Ischemic 
heart disease and left ventricular hypertrophy but does not match age and 
gender matched controls. 
 
8.2.2.3 Poster 
American Heart Association congress 2012, Los Angeles, US. High dose 
Allopurinol improves endothelial dysfunction in patients with Ischemic 
heart disease and left ventricular hypertrophy but does not match age and 
gender matched controls. 
 
 
 
 
 
